

## EXHIBIT 20

1 UNITED STATES DISTRICT COURT  
2 FOR THE NORTHERN DISTRICT OF OHIO  
3 EASTERN DIVISION  
4 - - -  
5 IN RE: NATIONAL )  
6 PRESCRIPTION ) MDL No. 2804  
7 OPIATE LITIGATION )  
8 \_\_\_\_\_ ) Case No.  
9 ) 1:17-MD-2804  
10 THIS DOCUMENT RELATES )  
11 TO ALL CASES ) Hon. Dan A. Polster  
12 - - -

13 VIDEOTAPED DEPOSITION OF THOMAS G. SCHOEN  
14 Wednesday, September 5, 2018  
15 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER  
16 CONFIDENTIALITY REVIEW  
17

18 - - -  
19 Videotaped deposition of THOMAS G. SCHOEN, held  
20 at the Hilton Inn Garden Toledo, 6165 Levis Commons  
21 Boulevard, Perrysburg, Ohio, commencing at 9:03 a.m., on  
22 the above date, before Carol A. Kirk, Registered Merit  
23 Reporter and Notary Public.  
24

25 - - -  
26  
27 GOLKOW LITIGATION SERVICES  
28 877.370.3377 ph | 917.591.5672 fax  
29 deps@golkow.com  
30

1 A P P E A R A N C E S :  
2 On behalf of the Plaintiffs:  
3 MCHUGH FULLER LAW GROUP  
4 BY: MICHAEL J. FULLER, JR., ESQUIRE  
5 mike@mchughfuller.com  
6 AMY J. QUEZON, ESQUIRE  
7 amy@mchughfuller.com  
8 97 Elias Whiddon Road  
9 Hattiesburg, Mississippi 39402  
10 601-261-2220  
11 On behalf of the Cardinal Health, Inc.:  
12 WILLIAMS & CONNOLLY LLP  
13 BY: JOSEPH S. BUSHUR, ESQUIRE  
14 jrbushur@wc.com  
15 725 Twelfth Street, N.W.  
16 Washington, DC 20005  
17 202-434-5420  
18 On behalf of the AmerisourceBergen:  
19 REED SMITH LLP  
20 BY: JAMES A. PETKUN, ESQUIRE  
21 jpetkun@reedsmith.com  
22 Three Logan Square  
23 1717 Arch Street, Suite 3100  
24 Philadelphia, Pennsylvania 19103  
25 215-851-8100  
26 On behalf of HBC:  
27 MARCUS & SHAPIRA LLP  
28 BY: JOSHUA A. KOBRIN, ESQUIRE  
29 kobrin@marcus-shapira.com  
30 (VIA TELECONFERENCE)  
31 One Oxford Center, 35th Floor  
32 301 Grant Street  
33 Pittsburgh, Pennsylvania 15219-6401  
34 412-338-5208

1 On behalf of Teva Pharmaceuticals USA, Inc., Cephalon,  
Inc., Watson Laboratories, Inc., Actavis LLC, Actavis  
2 Pharma, Inc., f/k/a Watson Pharma, Inc.:  
MORGAN, LEWIS & BOCKIUS LLP  
3 BY: ELLIOTT E. BROWN, ESQUIRE  
elliott.brown@morganlewis.com  
4 (VIA TELECONFERENCE)  
1111 Pennsylvania Avenue, NW  
5 Washington, DC 20004  
202-739-5833  
6  
On behalf of the Allergan Defendants:  
7 BARNES & THORNBURG LLP  
BY: WILLIAM E. PADGETT, ESQUIRE  
8 wpadgett@btlaw.com  
(VIA TELECONFERENCE)  
9 11 South Meridian Street  
Indianapolis, Indiana 46204  
10 317-236-1313  
11  
12 ALSO PRESENT:  
13 A.J. Elkins, McHugh Fuller  
Darnell Brown, Videographer  
14 Gina Veldman, Trial Technician

— — —

1 On behalf of Walmart:  
2 JONES DAY  
3 BY: KRISTIN S.M. MORRISON, ESQUIRE  
4 kmorrison@jonesday.com  
5 901 Lakeside Avenue East  
6 Cleveland, Ohio 44114  
7 216-586-7375  
8 On behalf of Prescription Supply, Inc.:  
9 PELINI, CAMPBELL & WILLIAMS LLC  
10 BY: PAUL B. RICARD, ESQUIRE  
11 pbricard@pelini-law.com  
12 CRAIG G. PELINI, ESQUIRE  
13 cgp@pelini-law.com  
14 SAMANTHA VOLEK, ESQUIRE  
15 svolek@pelini-law.com  
16 8040 Cleveland Avenue NW, Suite 400  
17 North Canton, Ohio 44720  
18 330-305-6400  
19 On behalf of Miami-Luken:  
20 JACKSON KELLY PLLC  
21 BY: WILLIAM J. AUBEL, ESQUIRE  
22 william.j.aubel@jacksonkelly.com  
23 (VIA TELECONFERENCE)  
24 500 Lee Street East, Suite 1600  
Charleston, West Virginia 25301  
304-340-1092  
On behalf of McKesson:  
COVINGTON & BURLING LLP  
BY: MEGHAN E. MONAGHAN, ESQUIRE  
mmonaghan@cov.com  
One CityCenter  
850 Tenth Street, NW  
Washington, DC 20001  
202-662-5531  
On behalf of Endo Pharmaceuticals, Inc. and  
Endo Health Solutions Inc.:  
ARNOLD & PORTER KAYE SCHOLER, LLP  
BY: ANGEL TANG NAKAMURA, ESQUIRE  
angel.nakamura@apks.com  
(VIA TELECONFERENCE)  
777 S. Figueroa Street, Suite 4400  
Los Angeles, California 90017  
213-243-4000

1 VIDEOTAPED DEPOSITION OF THOMAS G. SCHOEN  
2 INDEX TO EXAMINATION  
3 WITNESS PAGE  
4 THOMAS G. SCHOEN  
5 EXAMINATION BY MR. FULLER: 12

Page 6				Page 8			
1	VIDEOTAPED DEPOSITION OF THOMAS G. SCHOEN			1	VIDEOTAPED DEPOSITION OF THOMAS G. SCHOEN		
2	INDEX TO EXHIBITS			2	INDEX TO EXHIBITS (CONT'D)		
3	PSI-SCHOEN	DESCRIPTION	PAGE	3	PSI-SCHOEN	DESCRIPTION	PAGE
4	Exhibit 1	Second Amended First Notice of Deposition Pursuant to Rule 30(b)(6) and Document Request Pursuant to Rule 30(b)(2) and Rule 34 to Defendant Prescription Supply, Inc.	14	4	Exhibit 16	Memorandum for Asa Hutchinson from Mr. Fine, Bates-stamped PSI 30b_ 204 - 001 through 039	118
5				5			
6				6	Exhibit 17	Letter to Cardinal Health from Mr. Rannazzisi, dated 12/27/07, Bates-stamped PSI 30b_ 303 - 001 through 002	127
7				7			
8	Exhibit 2	Second Amended Second Notice of Deposition Pursuant to Rule 30(b)(6) and Document Request Pursuant to Rule 30(b)(2) and Rule 34 to Defendant Prescription Supply, Inc.	15	8			
9				9	Exhibit 18	Document titled "HDMA Industry Compliance Guidelines: Reporting Suspicious Orders and Preventing Diversion of Controlled Substances," Bates-stamped PSI 30b_ 305 - 001 through 015	134
10				10			
11	Exhibit 3	Prescription Supply, Inc.'s Objections and Responses to First and Second Notice of Deposition to Rule 30(b)(6)	15	11			
12				12			
13	Exhibit 4	Document titled "United States Code Annotated; Title 21. Food and Drugs; Chapter 13. Drug Abuse Prevention and Control; Subchapter I. Control and Enforcement; Parts A through C	18	13	Exhibit 19	PSI policies and procedures, Bates-stamped PSI 30b_ 404 - 001 through 005	153
14				14			
15				15	Exhibit 20	Document titled "Maximum Monthly Quantity," 10/2/08, Bates-stamped PSI0000280 through 285	190
16				16			
17	Exhibit 5	Legislative findings and history of the Controlled Substances Act, 101 pages	30	17	Exhibit 21	Document titled "Prescription Supply Maximum Monthly Units for OLS Systems," 10/2/2008, Bates-stamped PSI0000274 through 279	190
18				18			
19	Exhibit 6	21 C.F.R. 1301.74	39	19			
20	Exhibit 7	Document titled HathiTrust	47	20	Exhibit 22	State of Ohio Board of Pharmacy Written Response, October 25, 2017, Bates-stamped PSI0000007 through 83	193
21	Exhibit 8	861 Federal Reporter, 3d Series, Bates-stamped PSI 30b_ 106-001 through 025	54	21			
22				22			
23	Exhibit 9	Document titled "Ohio Administrative Code - 2002," Bates-stamped PSI 30b_ 112 - 001 through 004	61	23	Exhibit 23	Thumbdrive containing macro spreadsheet	206
24				24			
Page 7				Page 9			
1	VIDEOTAPED DEPOSITION OF THOMAS G. SCHOEN			1	VIDEOTAPED DEPOSITION OF THOMAS G. SCHOEN		
2	INDEX TO EXHIBITS (CONT'D)			2	INDEX TO EXHIBITS (CONT'D)		
3	PSI-SCHOEN	DESCRIPTION	PAGE	3	PSI-SCHOEN	DESCRIPTION	PAGE
4	Exhibit 10	Document titled "United States General Accounting Office GAO Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives, May 2002, Prescription Drugs, State Monitoring Programs Provide Useful Tool to Reduce Diversion"	73	4	Exhibit 24	E-mail to Mr. J. Schoen from Mr. Thomas Schoen, dated May 2, 2018, Bates-stamped PSI0003024	218
5				5			
6				6	Exhibit 25	Spreadsheet, Shaffer Pharmacy	221
7				7	Exhibit 26	Shaffer Pharmacy Total Monthly Oxycodone Sales, January 2008 - April 2009	221
8				8			
9				9	Exhibit 27	Shaffer Pharmacy Total Monthly Oxycodone Sales January 2013 - November 2014	221
10	Exhibit 11	Document titled "HathiTrust, OxyContin: Its Use and Abuse"	77	10			
11				11	Exhibit 28	Letter to Mr. Ohliger from the State of Ohio Board of Pharmacy, dated 10/6/15, Bates-stamped PSI0003419 through 3421	234
12	Exhibit 12	The National Center on Addiction and Substance Abuse at Columbia University, "Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S."	88	12			
13				13			
14				14	Exhibit 29	HDMA Boards of Directors newsletter	241
15	Exhibit 13	Letter to Cardinal Health from Mr. Rannazzisi, dated 9/27/06, Bates-stamped PSI 30b_ 301 - 001 through 004	95	15			
16				16	Exhibit 30	Amicus Curiae Brief of Healthcare Distribution Management Association in Support of Appellant Cardinal Health, Inc.	243
17	Exhibit 14	Diagram prepared by Attorney Fuller	106	17			
18				18			
19	Exhibit 15	PowerPoint presentation titled "Drug Enforcement Administration Pharmaceutical Industry Conference, Wholesale Distribution Diversion Control Program, September 11, 2007," Bates-stamped PSI 30b_ 601 - 001 through 044	113	19			
20				20			
21				21			
22				22			
23				23			
24				24			

<p style="text-align: right;">Page 10</p> <p>1               ---</p> <p>2               P R O C E E D I N G S</p> <p>3               ---</p> <p>4               THE VIDEOGRAPHER: Good morning. We are</p> <p>5 now on the record. My name is Darnell Brown, and</p> <p>6 I am a videographer with Golkow Litigation</p> <p>7 Services. Today's date is September 5, 2018, and</p> <p>8 the time is 9:03 a.m.</p> <p>9               This video deposition is being held in</p> <p>10 Perrysburg, Ohio, in the matter of In Re: Opioid Deps</p> <p>11 for the United States District Court for the Northern</p> <p>12 District of Ohio. The deponent is Thomas Schoen.</p> <p>13              Counsel will be noted on the stenographic</p> <p>14 record. The court reporter is Carol Kirk who will now</p> <p>15 swear in the witness.</p> <p>16              (Witness sworn.)</p> <p>17              THE VIDEOGRAPHER: You may begin.</p> <p>18              MR. FULLER: Aren't we supposed to all</p> <p>19 introduce ourselves?</p> <p>20              THE VIDEOGRAPHER: Yeah.</p> <p>21              MR. FULLER: All right. Mike Fuller on</p> <p>22 behalf of the Plaintiff.</p> <p>23              MR. ELKINS: AJ Elkins on behalf of the</p> <p>24 Plaintiff.</p>	<p style="text-align: right;">Page 12</p> <p>1 HBC.</p> <p>2              MS. NAKAMURA: Angel Nakamura on behalf</p> <p>3 of the Endo and Par Pharmaceutical Defendants.</p> <p>4              MR. AUBEL: Bill Aubel on behalf of</p> <p>5 Miami-Luken, Inc.</p> <p>6              MR. FULLER: I'm assuming that's</p> <p>7 everybody.</p> <p>8              ---</p> <p>9              THOMAS G. SCHOEN</p> <p>10 being by me first duly sworn, as hereinafter certified,</p> <p>11 deposes and says as follows:</p> <p>12              EXAMINATION</p> <p>13 BY MR. FULLER:</p> <p>14              Q. Mr. Schoen, please state your name,</p> <p>15 spelling your last name for the record.</p> <p>16              A. My name is Thomas G. Schoen. Last name</p> <p>17 Schoen, S-c-h-o-e-n.</p> <p>18              Q. And, Mr. Schoen, are you the owner and</p> <p>19 operator of a company called Prescription Supply,</p> <p>20 Inc.?</p> <p>21              A. I am an owner. There are more than one.</p> <p>22 And I'm president of Prescription Supply,</p> <p>23 Incorporated.</p> <p>24              Q. Who are the other owners?</p>
<p style="text-align: right;">Page 11</p> <p>1              MS. QUEZON: Amy Quezon on behalf of the</p> <p>2 Plaintiff.</p> <p>3              MS. VELDMAN: Gina Veldman on behalf of</p> <p>4 the Plaintiff.</p> <p>5              MR. PELINI: Craig Pelini. I represent</p> <p>6 PSI.</p> <p>7              MR. BUSHUR: Joseph Bushur on behalf of</p> <p>8 Cardinal Health.</p> <p>9              MR. PETKUN: James Petkun for</p> <p>10 AmerisourceBergen Corporation.</p> <p>11              MS. MONAGHAN: Meghan Monaghan on behalf</p> <p>12 of McKesson.</p> <p>13              MS. MORRISON: Kristin Morrison on</p> <p>14 behalf of Walmart.</p> <p>15              MS. VOLEK: Samantha Volek on behalf of</p> <p>16 PSI.</p> <p>17              MR. RICARD: Paul Ricard, PSI.</p> <p>18              MR. FULLER: And anybody on the phone?</p> <p>19 Can you note your appearance for the record.</p> <p>20              MR. PADGETT: Bill Padgett on behalf of</p> <p>21 HD Smith.</p> <p>22              MR. BROWN: Elliott Brown on behalf of</p> <p>23 Teva.</p> <p>24              MR. KOBRIN: Joshua Kobrin on behalf of</p>	<p style="text-align: right;">Page 13</p> <p>1              A. All family members.</p> <p>2              Q. Okay. Your family, I'm assuming?</p> <p>3              A. My family and my sister's family.</p> <p>4              Q. Fair enough.</p> <p>5              And your company has been around since,</p> <p>6 I think, about 1955; is that correct?</p> <p>7              A. That's correct.</p> <p>8              Q. And has it always been family owned --</p> <p>9              A. It has.</p> <p>10             Q. -- and operated?</p> <p>11             A. Yes, it has.</p> <p>12             Q. Okay. And you're aware that -- and tell</p> <p>13 me if it's okay -- but I heard counsel do it, so</p> <p>14 I'm assuming it is -- referring to Prescription</p> <p>15 Supply, Inc., as PSI.</p> <p>16             A. That's acceptable.</p> <p>17             Q. Okay. And you're aware that PSI has</p> <p>18 been sued in this litigation involving the opioid</p> <p>19 epidemic, correct?</p> <p>20             A. I'm aware.</p> <p>21             Q. You were also -- well, let me just</p> <p>22 attach the exhibits. We're going to attach as</p> <p>23 Plaintiff's 1 a copy of the notice. And this is</p> <p>24 more housekeeping for counsel and I. It's the</p>

Page 14

1 second amended first notice will be Exhibit 1.  
2 Here. Let me just give you all the copies and  
3 you can pass them out.

4 - - -

5 (PSI-Schoen Exhibit 1 marked.)

6 - - -

7 BY MR. FULLER:

8 Q. Mr. Schoen, just so you know, the first  
9 little bit here, we're going to just -- sort of  
10 going to be like housekeeping, just some notices  
11 and objections and things like that that I'll make  
12 sure as we get as part of the record of this  
13 deposition. Okay?

14 Now, I'm going to assume -- and correct  
15 me if I am wrong -- that you have seen this notice  
16 prior to today; is that correct? Take a minute  
17 and flip through it.

18 A. Actually, I don't know that I've seen  
19 this notice. But, yes, I've seen perhaps the  
20 first notice.

21 Q. Fair enough. And particularly starting  
22 on page 5, I believe it is, the areas of inquiry.  
23 Do you see those listed there? And it goes on to  
24 page 6.

Page 15

1 A. Yes.

2 Q. And have you had an opportunity to  
3 review those before today?

4 A. I have.

5 - - -

6 (PSI-Schoen Exhibit 2 marked.)

7 - - -

8 Q. Okay. The second exhibit is going to be  
9 the second amended notice for the second 30(b).

10 Mr. Schoen, it also starts on page 5,  
11 certain topic areas. And, again, I'd just ask if  
12 you have had an opportunity to make yourself  
13 familiar with those areas of inquiry prior to  
14 today?

15 A. I have.

16 - - -

17 (PSI-Schoen Exhibit 3 marked.)

18 - - -

19 Q. Okay. And the third exhibit is going to  
20 be the Defendants' objections to our notice.

21 We're just making those part of the  
22 record. I don't know if you've reviewed them or  
23 not, and it really doesn't matter to me, so don't  
24 worry about it.

Page 16

1 A. Actually, I have not reviewed this one.

2 Q. Fair enough.

3 Now, today -- and I'm sure you've been  
4 told -- you've been designated as a 30(b) witness,  
5 okay? And what that means is that you're here  
6 today to speak on behalf of a company; in this  
7 particular case, PSI.

8 Are you aware of that?

9 A. Yes.

10 Q. So it's going to be a little awkward  
11 probably at times because I'm going to be asking  
12 you for information that PSI knows, not just  
13 Thomas Schoen; is that fair?

14 A. Fair.

15 Q. And for purposes of the 30(b), we're  
16 going to be limited to the subject matters set  
17 out, with one exception. Your counsel and I have  
18 talked over the past couple of weeks and reached  
19 certain agreements with certain topics set out in  
20 the notices.

21 MR. FULLER: And, Counsel, you can  
22 correct me if I am wrong, but I'm going to read  
23 from my e-mail as to what we, I think, agreed to.  
24 And the first 30(b) notice, Subject Matter O, will

Page 17

1 be subject to a written response. And the second  
2 30(b) notice is going to be numbers 1, 2, 3, 4, 5,  
3 9, 10, 11, and 18.

4 Here you go, Counsel. Here's a copy of that  
5 e-mail that I sent you.

6 MR. RICARD: That's correct.

7 MR. FULLER: Okay.

8 BY MR. FULLER:

9 Q. So, Mr. Schoen, what your counsel and I  
10 did for you is hopefully shortened the amount of  
11 time that you have to sit here today.

12 A. Thank you.

13 Q. You're more than welcome. And, again, I  
14 appreciate you coming and being here for us.

15 Now, you mentioned that you don't really  
16 operate. What is your role currently with PSI?  
17 What do you do on a day-to-day basis?

18 A. I'm the president. I do pretty much  
19 everything. I -- okay.

20 Q. Give me, if you will, just a thumbnail  
21 sketch of what your average day is these days.

22 A. We're going through constant changes in  
23 our software, so I'm reviewing and giving some  
24 ideas on software changes. I'm hiring people

<p style="text-align: right;">Page 18</p> <p>1 because we need them at this time of year. I</p> <p>2 don't know. It just -- I don't have any more</p> <p>3 fixed responsibilities, as far as I do whatever</p> <p>4 has to be done when it has to be done.</p> <p>5 Q. Fair enough. Fair enough. I get that.</p> <p>6 I get that.</p> <p>7 Now, Prescription Supply is a registrant</p> <p>8 with the DEA related to controlled substances,</p> <p>9 correct?</p> <p>10 A. Yes.</p> <p>11 Q. And as such, you take on certain</p> <p>12 statutory and regulatory obligations; is that</p> <p>13 correct?</p> <p>14 A. Yes.</p> <p>15 Q. And we're going to mark as Plaintiff's</p> <p>16 Exhibit Number 4 --</p> <p>17 MR. FULLER: It's going to be 101, Gina.</p> <p>18 ---</p> <p>19 (PSI-Schoen Exhibit 4 marked.)</p> <p>20 ---</p> <p>21 BY MR. FULLER:</p> <p>22 Q. Now, I'm going to assume that you are</p> <p>23 somewhat familiar, Mr. Schoen, with the Controlled</p> <p>24 Substances Act; is that correct?</p>	<p style="text-align: right;">Page 20</p> <p>1 that this seeks any legal conclusions?</p> <p>2 MR. FULLER: Sure.</p> <p>3 BY MR. FULLER:</p> <p>4 Q. And you'll see up there to the upper</p> <p>5 left, Mr. Schoen, that -- the seal of the United</p> <p>6 States Congress, correct?</p> <p>7 A. I do.</p> <p>8 Q. And this is part of the United States</p> <p>9 Code, which is the statutes promulgated by the</p> <p>10 federal government. And you'll see this is</p> <p>11 Chapter 13. Drug Abuse, Prevention, and Control.</p> <p>12 Do you see that? If you look on the</p> <p>13 screen right in front of you, it's highlighted.</p> <p>14 A. Okay. Yes.</p> <p>15 Q. Okay. The screen is sort of like your</p> <p>16 cheat sheet.</p> <p>17 A. All right.</p> <p>18 Q. It will help get you right where I'm</p> <p>19 looking, too, okay? And you're aware that that is</p> <p>20 part of the Controlled Substances Act?</p> <p>21 A. Yes.</p> <p>22 Q. Okay. And this is Section 801, and it</p> <p>23 says the Congressional findings and declarations</p> <p>24 related to controlled substances. "The Congress</p>
<p style="text-align: right;">Page 19</p> <p>1 A. Yes, in general.</p> <p>2 THE VIDEOGRAPHER: Could the person on</p> <p>3 the phone -- could you guys please put your phone</p> <p>4 on mute, because we can now hear you in the</p> <p>5 background. Please.</p> <p>6 MR. FULLER: I'm sorry. I wasn't paying</p> <p>7 attention to it.</p> <p>8 BY MR. FULLER:</p> <p>9 Q. And what you have -- and you have a hard</p> <p>10 copy, which has been marked as an exhibit. You</p> <p>11 should also have a digital copy in that screen</p> <p>12 right in front of you. And then there's a big</p> <p>13 screen up to your right as well. And you can look</p> <p>14 at any or all of them, okay?</p> <p>15 And what's going to happen is, as I go</p> <p>16 through some of this document, the one in front of</p> <p>17 you on the digital copy, Mr. Schoen, is going to</p> <p>18 be highlighted as to wherever I'm referring to to</p> <p>19 help direct you to certain areas. Okay?</p> <p>20 A. Yes.</p> <p>21 Q. Okay.</p> <p>22 MR. RICARD: Before you start on this,</p> <p>23 can we, notwithstanding any form objections, agree</p> <p>24 to a standing objection to any -- to the extent</p>	<p style="text-align: right;">Page 21</p> <p>1 makes the following findings and declarations."</p> <p>2 Could you read, in all fairness, the</p> <p>3 first declaration that they made to us,</p> <p>4 Mr. Schoen.</p> <p>5 A. "Many of the drugs included within this</p> <p>6 subchapter have a useful and legitimate medical</p> <p>7 purpose and are necessary to maintain the health</p> <p>8 and general welfare of the American people."</p> <p>9 Q. And does PSI accept that declaration by</p> <p>10 U.S. Congress as being true?</p> <p>11 A. Yes.</p> <p>12 Q. And many of the drugs that you deliver,</p> <p>13 Schedules II through Vs, do have legitimate</p> <p>14 medical purposes --</p> <p>15 A. Yes.</p> <p>16 Q. -- is that correct?</p> <p>17 And another thing, Mr. Schoen, is we</p> <p>18 go -- if you will let me finish my question</p> <p>19 completely before you answer -- in normal</p> <p>20 conversation when you know what I'm going to ask,</p> <p>21 we usually start answering each other, but because</p> <p>22 of Madam Court Reporter and we want to make sure</p> <p>23 the record is clear, you let me finish.</p> <p>24 Your counsel may object from time to</p>

<p style="text-align: right;">Page 22</p> <p>1 time. Let him get out his objection. And then  2 you can answer. And I'll certainly try to let you  3 finish your answer before I ask another question.  4 Okay?  5 A. Yes.  6 Q. Now, if you will, read the second  7 declaration to us, please.  8 A. "The illegal importation, manufacture,  9 distribution, and possession and improper use of  10 controlled substances has a substantial and  11 detrimental effect on the health and general  12 welfare of the American people."  13 Q. And does PSI as a registrant agree and  14 accept that declaration by the U.S. Congress?  15 MR. RICARD: Objection to form.  16 Q. That's him stating his objection for the  17 record, but you can go ahead and answer the  18 question.  19 A. Yes.  20 Q. Now, with one caveat. The only time you  21 wouldn't answer is if he tells you "Hey,  22 Mr. Schoen, don't answer that question." Okay?  23 A. I'm afraid I didn't understand that.  24 Q. I'm sorry. The only time you wouldn't</p>	<p style="text-align: right;">Page 24</p> <p>1 controlled substances.  2 Do you see that there?  3 A. Yes.  4 Q. And PSI is aware that there are several  5 different schedules for controlled substances  6 depending on certain factors that relate to that  7 particular medication, correct?  8 A. Yes.  9 Q. Now, I'm going to tell you that most of  10 today we're going to be talking about what is  11 called Schedule IIs. And you know what those are;  12 is that right?  13 A. Yes.  14 Q. PSI is also a distributor of Schedule  15 IIs; are they not?  16 A. Yes.  17 Q. Tell us what -- under Schedule II, what  18 the three factors are, and start with factor A, if  19 you would.  20 A. "The drug or other substance has a high  21 potential of abuse.  22 "(B) The drug or other substance has a  23 currently accepted medical use in treatment in the  24 United States or is currently accepted medical use</p>
<p style="text-align: right;">Page 23</p> <p>1 answer the question is if counsel tells you not to  2 answer.  3 A. Oh, okay.  4 Q. Fair enough?  5 A. Fair enough.  6 Q. Okay. Now, PSI -- you sitting here as  7 PSI are a distributor, correct?  8 A. That's correct.  9 Q. And Section 2 here refers to the --  10 amongst other things, the illegal distribution?  11 A. Yes.  12 Q. And you would agree as PSI that the  13 illegal distribution of controlled substances have  14 a substantial and detrimental effect on the health  15 and general welfare of the American people,  16 correct?  17 MR. RICARD: Objection to form.  18 A. Yes.  19 Q. Okay. If you'll turn to the next page,  20 you'll see again the -- on the upper left, a  21 symbol of the great U.S. Congress, correct?  22 A. Yes.  23 Q. And it's still Chapter 13, but this is  24 Section 812, and it deals with schedules of</p>	<p style="text-align: right;">Page 25</p> <p>1 for severe -- with severe restrictions.  2 "Abuse of the drug or other substance  3 may lead to severe psychological or physical  4 dependency."  5 Q. And PSI accepts those as all the  6 requirements for Schedule II drugs, correct?  7 MR. RICARD: Object to form.  8 A. Yes.  9 Q. Now -- and let's talk about it just for  10 a second. The reason we have these different  11 schedules, as PSI is well aware, is because there  12 are some medications out there that have -- while  13 legitimate purposes, if they go unchecked, can be  14 very dangerous, correct?  15 MR. RICARD: Objection to form.  16 A. Yes.  17 Q. And one of the things that we want to  18 ensure -- and I say "we." One of the things that  19 PSI wants to ensure is that we're dealing with  20 these dangerous drugs in the right way, that we're  21 preventing them from getting into the illicit  22 market?  23 MR. RICARD: Objection to form.  24 Q. Correct?</p>

Page 26

1 A. Yes.

2 Q. Okay. If you'll turn to the next page,  
3 and you see this is Section 821 of Chapter 13.

4 Do you see that?

5 A. I do.

6 Q. Okay. And this deals with rules and  
7 regulations, and it says, "The Attorney General is  
8 authorized to promulgate rules and regulations and  
9 to charge reasonable fees related to the  
10 registration and control of the manufacture,  
11 distribution, and dispensing of controlled  
12 substances and listed chemicals."

13 Does PSI accept that the Attorney  
14 General is the one with the authority to regulate  
15 its industry?

16 A. Yes.

17 MR. RICARD: Objection to form.

18 Q. And if you'll turn to the final page, I  
19 think, of this exhibit. We're at Section 823,  
20 registration requirements.

21 Do you see that there?

22 A. I do.

23 Q. And then -- and, again -- and I may not  
24 have stated this in the beginning. These are

Page 27

1 portions of the regs -- or excuse me -- portions  
2 of the code that I've pulled out, so it doesn't  
3 have the whole code. I only pulled out what I  
4 needed for the purposes of this deposition, okay,  
5 Mr. Schoen? I just want you to understand it's  
6 not every section, and that's why this section  
7 starts with (b). Fair enough?

8 A. Yes.

9 Q. Okay. It says, "In determining the  
10 public interest, the following factors should be  
11 considered: The maintenance of effective controls  
12 against diversion of particular controlled  
13 substances into other than legitimate medical,  
14 scientific, and industrial channels."

15 Do you see that there?

16 A. Yes.

17 Q. And PSI agrees that it has an obligation  
18 to maintain effective controls against diversion  
19 when it comes to controlled substances, correct?

20 MR. RICARD: Objection to form.

21 A. Yes.

22 Q. Now -- and I'm asking you as PSI. When  
23 we see effective controls against diversion, that  
24 means the systems in place and controls to prevent

Page 28

1 diversion; is that correct?

2 MR. RICARD: Objection to form.

3 A. Yes.

4 Q. Tell us, tell the jury, why we want to  
5 prevent diversion of controlled substances.

6 A. Well, as it states, we -- it can be  
7 dangerous. People can die. People can have bad  
8 effects, and they can be abused. None of that is  
9 something that we want to happen. We want the  
10 good effects, not the bad effects.

11 Q. Right. And we're talking about  
12 diversion. Just so we're on the same page, we're  
13 talking about diversion, the non-proper medical  
14 use, correct?

15 A. Correct.

16 Q. And when we have increased diversion,  
17 we're likely to have increased abuse and addiction  
18 as you mentioned, right?

19 MR. RICARD: Objection to form.

20 A. Yes.

21 Q. And when we're talking about that, we're  
22 talking about the general public at large, our  
23 children and our communities, correct?

24 A. Yes.

Page 29

1 Q. And you understand that the Controlled  
2 Substances Act that was enacted back in October of  
3 1970 was Congress' attempt to try to keep our  
4 children and our community safe from these  
5 controlled substances?

6 MR. RICARD: Objection to form.

7 A. Yes.

8 Q. Okay. Now, Mr. Schoen, your family has  
9 been in the business a very long time. When did  
10 you first start working in the industry? Probably  
11 as a little kid, huh?

12 A. I'm afraid that's true, yes. 1958. As  
13 an eighth grader, I tore down some shelving.

14 Q. Wow.

15 A. Yes. I've been active somewhat most of  
16 my life.

17 Q. So you literally started at the bottom  
18 and worked your way up, huh?

19 A. I certainly have. I've worked roughly  
20 every position.

21 Q. Holy cow. Well, good for you.

22 I'm going to now -- and that was  
23 actually even before the Controlled Substances Act  
24 was enacted, correct?

<p style="text-align: right;">Page 30</p> <p>1 A. Well, yes. I was in the Army '68 to 2 '69. 3 Q. Okay. And when you got out of the Army, 4 did you come back home to the family business, or 5 did you go somewhere else first? 6 A. I was in graduate school for a short 7 time. 8 Q. Where at? 9 A. University of Minnesota. 10 Q. Okay. As long as it wasn't OSU. Me and 11 Mr. Craig, at the end of the table, have some 12 issues with OSU. 13 MR. PELINI: We'll stipulate to that, 14 Mr. Fuller. 15 MR. FULLER: Thank you. Thank you, 16 Counsel. 17 BY MR. FULLER: 18 Q. Now, Mr. Schoen, you're not an OSU fan, 19 are you? 20 A. Is that really a -- 21 Q. No, no. You can plead the Fifth on that 22 one. 23 --- 24 (PSI-Schoen Exhibit 5 marked.)</p>	<p style="text-align: right;">Page 32</p> <p>1 MR. FULLER: Gina, if you could go to 2 page -- you're already there. Page 5. 3 THE WITNESS: I can't read that either. 4 Q. Well, see if this helps. How about now? 5 A. That helps, yeah. 6 Q. It helps me, too. I'm getting to that 7 age where my eyesight is going as well. 8 So, Mr. Schoen, this is the legislative 9 history and findings related to the Controlled 10 Substances Act, the things Congress did when it 11 was passing the act and some of the reasoning 12 behind it, and we're not going to go through the 13 whole thing. We're going to go through certain 14 portions of it, if that's okay. All right? 15 A. Yes. 16 Q. All right. And this says, "Title 2: 17 Control and Enforcement." It says, "This bill 18 provides for the control by the Justice Department 19 of problems related to drug abuse through 20 registration of manufacturers, wholesalers, 21 retailers, and all others in the legitimate 22 chain -- excuse me -- legitimate distribution 23 chain that makes transactions outside the 24 legitimate distribution chain illegal."</p>
<p style="text-align: right;">Page 31</p> <p>1 --- 2 Q. What I have marked as Exhibit 3 Number 5 -- and you have in front of you -- is the 4 legislative findings and history of the Controlled 5 Substances Act. 6 A. All right. 7 Q. And I'm going to ask that you read all 8 211 pages. No. I'm kidding. I'm kidding. 9 And you're welcome to follow along in 10 the document. But, again, in front of you, 11 Mr. Schoen, is a digital copy. 12 A. To be honest, I can't read the digital 13 copy. 14 Q. Oh. Well, now, the parts I read from do 15 blow up. 16 A. Okay. 17 Q. So that may help, okay? 18 A. Yes. 19 MR. RICARD: Mike, before you start -- 20 MR. FULLER: Yes, sir. 21 MR. RICARD: -- I'd just like to note a 22 standing objection to any questions pertaining to 23 this document, as it calls for a legal conclusion. 24 MR. FULLER: Fair enough.</p>	<p style="text-align: right;">Page 33</p> <p>1 Does PSI concur that that is the goal 2 behind the Controlled Substances Act? 3 MR. RICARD: Objection to form. 4 MR. FULLER: I'm sorry. 5 A. Yes. 6 Q. Okay. And PSI understands that the way 7 the Controlled Substances Act works is that 8 everybody in that chain of distribution starting 9 from the manufacturer all the way down to the 10 pharmacy has to be registered with the Department 11 of Justice via the DEA? 12 A. Yes. 13 Q. And, again, as we mentioned earlier, PSI 14 is one of those registrants? 15 A. Yes. 16 Q. Does PSI also agree that transactions 17 outside of this legitimate chain or a 18 noncompliance with the Controlled Substances Act 19 would be illegal, meaning breaking the law? 20 MR. RICARD: Objection to form. 21 A. Yes. 22 Q. If you go to page 8. 23 MR. RICARD: For the record, we're 24 looking at the Bates number 89, not the Westlaw?</p>

<p style="text-align: right;">Page 34</p> <p>1 MR. FULLER: I'm sorry. Yes, sir.  2 Upper right-hand corner of the page.  3 BY MR. FULLER:  4 Q. Mr. Schoen, not the page number on the  5 bottom. I apologize. It's the one on the upper  6 right-hand side --  7 A. Okay.  8 Q. -- which looks like they're one page off  9 from each other. Sorry. It can be confusing. I  10 apologize.  11 On page 8, it says, "This bill is  12 designed to improve the administration and  13 regulation of the manufacturing, distribution, and  14 dispensing of controlled substances by providing  15 for a closed system of drug distribution for  16 legitimate handlers of such drugs."  17 Do you have an understanding,  18 Mr. Schoen, of what it means by "closed system"?  19 A. I believe so.  20 Q. And that is that there are limited  21 participants, right?  22 A. Yes.  23 Q. Not just anybody can do what PSI does?  24 A. Yes.</p>	<p style="text-align: right;">Page 36</p> <p>1 A. Correct.  2 Q. It's given certain -- it's given certain  3 persons a specific right to do that, for example,  4 PSI, and you agree with that, correct?  5 A. Yes.  6 Q. Now, if you go to page 11 as numbered in  7 the upper right-hand corner. It says, "The price  8 for participation in this traffic should be  9 prohibitive. It should be made too dangerous to  10 be attractive."  11 And there this code section or this code  12 of this Congressional history is talking about the  13 illegal traffic. And PSI agrees that what  14 Congress is trying to do is trying to make  15 penalties for the illegal market so significant  16 that people won't want to take part in the illicit  17 market, correct?  18 A. Yes.  19 MR. RICARD: Objection to form.  20 A. Yes.  21 MR. RICARD: Tom, give me a second to  22 object if I need to.  23 THE WITNESS: Yes.  24 MR. RICARD: Thanks.</p>
<p style="text-align: right;">Page 35</p> <p>1 Q. You have a special ticket or  2 registration to be a manufacturer, distributor, or  3 a pharmacy, correct?  4 MR. RICARD: Objection to form.  5 A. We're a distributor, yes.  6 Q. Right. It goes on to say that "Such a  7 closed system should significantly reduce the  8 widespread diversion of these drugs out of  9 legitimate channels into the illicit market, while  10 at the same time providing the legitimate drug  11 industry with a unified approach to narcotic and  12 dangerous drug control."  13 Does PSI understand and agree that this  14 closed system is probably one of the best ways to  15 try to prevent diversion?  16 A. Yes.  17 Q. And that what Congress has done here is  18 it's basically done away with, to some degree,  19 capitalism. It says not anybody can participate  20 in this market. For example, Paul, your counsel,  21 and myself, we can't go out today and start buying  22 and selling controlled substances, at least not  23 legally, correct?  24 MR. RICARD: Objection to form.</p>	<p style="text-align: right;">Page 37</p> <p>1 BY MR. FULLER:  2 Q. And you have seen that over the history  3 of your operation in this industry, correct?  4 A. Yes.  5 Q. Not only with illegal doctors getting  6 arrested and fined and put in prison, but also  7 with other wholesale distributors, correct?  8 MR. RICARD: Objection to form.  9 A. Yes.  10 Q. For example, you know that Cardinal and  11 McKesson both had agreements with the federal  12 government to pay certain fines, and those fines  13 have gotten larger over time, correct?  14 MR. RICARD: Objection to form.  15 MS. MONAGHAN: Objection.  16 A. I'm aware that they've been fined, yes.  17 Q. Okay. And are you aware that those  18 fines have increased over time?  19 A. Yes.  20 MR. BUSHUR: Objection; form.  21 Q. And does PSI agree that as it relates to  22 the illegal traffic, that the fines should be high  23 so we can try to prevent any potential  24 diversion from occurring?</p>

<p style="text-align: right;">Page 38</p> <p>1 MR. RICARD: Objection to form.</p> <p>2 A. Yes.</p> <p>3 Q. If you go to page 34, Mr. Schoen. And</p> <p>4 if you can -- and, again, if you can see it,</p> <p>5 Mr. Schoen, can you read that out loud to us?</p> <p>6 A. "The illegal importation, manufacture,</p> <p>7 distribution, and possession and improper use of</p> <p>8 controlled substances has a substantial</p> <p>9 detrimental effect on the public health and</p> <p>10 general welfare."</p> <p>11 Q. And does PSI agree and accept that</p> <p>12 Congressional finding as well?</p> <p>13 A. Yes.</p> <p>14 Q. And does PSI in its operations strive to</p> <p>15 prevent any illegal distribution of controlled</p> <p>16 substances?</p> <p>17 A. Yes.</p> <p>18 Q. And when we're talking about the general</p> <p>19 effect on the public's health and welfare, we're</p> <p>20 talking about the impact it can have on our</p> <p>21 children and our communities, correct?</p> <p>22 A. Among others, yes.</p> <p>23 Q. Because what you do is you distribute</p> <p>24 these controlled substances into different</p>	<p style="text-align: right;">Page 40</p> <p>1 Q. Now, up in the upper left and upper</p> <p>2 right respectfully we now have the seals of the</p> <p>3 Department of Justice who you testified earlier is</p> <p>4 the ones that regulate this industry that you</p> <p>5 operate in, correct?</p> <p>6 A. Yes.</p> <p>7 Q. And on the right, we have United States</p> <p>8 Justice Department, Drug Enforcement</p> <p>9 Administration, or the DEA, who carries out that</p> <p>10 function on behalf of the Department of Justice,</p> <p>11 correct?</p> <p>12 A. Yes.</p> <p>13 Q. And that's who you're registered with;</p> <p>14 is that right?</p> <p>15 A. Yes.</p> <p>16 Q. And you see it's Chapter 2, Part 1301,</p> <p>17 and it deals with security requirements.</p> <p>18 Do you see that there?</p> <p>19 A. Oh, yes. Yes.</p> <p>20 Q. And it says under Section 1301.74,</p> <p>21 "Other security controls for non-practitioners,</p> <p>22 narcotic treatment programs, and compounds for</p> <p>23 narcotic treatment programs."</p> <p>24 And you see letter b down there?</p>
<p style="text-align: right;">Page 39</p> <p>1 pharmacies and doctors' offices and drugstores;</p> <p>2 and for your company, mainly in the Ohio area,</p> <p>3 correct?</p> <p>4 MR. RICARD: Objection to form.</p> <p>5 A. We distribute in a number of states.</p> <p>6 Q. Sure.</p> <p>7 A. Okay. But, yes, in general, yes, that's</p> <p>8 correct.</p> <p>9 Q. And we'll get into actually where and</p> <p>10 all that detail down the road.</p> <p>11 A. Okay.</p> <p>12 Q. So, Mr. Schoen, what we're going to do</p> <p>13 is mark next as Plaintiff's Exhibit 6 part of the</p> <p>14 Code of Federal Regulations.</p> <p>15 MR. RICARD: Same objection to legal</p> <p>16 conclusions, Mike.</p> <p>17 MR. FULLER: Sure.</p> <p>18 - - -</p> <p>19 (PSI-Schoen Exhibit 6 marked.)</p> <p>20 - - -</p> <p>21 BY MR. FULLER:</p> <p>22 Q. It's 21 C.F.R. 1301.74.</p> <p>23 Do you see that, Mr. Schoen?</p> <p>24 A. I see it.</p>	<p style="text-align: right;">Page 41</p> <p>1 A. Yes.</p> <p>2 Q. Where it says, "The registrant shall</p> <p>3 design and operate a system to disclose to the</p> <p>4 registrant suspicious orders of controlled</p> <p>5 substances. The registrant shall inform the Field</p> <p>6 Division Office of the Administration in his area</p> <p>7 of suspicious orders when discovered by the</p> <p>8 registrant. Suspicious orders include orders of</p> <p>9 unusual size, orders deviating substantially from</p> <p>10 a normal pattern, and orders of unusual</p> <p>11 frequency."</p> <p>12 You are familiar with this regulation as</p> <p>13 it pertains to suspicious orders, correct?</p> <p>14 A. Yes.</p> <p>15 Q. And PSI is aware that it has to comply</p> <p>16 with this regulation as it relates to suspicious</p> <p>17 orders?</p> <p>18 A. Yes.</p> <p>19 Q. When we say "suspicious orders," it's</p> <p>20 PSI's understanding that we're talking about</p> <p>21 orders that may be suspicious for potential</p> <p>22 diversion, correct?</p> <p>23 MR. RICARD: Objection to form.</p> <p>24 A. Yes. It may be, yes.</p>

<p style="text-align: right;">Page 42</p> <p>1 Q. And it's not that PSI has to know for                  2 sure they're being diverted. You just have to                  3 have a suspicion, correct?                  4 MR. RICARD: Objection to form.                  5 A. I would guess that's true, yeah.                  6 Q. Well --                  7 A. I mean, we -- you know, we -- go ahead.                  8 Q. Sure. And I don't want you to guess,                  9 okay? That's what I don't want you to do here                  10 today. I want to know what you know. And if you                  11 don't know, I want you to tell us that, okay?                  12 When we're talking about suspicious                  13 orders, we have to know -- as a registrant, as                  14 PSI, we have to know suspicious of what, correct?                  15 A. Correct.                  16 Q. And we know it's suspicious of diversion                  17 or illicit activity, correct?                  18 A. Yes.                  19 MR. RICARD: Objection to form.                  20 Q. And we know as PSI that the DEA has told                  21 us that we can look for orders of unusual size,                  22 orders deviating substantially from a normal                  23 pattern, and orders of unusual frequency as some                  24 of the factors to look to, correct?</p>	<p style="text-align: right;">Page 44</p> <p>1 doctor or somebody else in the distribution chain                  2 needs to be shut down, right?                  3 MR. RICARD: Objection to form.                  4 A. Yes.                  5 Q. And unless we're telling them and                  6 providing them that information as a registrant,                  7 it makes it much harder on them to do their jobs,                  8 correct?                  9 A. Yes.                  10 Q. So one of the ways that we're trying to                  11 keep our -- again, our communities and our                  12 children safe is by putting upon the registrant,                  13 such as PSI, the obligation to report suspicious                  14 orders --                  15 MR. RICARD: Objection to form.                  16 Q. -- correct?                  17 A. Yes.                  18 Q. Okay. Now, we're going to talk about it                  19 in more detail later, but you're aware that there                  20 is a know your customer requirement, due diligence                  21 that has to be done, when you're dealing with                  22 suspicious orders and controlled substances as                  23 well, correct?                  24 A. Yes.</p>
<p style="text-align: right;">Page 43</p> <p>1 MR. RICARD: Objection to form.                  2 A. Yes.                  3 Q. And, again, when we're talking about                  4 suspicious, it's suspicious of diversion or some                  5 sort of illicit activity because that is what                  6 you're trying to prevent as a wholesale                  7 distributor?                  8 MR. RICARD: Same objection.                  9 A. Yes.                  10 Q. Okay. Now, let's go back to that part                  11 where we had that little hiccup a moment ago.                  12 There's nothing in this regulation that                  13 says PSI has to determine that they're actually                  14 being diverted, does it?                  15 A. No.                  16 Q. It's the mere suspicion of diversion                  17 that should be reported, correct?                  18 MR. RICARD: Objection to form.                  19 A. Yes.                  20 Q. And there's a reason for that, right?                  21 And the reason is because we want to get those                  22 involved, the DEA, if there's even the potential                  23 for diversion so that they can do their                  24 investigation to determine whether a pharmacy or a</p>	<p style="text-align: right;">Page 45</p> <p>1 Q. And you may find this interesting. So I                  2 will fully admit I'm a little bit of a book nerd,                  3 okay? And if you -- in studying history in                  4 college, if you look back -- well, strike that.                  5 Let me start with another premise.                  6 You would agree that we are in the                  7 middle of an opioid epidemic in this country,                  8 correct?                  9 A. Yes.                  10 Q. Okay. And if you go back and look                  11 through history, it's not the first time that                  12 we've had opioid issues in this world. If you                  13 think back, back at the late 18th century, early                  14 19th, you had the opium wars going on --                  15 A. Yes.                  16 Q. -- on the other side of the world.                  17 A. In China, yes.                  18 Q. And then I don't know if you're familiar                  19 with the Harrison Act that was passed in the early                  20 1900s.                  21 A. I'm not.                  22 Q. So I went and pulled the Congressional                  23 Record from the Harrison Act, and this is going to                  24 be -- let me grab it. And I told you I'm a little</p>

<p style="text-align: right;">Page 46</p> <p>1 bit of a book nerd. I really mean I'm a little  2 bit of a book nerd.  3       So -- and tell me -- and, again, not to  4 pick on you at all, but have you ever heard that  5 history tends to repeat itself?  6     A. Yes.  7     Q. And if we look back through time, it  8 seems to be true, doesn't it?  9     A. Yes.  10    Q. Now, the Harrison Act, that was  11 legislation that was passed back in the early  12 1900s, and this is a legislative history and  13 another tidbit -- I'm not really going to go into  14 with you, but Donald McKesson actually spoke at  15 this legislative hearing.  16       Do you know who Donald McKesson is?  17     A. I certainly know what McKesson is, yes.  18     Q. He is one of the founders of that  19 company that now exists still today.  20     A. Yes.  21     Q. The Harrison Act was being considered  22 back during the early 1900s because we were having  23 a problem with opium dens in the United States,  24 and there wasn't a way to control it. And the</p>	<p style="text-align: right;">Page 48</p> <p>1 says, "I would like to point out, as is shown by  2 my report, that this country -- that in this  3 country, we are importing over 400,000 pounds of  4 opium and using it. Over 75 percent of that  5 opium, gentlemen, is manufactured into morphine."  6       And, Mr. Schoen, you know what morphine  7 is, correct?  8     A. I do.  9     Q. And it's another type of pain  10 medication?  11     A. Yes.  12     Q. Okay. "And I have reliable information  13 that 75 percent to 90 percent of that morphine is  14 used outside of legitimate medical channels,"  15 which would be the equivalent to our illicit  16 market today, correct?  17       MR. RICARD: Objection to form.  18     A. Apparently, yes.  19     Q. And in the next section, "In Germany, as  20 I have pointed out in my report, with a population  21 nearly equal to that of the United States, they  22 have a net consumption of 16,000 pounds of opium  23 against 400,000 pounds in this country."  24       Seems shocking, doesn't it, Mr. Schoen?</p>
<p style="text-align: right;">Page 47</p> <p>1 Harrison Act is actually a tax-based act, because  2 way back then, the great U.S. Congress didn't have  3 the expansive powers of the commerce clause to do  4 anything they wanted to. They could only do  5 things they were specifically given power, and one  6 was tax. So this is the Congressional history  7 related to that.  8       ---  9       (PSI-Schoen Exhibit 7 marked.)  10       ---  11     Q. And we're just going to touch on a  12 couple sections. Page 25 -- and before I actually  13 start reading that with you, Mr. Schoen, are you  14 aware that the U.S. uses over 95 percent of the  15 opium produced in the entire world?  16     A. No, I'm not aware of that.  17     Q. Okay. Would it surprise you to know  18 that the U.S. uses over 95 percent of the opium  19 produced in the entire world?  20     A. It does surprise me that 95 percent,  21 yes.  22     Q. And, remember, history repeats itself.  23 So let's take a look. And this is a Mr. Wright  24 speaking to our United States Congress. And he</p>	<p style="text-align: right;">Page 49</p> <p>1     A. Yes. I mean, it's --  2     Q. Now, let's go to page 29. And many of  3 these people speaking during this Congressional  4 hearing, Mr. Schoen, were members of the industry,  5 for example, Mr. McKesson.  6       And here on 29, again, the highlighted  7 area, it says, "Gentlemen, it is the manufacturers  8 and wholesalers, the people higher up, that sell  9 these drugs promiscuously that we want to reach  10 and must reach if we ever hope to break up this  11 traffic. Scotch the snake at its lair."  12       Have you ever heard that saying before,  13 "Scotch the snake at its lair"?  14     A. Never.  15     Q. I looked it up. It's a quote from  16 Macbeth. It means go to the home of the snake and  17 kill it. Okay?  18       Now, here it's talking about  19 manufacturers and wholesalers selling drugs  20 promiscuously. And you have an understanding of  21 what that means, correct?  22     A. Outside the appropriate channels, I  23 think.  24     Q. Sure. And you are aware that -- I'm</p>

<p style="text-align: right;">Page 50</p> <p>1 going to exclude PSI from this.</p> <p>2 You are aware that other distributors</p> <p>3 have sold drugs outside of the legitimate</p> <p>4 channels --</p> <p>5 MR. RICARD: Objection to form.</p> <p>6 Q. -- correct?</p> <p>7 A. I really -- I really don't know that</p> <p>8 they have, no. I mean, it's just because I don't</p> <p>9 know.</p> <p>10 Q. Sure. I will tell you with the second</p> <p>11 memorandum of agreements that both McKesson and</p> <p>12 Cardinal entered with the United States</p> <p>13 government, that they admitted to breaking the</p> <p>14 law.</p> <p>15 MR. RICARD: Objection to form.</p> <p>16 Objection to scope.</p> <p>17 Q. If that is the case, then you could</p> <p>18 agree then that others have acted promiscuously in</p> <p>19 this industry, correct?</p> <p>20 MR. RICARD: Same objection.</p> <p>21 A. Apparently, yes.</p> <p>22 Q. Let's go on. "The poor unfortunate</p> <p>23 'dope fiend' is more sinned against than sinning.</p> <p>24 Had the law provided sufficient safeguards around</p>	<p style="text-align: right;">Page 52</p> <p>1 Q. And this is way back from 1910. It's</p> <p>2 pretty impressive how history repeats itself,</p> <p>3 isn't it?</p> <p>4 A. Yes.</p> <p>5 Q. It goes on to say, "Since he won't do it</p> <p>6 on moral grounds, it becomes the duty of the</p> <p>7 government to compel him to do it by law."</p> <p>8 Do you see that?</p> <p>9 A. I see that.</p> <p>10 Q. And it's the same thing with the</p> <p>11 enactment of the Controlled Substances Act, right?</p> <p>12 MR. RICARD: Objection to form.</p> <p>13 Q. We needed governmental safeguards out</p> <p>14 there to ensure that the people in the supply</p> <p>15 chain were doing the right thing, correct?</p> <p>16 A. Yes.</p> <p>17 Q. The next section reads, "Throw on the</p> <p>18 limelight of publicity such as this act provides.</p> <p>19 Make every man that handles these drugs</p> <p>20 responsible for his actions so that we have a</p> <p>21 record of the transactions from the time of</p> <p>22 manufacture until it reaches the consumer."</p> <p>23 And, again, that is why the Controlled</p> <p>24 Substances Act is created, correct?</p>
<p style="text-align: right;">Page 51</p> <p>1 the sale and distribution of these drugs, he would</p> <p>2 never have acquired such a habit."</p> <p>3 Do you see that there, Mr. Schoen?</p> <p>4 A. I see it.</p> <p>5 Q. And does PSI agree that the system as</p> <p>6 set up with the Controlled Substances Act is</p> <p>7 designed with safeguards to protect people from</p> <p>8 becoming addicts, or at least to try to?</p> <p>9 A. Yes.</p> <p>10 Q. And that's part of the purpose behind</p> <p>11 it, correct?</p> <p>12 A. Yes.</p> <p>13 Q. It says, "Had the manufacturers who sell</p> <p>14 these drugs any conscious, he would make his</p> <p>15 business to know who to he sold them in unusual</p> <p>16 quantities."</p> <p>17 Now, think about that for one second,</p> <p>18 and let me ask you, does that sound like the know</p> <p>19 your customer requirement?</p> <p>20 A. Yes.</p> <p>21 MR. RICARD: Objection to form.</p> <p>22 Q. You have to know who you're selling to</p> <p>23 before you just selling to them?</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 53</p> <p>1 A. That's their attempt, yes.</p> <p>2 Q. And even in 1910, it's sort of crazy how</p> <p>3 people saw that being part of the solution on how</p> <p>4 to get control of these controlled substances,</p> <p>5 correct?</p> <p>6 A. Yes.</p> <p>7 Q. And PSI recognizes that if we don't have</p> <p>8 these safeguards, these what we call them safety</p> <p>9 rules, that it becomes dangerous for the American</p> <p>10 public?</p> <p>11 A. Yeah.</p> <p>12 MR. RICARD: Objection to form.</p> <p>13 Q. Now, as an operator and, again, one who</p> <p>14 is a registrant, you have a special</p> <p>15 responsibility, do you not, when you're dealing</p> <p>16 with controlled substances?</p> <p>17 A. Yes.</p> <p>18 Q. And that responsibility is to act in a</p> <p>19 manner which tries to make the safest decisions</p> <p>20 for the American public, correct?</p> <p>21 MR. RICARD: Objection to form.</p> <p>22 A. Yes.</p> <p>23 Q. And that includes complying with these</p> <p>24 safety rules that we've already been discussing?</p>

Page 54

1 A. Yes.

2 MR. FULLER: Okay. And then next is

3 Exhibit 8, which, Gina, is 108 -- or, no, it's

4 not.

5 MS. VELDMAN: It's good. I've got it.

6 MR. RICARD: Same objection on legal

7 conclusions, Mike.

8 MR. FULLER: Sure.

9 Gina, it's 106.

10 ---

11 (PSI-Schoen Exhibit 8 marked.)

12 ---

13 BY MR. FULLER:

14 Q. Now, Mr. Schoen, I know you are not a

15 lawyer.

16 A. Correct.

17 Q. I completely understand that. So I'm

18 going to make this brief.

19 Now, I believe you probably have been

20 given a copy of this case, am I correct, Masters

21 Pharmaceutical?

22 A. I've seen a copy of it. I haven't read

23 it. Yes.

24 Q. Well, where did you get your copy?

Page 55

1 These guys?

2 A. Yes.

3 Q. Okay. Now, I would assume that that may

4 have been more recently when you were getting

5 ready for this deposition, correct?

6 A. Correct.

7 Q. Okay. Now, this decision came out in

8 June of last year. Were you made aware -- did

9 anybody talk to you about the ramifications of

10 this case back in June of last year when the

11 opinion was rendered by the DC Circuit Court of

12 Appeals?

13 A. No.

14 Q. And before -- well, up until the point

15 where you were preparing for your deposition, had

16 you ever heard of this case or its implications?

17 A. No. I'd heard -- I heard Masters got in

18 trouble, but that's it.

19 Q. Well, they did. Whoever told you that

20 was right. They got in trouble.

21 Let me ask you -- and I'll ask you to

22 turn to page 7. Now, you can either turn or look

23 at the electronic copy, because the print on that

24 printout is small as well.

Page 56

1 MR. FULLER: And, Gina, if you'll

2 highlight or enlarge that highlighted section for

3 me.

4 BY MR. FULLER:

5 Q. Now, do you see that there? This is

6 just a portion of the opinion that I'm just going

7 to focus on for a brief moment, okay, Mr. Schoen?

8 And it talks about -- you see "The security

9 requirement" in quotes there?

10 A. Yes.

11 Q. Now, that has significance, because if

12 we go back to the earlier exhibit that was 21

13 C.F.R. 1301.74, that suspicious order regulation,

14 it was entitled the security requirements section,

15 wasn't it?

16 MR. RICARD: Objection to form.

17 A. Yes.

18 Q. Okay. It says -- and this opinion

19 reads, "The security requirement at the heart of

20 the case mandates that distributors design and

21 operate a system to identify suspicious orders of

22 controlled substances and report those orders to

23 the DEA." And then in parentheses, it has "the

24 Reporting Requirement."

Page 57

1 Have you ever heard, Mr. Schoen, of "the

2 Reporting Requirement"?

3 A. Yes.

4 Q. Okay. And that was that regulation we

5 looked at earlier, correct?

6 A. Correct.

7 Q. And PSI agrees that it has had a

8 reporting requirement since that regulation was

9 enacted in 1971, correct?

10 MR. RICARD: Objection to form.

11 A. Yes.

12 Q. And that reporting requirement by law

13 requires PSI or any distributor to report

14 suspicious orders that it receives to the DEA,

15 correct?

16 MR. RICARD: Objection to form.

17 A. Yes.

18 Q. And that if it doesn't report suspicious

19 orders to the DEA, then that distributor is

20 breaking the law, correct?

21 A. Yes.

22 MR. RICARD: Objection to form.

23 Q. Okay. Now, it goes on to say that "The

24 reporting requirement is a relatively modest one.

<p style="text-align: right;">Page 58</p> <p>1 It requires only that a distributor provide basic  2 information about certain orders to DEA so that  3 DEA investigators in the field can aggregate  4 reports from every point along the legally  5 regulated supply chain and use the information to  6 ferret out potential illegal activity."  7 Did I read that correctly?  8 A. I wasn't following it, but I'm sure you  9 have, yes.  10 Q. You're too trusting, Mr. Schoen. I'm  11 kidding.  12 What I read to you exemplifies what we  13 talked about earlier; does it not?  14 A. Yes.  15 Q. And that the design of the system is  16 such that distributors have to provide information  17 to the DEA for the DEA to be able to do their job  18 effectively to prevent diversion?  19 MR. RICARD: Objection to form.  20 A. Yes.  21 Q. And PSI agrees with that, understands  22 that, and lives up to that obligation, correct?  23 MR. RICARD: Objection to form.  24 A. Yes.</p>	<p style="text-align: right;">Page 60</p> <p>1 MR. RICARD: Objection to form.  2 A. Yes.  3 Q. Okay. Now, let's talk about it and why  4 that makes sense, okay?  5 If you get a suspicious order -- strike  6 that.  7 Not you. Somebody at your business. If  8 PSI gets a suspicious order, we understand that  9 that means it's suspicious for potential  10 diversion, correct?  11 A. There's something about it brought our  12 attention to it, yes.  13 Q. And something is wrong with it, correct?  14 A. Potentially, yes.  15 Q. We don't want to then -- if we think  16 there's a potential of it being diverted, we don't  17 want to send that order off, do we?  18 A. No.  19 Q. Because --  20 A. If we think it's going to be diverted,  21 we won't send it off.  22 Q. And that's because that's part of your  23 obligation under the regulations, to maintain an  24 effective system to prevent diversion, correct?</p>
<p style="text-align: right;">Page 59</p> <p>1 Q. Okay. Next it goes on -- it says, "Once  2 a distributor has reported a suspicious order, it  3 must make one of two choices: Decline to ship the  4 order or conduct due diligence."  5 Do you see that there?  6 A. I see it.  7 Q. This is ultimately referred to as "the  8 shipping requirement."  9 Have you ever heard of that term?  10 A. I've heard the term.  11 Q. What is your understanding of the  12 shipping requirement? And, quite honestly, it  13 shouldn't be the shipping requirement. It should  14 be the anti-shipping requirement, right?  15 A. That's correct.  16 Q. Okay. And is it your understanding that  17 the shipping requirement means that if we have a  18 suspicious order, we need not to ship it?  19 MR. RICARD: Objection to form.  20 A. Yes.  21 Q. And that that has been the obligation  22 not just upon PSI but upon all distributors, to  23 your understanding, since 1971 when this  24 regulation was passed?</p>	<p style="text-align: right;">Page 61</p> <p>1 A. Yes.  2 Q. Okay. All right. We're done with that.  3 No more legal cases. I can't say that for sure.  4 There may be another one, now that I think about  5 it.  6 All right.  7 MR. RICARD: Are you doing okay?  8 THE WITNESS: Fine.  9 MR. FULLER: Okay. This is going to be  10 112, Gina.  11 ---  12 (PSI-Schoen Exhibit 9 marked.)  13 ---  14 BY MR. FULLER:  15 Q. So what I'm going to pass you next is  16 Plaintiff's Exhibit Number 9, and I'll explain it  17 to you first, Mr. Schoen. It is a State of Ohio  18 Administrative Code 202 -- or 2002. And I'll  19 represent to you that it is the current code. As  20 you can see from the bottom of the enlarged area,  21 current through December 31, 2002.  22 Do you see that there?  23 A. I see it.  24 Q. Okay.</p>

<p style="text-align: right;">Page 62</p> <p>1 MR. RICARD: Real quick, same objection</p> <p>2 as to legal conclusion.</p> <p>3 MR. FULLER: Absolutely.</p> <p>4 BY MR. FULLER:</p> <p>5 Q. And it's Ohio Administrative Code</p> <p>6 Section 4729-9-16.</p> <p>7 Have you ever seen this before,</p> <p>8 Mr. Schoen?</p> <p>9 A. Not that I recall.</p> <p>10 Q. Okay. Fair enough that you may have</p> <p>11 seen it; you just don't recall it?</p> <p>12 A. That's true.</p> <p>13 Q. Okay. And it says it's Baldwin's Ohio</p> <p>14 Administrative Code, Board of Pharmacy, relating</p> <p>15 to dangerous drugs.</p> <p>16 Do you see that there?</p> <p>17 A. Okay. Yes.</p> <p>18 Q. And I'm not going to do much with this.</p> <p>19 I just wanted to get your attention to --</p> <p>20 MR. FULLER: Gina, I think it's page 6.</p> <p>21 A. Page 6?</p> <p>22 MR. RICARD: We only have four pages.</p> <p>23 MS. VELDMAN: I don't have a page 6.</p> <p>24 MR. FULLER: It's actually page 6.</p>	<p style="text-align: right;">Page 64</p> <p>1 controlled substances and other dangerous drugs</p> <p>2 subject to abuse."</p> <p>3 And Section i says that -- did we lock</p> <p>4 someone out of this room?</p> <p>5 MR. PELINI: Locked the old man out.</p> <p>6 MR. FULLER: Dude, you can't take a</p> <p>7 hint?</p> <p>8 MR. PELINI: I can now.</p> <p>9 MR. FULLER: You leave again, we're not</p> <p>10 letting you back in.</p> <p>11 MR. PELINI: I understand.</p> <p>12 MR. FULLER: That bladder, huh?</p> <p>13 Kidding.</p> <p>14 BY MR. FULLER:</p> <p>15 Q. It says under Section i, "The wholesaler</p> <p>16 shall inform the State Board of Pharmacy of</p> <p>17 suspicious orders for drugs when discovered.</p> <p>18 Suspicious orders are those which, in relation to</p> <p>19 the wholesaler's record as a whole, are of unusual</p> <p>20 size, unusual frequency, or deviates substantially</p> <p>21 from established buying patterns."</p> <p>22 Correct?</p> <p>23 MR. RICARD: Objection to form.</p> <p>24 Objection to scope.</p>
<p style="text-align: right;">Page 63</p> <p>1 Do you not have a page 6?</p> <p>2 MR. RICARD: It has four pages.</p> <p>3 MR. FULLER: Hold on. Maybe I've got</p> <p>4 the wrong one.</p> <p>5 BY MR. FULLER:</p> <p>6 Q. Mr. Schoen, that's what happens when you</p> <p>7 don't copy stuff yourself.</p> <p>8 A. That happens.</p> <p>9 Q. See, you know. You've been there, huh?</p> <p>10 MR. RICARD: Could I look at that real</p> <p>11 quick?</p> <p>12 MR. FULLER: Yeah. It's just the State</p> <p>13 code on suspicious orders.</p> <p>14 Will it focus?</p> <p>15 BY MR. FULLER:</p> <p>16 Q. Okay. Not that that is real clear --</p> <p>17 and I apologize for that, Mr. Schoen, but I'm</p> <p>18 going to read it to you this time. And this deals</p> <p>19 with the Ohio State Board of Pharmacy Code.</p> <p>20 You're aware there is a Board of Pharmacy Code,</p> <p>21 correct?</p> <p>22 A. Yes.</p> <p>23 Q. Okay. And this says, "A system shall be</p> <p>24 designed and operate to disclose orders for</p>	<p style="text-align: right;">Page 65</p> <p>1 A. Yes.</p> <p>2 Q. Okay. And PSI as a distributor here in</p> <p>3 Ohio has to comply with that regulation as well?</p> <p>4 MR. RICARD: Same objections.</p> <p>5 A. Yes.</p> <p>6 Q. Okay. So let's take a minute and recap</p> <p>7 what we just went over, okay, so I can make sure</p> <p>8 it's clear and that you and I are on the same</p> <p>9 page.</p> <p>10 Prescription Supply, Inc., agrees that</p> <p>11 it must comply with the Controlled Substances Act</p> <p>12 as enacted in 1970 by the U.S. Congress, correct?</p> <p>13 A. Yes.</p> <p>14 Q. Prescription Supply also agrees that as</p> <p>15 a licensed entity to distribute controlled</p> <p>16 substances, it has an obligation to try to make</p> <p>17 the safest choices to keep our children and</p> <p>18 communities safe related to those drugs?</p> <p>19 A. Yes.</p> <p>20 MR. RICARD: Objection to form.</p> <p>21 Q. Prescription Supply agrees and accepts</p> <p>22 that from 1971 forward, that there is a suspicious</p> <p>23 order reporting requirement requiring</p> <p>24 suspicious -- or excuse me -- requiring</p>

<p style="text-align: right;">Page 66</p> <p>1 Prescription Supply to report any suspicious 2 orders that it receives from any of its potential 3 customers? 4 MR. RICARD: Objection to form. 5 A. Yes. 6 Q. And that the reason and basis for 7 reporting suspicious orders is to enable the DEA 8 to do its job in enforcement of the law in 9 preventing diversion? 10 A. Yes. 11 Q. That Prescription Supply also agrees and 12 accepts that since 1971, there has been a shipping 13 requirement, meaning that it cannot ship orders 14 that are in any way suspicious? 15 MR. RICARD: Objection to form. 16 A. Yes. 17 Q. And that the reason we don't ship 18 suspicious orders is because we don't want to 19 contribute to potential diversion of controlled 20 substances? 21 A. Yes. 22 Q. And that, as we've seen through history, 23 Congress not just once, but now twice, has put 24 into place a regulatory scheme, we'll call them</p>	<p style="text-align: right;">Page 68</p> <p>1 customers because they look sketchy, correct? 2 A. That's correct. 3 Q. Because of one factor or another. Maybe 4 they were off in a far different state. Maybe 5 there were other indicators. But Prescription 6 Supply has declined to do business with people who 7 it felt may be involved in some sort of diversion? 8 A. Many. 9 Q. Making those type of choices has a 10 financial impact on the company's operation; does 11 it not? 12 A. It does. 13 Q. It can actually hamper a company's 14 operations financially, correct? 15 A. Yes. So can not making those choices. 16 Q. Absolutely. But Prescription Supply 17 would agree that a less safe choice should not be 18 made just for financial gain? 19 A. Yes. 20 Q. The financial gain should not weigh in 21 when trying to decide whether to report a 22 suspicious order or to halt orders? 23 A. Yes. 24 Q. And that if it does, it's not good for</p>
<p style="text-align: right;">Page 67</p> <p>1 safety rules, to try to keep the communities, our 2 children, safe from these dangerous drugs? 3 MR. RICARD: Objection to form. 4 Objection to scope. 5 A. Yes. 6 Q. And that as a link in the chain of 7 distribution, wholesalers have an obligation to 8 make the safest choices when distributing these 9 dangerous drugs to protect our children and our 10 families and our communities? 11 MR. RICARD: Objection to form. 12 A. Yes. 13 Q. And Prescription Supply, Inc., would 14 agree that in distributing these controlled 15 substances, every distributor needs to comply with 16 the public safety rules and make the safest 17 choices related to the distribution of these 18 controlled substances? 19 MR. RICARD: Objection to form. 20 A. Yes. 21 Q. Now -- and I'll be upfront. I've seen 22 it in the documents that have been provided by 23 your counsel that Prescription Supply has on 24 occasion declined to do business with potential</p>	<p style="text-align: right;">Page 69</p> <p>1 the American public? 2 A. Yes. 3 MR. FULLER: Okay. Guys, we've been 4 going a little over an hour. Do you want to take 5 a break? 6 MR. RICARD: Sure. 7 THE VIDEOGRAPHER: The time is now 8 10:13. Going off the record. 9 (Recess taken.) 10 THE VIDEOGRAPHER: The time is now 11 10:27. Back on the record. 12 BY MR. FULLER: 13 Q. And, Mr. Schoen, I'm sorry because I 14 didn't tell you this at the beginning. If you 15 need a break at any time for anything, use the 16 restroom, take a phone call, whatever it may be, 17 just let us know. This isn't meant to be 18 unbearable, uncomfortable. I know it's not 19 necessarily pleasurable being here. 20 A. It's not meant to be, yes. 21 Q. But we'll try to do everything we can, 22 including keeping you with some Diet Coke, if 23 necessary. 24 A. Thank you.</p>

<p style="text-align: right;">Page 70</p> <p>1 Q. Now, you put cream in tea?</p> <p>2 A. I'd rather put milk in it, but -- that's</p> <p>3 the way I was brought up. You know, it's a</p> <p>4 very --</p> <p>5 Q. English thing?</p> <p>6 A. Yes.</p> <p>7 Q. I was going to say.</p> <p>8 A. My mother-in-law, who has passed away,</p> <p>9 was a war bride.</p> <p>10 Q. Oh, really?</p> <p>11 A. And she -- but she was there during the</p> <p>12 war, and during the depression, which didn't hit</p> <p>13 England as hard.</p> <p>14 Q. Sure.</p> <p>15 A. So she never used milk in her tea.</p> <p>16 Q. No?</p> <p>17 A. She never used it in her tea because</p> <p>18 they couldn't afford it.</p> <p>19 Q. Not because she didn't want it?</p> <p>20 A. It's the world, you know.</p> <p>21 Q. Not because she didn't want it?</p> <p>22 A. Well, perhaps. What she doesn't know --</p> <p>23 what she didn't know, she didn't --</p> <p>24 Q. You don't miss, right?</p>	<p style="text-align: right;">Page 72</p> <p>1 Q. But 120 people a day?</p> <p>2 A. It was shocking to me that Limbaugh got</p> <p>3 hooked on it.</p> <p>4 Q. And let me ask, unlike a lot of the</p> <p>5 other Defendants here, you've been in the industry</p> <p>6 personally yourself for a very long time. Did you</p> <p>7 ever think you would see an epidemic develop like</p> <p>8 has developed in this country?</p> <p>9 A. There -- I was in college just before</p> <p>10 the -- I'm going to say the drug revolution at</p> <p>11 least hit in my area. I wasn't -- I graduated</p> <p>12 St. Thomas in Saint Paul, Minnesota.</p> <p>13 Q. Yes, sir.</p> <p>14 A. We didn't know about -- I mean, we knew</p> <p>15 marijuana, but we didn't use it. I never knew</p> <p>16 anybody that used it. We knew that at the</p> <p>17 university, some people were experimenting with</p> <p>18 LSD, but I didn't know anybody personally.</p> <p>19 I went into the Army, came back, went</p> <p>20 into graduate school. I graduated in '67, went in</p> <p>21 the Army '68, '69, came back, went to graduate</p> <p>22 school, and the world was a different place.</p> <p>23 And to that extent, I'm not surprised</p> <p>24 that addiction is a problem in this country. And</p>
<p style="text-align: right;">Page 71</p> <p>1 A. That's right.</p> <p>2 Q. What I always tell everybody, growing up</p> <p>3 we didn't have air-conditioning until I was in</p> <p>4 high school, which wasn't necessarily back in the</p> <p>5 depression. I mean, this is in the --</p> <p>6 A. Where were you --</p> <p>7 Q. I was born and raised in Plant City,</p> <p>8 Florida. It's a strawberry farming town outside</p> <p>9 of Tampa.</p> <p>10 MS. QUEZON: You need air conditioning.</p> <p>11 Q. So it's the south.</p> <p>12 All right. And, Mr. Schoen,</p> <p>13 Prescription Supply, Inc., does recognize that we</p> <p>14 are currently in an opioid crisis, correct?</p> <p>15 A. Yes.</p> <p>16 Q. And that currently -- I think the last</p> <p>17 number was somewhere around 120 people are dying</p> <p>18 of prescription-related overdoses every day in</p> <p>19 this country?</p> <p>20 A. I wasn't aware of that, but I'll accept</p> <p>21 it.</p> <p>22 Q. Assuming that that figure is correct, is</p> <p>23 that shocking to you?</p> <p>24 A. Certainly anybody dying is shocking.</p>	<p style="text-align: right;">Page 73</p> <p>1 people that claim that marijuana is not a problem</p> <p>2 are wrong as far as I'm concerned.</p> <p>3 Q. Well, I appreciate that. I do. Now</p> <p>4 we're facing an opioid epidemic on top of</p> <p>5 everything else, which Prescription Supply</p> <p>6 recognizes, correct?</p> <p>7 A. I do.</p> <p>8 Q. And we're going to talk a little bit now</p> <p>9 about that crisis and how long it's been going and</p> <p>10 developing.</p> <p>11 MR. FULLER: Hey, AJ, give me 201.</p> <p>12 Thanks.</p> <p>13 - - -</p> <p>14 (PSI-Schoen Exhibit 10 marked.)</p> <p>15 - - -</p> <p>16 BY MR. FULLER:</p> <p>17 Q. Mr. Schoen, have you ever heard of the</p> <p>18 United States General Accounting Office or</p> <p>19 sometimes referred to as the GAO?</p> <p>20 A. Probably I've heard of it. I don't know</p> <p>21 anything about it.</p> <p>22 Q. So it is a federal body that does</p> <p>23 accountability, integrity, and reliability related</p> <p>24 to different issues going on in our country, as</p>

<p style="text-align: right;">Page 74</p> <p>1 well as within our federal government. So there  2 has been a GAO looking into the DEA. This one is  3 looking into, as you can see, prescription drugs.  4 And as you can see, it's entitled "United States  5 General Accounting Office, GAO Report to  6 Subcommittee on Oversight and Investigations,  7 Committee on Energy and Commerce, House of  8 Representatives."  9 And you understand that that is one of  10 the investigative bodies within our United States  11 House of Representatives, correct?  12 MR. RICARD: Objection to form.  13 Objection to scope.  14 A. I do.  15 Q. And that the title of this -- and it's  16 dated May of 2002. So we're going back about 16  17 years, correct --  18 A. Apparently.  19 Q. -- if I did my math right?  20 A. Yes.  21 Q. And it says, "Prescription Drugs, State  22 Monitoring Programs Provide Useful Tool to Reduce  23 Diversion."  24 And you know what state monitoring</p>	<p style="text-align: right;">Page 76</p> <p>1 substantial value on the black market?  2 MR. RICARD: Objection to form.  3 Objection to scope.  4 A. I do.  5 Q. And that's part of the problem, because  6 that incentivizes people to participate in the  7 illicit market when you're dealing with controlled  8 substances, correct?  9 A. Yes.  10 Q. And that takes us back to what we looked  11 at earlier on the Congressional history from 1970,  12 is we basically got to make sure the punishment or  13 potential punishment significantly outweighs  14 whatever potential gains are there in order for  15 the system to be effective, correct?  16 A. Yes.  17 Q. PSI recognizes that and suggests that  18 that's part of the way we can get control of this  19 epidemic, correct?  20 MR. RICARD: Objection to form.  21 A. Yes.  22 Q. They go on to state, "A single  23 40-milligram OxyContin tablet legally selling for  24 about \$4 is worth about \$40 on the illicit</p>
<p style="text-align: right;">Page 75</p> <p>1 programs are, correct?  2 A. I do.  3 Q. Okay. And if you turn -- and I'll tell  4 you, I didn't provide you the whole document, I  5 don't think. I think I just provided you the  6 relevant page. So if you'll turn to the second  7 page where it talks to the background, and it  8 says, "The diversion and abuse of prescription  9 drugs are associated with incalculable costs to  10 society in terms of addiction, overdose, death,  11 and related criminal activities."  12 Does Prescription Supply agree that  13 diversion -- it's foreseeable that diversion would  14 cause all those issues; addiction, overdose,  15 death, and criminal related activities?  16 MR. RICARD: Objection to form.  17 Objection to scope.  18 A. Yes.  19 Q. It goes on to say the "DEA has stated  20 that the diversion and abuse of legitimately  21 produced controlled pharmaceuticals constitutes a  22 multibillion-dollar illicit market nationwide."  23 Does Prescription Supply recognize that  24 the controlled substances that you deal in has a</p>	<p style="text-align: right;">Page 77</p> <p>1 market."  2 Does that coincide with what you've  3 heard as Prescription Supply, Inc.? Not to  4 suggest that you've been out buying pills  5 illegally.  6 A. Yes.  7 Q. Okay. Now, keep in mind -- and this is  8 in 2002. So we're going back well over a decade,  9 16 years.  10 MR. FULLER: 202. Well, I've got one  11 copy of 202. It's this whole folder. There we  12 go.  13 BY MR. FULLER:  14 Q. I put my sticker on my copy. I do that.  15 I get like -- multitasking, not my strong suit.  16 A. Which is why you let other people do  17 your copying.  18 Q. Yeah, and then see what happens.  19 ---  20 (PSI-Schoen Exhibit 11 marked.)  21 ---  22 Q. All right. This is going to be  23 Plaintiff's Exhibit Number 11. And we've seen  24 this once before, I think, Mr. Schoen. Do you see</p>

<p style="text-align: right;">Page 78</p> <p>1 this? And I'm holding it up. The HathiTrust?</p> <p>2 A. Yes.</p> <p>3 Q. You've probably never heard of it, have</p> <p>4 you?</p> <p>5 A. I have not, no.</p> <p>6 Q. It is a non-profit that collects -- and</p> <p>7 I didn't learn about it until this litigation --</p> <p>8 collects old documents or older documents. That's</p> <p>9 how I gained access to that 1910 Congressional</p> <p>10 Record, because otherwise you would have to go to</p> <p>11 the Congress archives in DC and try to dig it out.</p> <p>12 So a lot of this stuff, fortunately, is online</p> <p>13 now.</p> <p>14 So if you'll turn to page 2. This is</p> <p>15 another United States Congressional hearing. The</p> <p>16 title of it is, "OxyContin: Its Use and Abuse."</p> <p>17 Now, you are aware of what OxyContin is,</p> <p>18 correct, Mr. Schoen?</p> <p>19 A. I'm not a pharmacologist, but yes. I'm</p> <p>20 basically aware that it is a pain drug.</p> <p>21 Q. And you're aware that it's an</p> <p>22 opioid-based pain medication?</p> <p>23 A. I am aware.</p> <p>24 Q. And I'll tell you, if you're aware or</p>	<p style="text-align: right;">Page 80</p> <p>1 MR. RICARD: Objection to form.</p> <p>2 A. To be -- I mean, I've heard something</p> <p>3 about it. That's --</p> <p>4 Q. But you don't know the details?</p> <p>5 A. I certainly don't.</p> <p>6 Q. Fair enough. And, again, if you don't,</p> <p>7 just tell me that.</p> <p>8 A. Okay.</p> <p>9 Q. That is a legitimate answer as long as</p> <p>10 it's a truthful answer, okay?</p> <p>11 A. All right.</p> <p>12 Q. So this hearing is before the</p> <p>13 Subcommittee on Oversight and Investigations of</p> <p>14 the Committee on Energy and Commerce, House of</p> <p>15 Representatives, One Hundred Seventh Congress,</p> <p>16 first session, August 28, 2001.</p> <p>17 So here going back a year prior to the</p> <p>18 last document that we looked at, which was a GAO</p> <p>19 report, this is going back to 2001, and it's the</p> <p>20 abuse -- the use and abuse of OxyContin.</p> <p>21 And if you will turn to page 6. It</p> <p>22 says, "The use and abuse of OxyContin provides</p> <p>23 quite a dilemma for us in the U.S. Congress" --</p> <p>24 excuse me -- "for us in Congress and for the</p>
<p style="text-align: right;">Page 79</p> <p>1 not, that it was launched in approximately 1996.</p> <p>2 Does that seem to coincide with your</p> <p>3 recollection?</p> <p>4 A. Yes.</p> <p>5 Q. And are you aware that -- it was created</p> <p>6 by Purdue Pharma, which you know who they are,</p> <p>7 correct?</p> <p>8 A. (Indicates affirmatively.)</p> <p>9 MR. RICARD: You have to say yes or no.</p> <p>10 A. Yes. I'm sorry.</p> <p>11 Q. That's all right. Again, we get into</p> <p>12 that conversational tone and we forget sometimes.</p> <p>13 I apologize.</p> <p>14 Are you aware that the -- that multiple</p> <p>15 entities have been very critical of Purdue Pharma</p> <p>16 for the way it marketed OxyContin to doctors and</p> <p>17 patients?</p> <p>18 MR. RICARD: Objection to form.</p> <p>19 Q. And if you're not aware --</p> <p>20 A. I'm really -- in particular, no, I'm not</p> <p>21 aware of it.</p> <p>22 Q. Are you aware that they got in trouble</p> <p>23 with the DEA for the way they market their</p> <p>24 product?</p>	<p style="text-align: right;">Page 81</p> <p>1 American public. For some, OxyContin is the angel</p> <p>2 of mercy; and for others, it's the angel of</p> <p>3 death."</p> <p>4 Does Prescription Supply agree that if</p> <p>5 used appropriately, OxyContin has its place and</p> <p>6 can be a, for lack of a better analogy, angel of</p> <p>7 mercy; and if used illicitly, can also bring about</p> <p>8 death?</p> <p>9 MR. RICARD: Objection to form.</p> <p>10 A. Yes.</p> <p>11 Q. It says, "Today, we will hear from law</p> <p>12 enforcement officials who argue that OxyContin is</p> <p>13 quickly becoming the abuser's drug of choice,</p> <p>14 surpassing heroin and cocaine in some</p> <p>15 jurisdictions."</p> <p>16 Does Prescription Supply agree and</p> <p>17 recognize that as early as 2001, we were seeing</p> <p>18 the opioid epidemic blossom and bloom?</p> <p>19 A. To be honest, in 2001, I don't believe I</p> <p>20 was aware of that.</p> <p>21 Q. Whether you were --</p> <p>22 A. I'm aware of it now.</p> <p>23 Q. Sure. Let's go on, and then I'll ask</p> <p>24 the next question.</p>

<p style="text-align: right;">Page 82</p> <p>1 If you'll turn to page 8. It says,  2 "These actions, though commendable, also appear  3 long overdue. According to DEA, the number of  4 oxycodone-related deaths has increased 400 percent  5 since 1996, the same time period in which the  6 annual number of prescriptions for OxyContin has  7 risen from approximately 300,000 to almost  8 6 million."  9 We're looking at the time frame,  10 Mr. Schoen, of 1996 to 2001. Prescription Supply  11 would agree that that is an unusual increase in  12 the prescriptions for any drug going from 300,000  13 to 6 million?  14 MR. RICARD: Objection to form.  15 Q. Do you know how many times that is  16 increased --  17 A. No.  18 Q. -- or what percentage?  19 A. No.  20 Q. So I had to do the math on the  21 calculator.  22 A. Okay.  23 Q. That's a 2,000 percent increase in five  24 years.</p>	<p style="text-align: right;">Page 84</p> <p>1 ask you.  2 You're not saying that there weren't  3 other opioid-based pain medications, because we  4 know morphine --  5 A. Yes.  6 Q. -- was around?  7 A. Yes.  8 Q. We know Lortab was around. Vicodin was  9 around.  10 A. Yeah.  11 Q. Those are all other pain medications,  12 right?  13 A. Well, yeah, there are. When I think of  14 morphine, I think of even worse than, you know ...  15 Q. It would shock you that that's not the  16 case, huh?  17 A. I am shocked that that's not the case,  18 yes. I did not know that.  19 Q. So take that increase, that  20 2,000 percent increase --  21 A. Yes.  22 Q. -- in light of the earlier sentence, a  23 400 percent increase in oxycodone-related deaths  24 during the same time frame. That's not right, is</p>
<p style="text-align: right;">Page 83</p> <p>1 A. Mm-hmm.  2 Q. Does that cause you any concern as  3 someone in the industry knowing that this is a  4 Schedule II controlled substance?  5 A. It depends on what it's being used for,  6 doesn't it?  7 Q. Right.  8 A. When my wife broke her leg --  9 Q. Yes, sir.  10 A. -- okay, she got a prescription, okay,  11 and at that time I asked a nurse, who happened to  12 have been a neighbor of ours at one time, that was  13 there, "Why this? Why that drug?"  14 And she said, "Because there's nothing  15 else available," which could explain the rise in  16 this. I mean, it used to be when I was in the  17 Army and had my teeth pulled, they gave me Darvon  18 Compound or something.  19 Q. Sure.  20 A. And that's gone. A lot of the drugs  21 that were out there have disappeared, and that  22 would allow them to gain a certain market share.  23 I'm not defending. I'm just saying that that's --  24 Q. Sure. And you're not -- well, let me</p>	<p style="text-align: right;">Page 85</p> <p>1 it? People shouldn't be dying from prescription  2 medication, should they?  3 MR. RICARD: Objection to form.  4 A. No.  5 Q. Okay.  6 A. But people do die from taking  7 prescription medication. Very few hopefully.  8 Q. You wouldn't expect --  9 A. But I wouldn't expect 400 percent, no.  10 Q. Right. Now, if during this time frame  11 we are mismarketing medications, during this time  12 frame if we are -- and I say "we." People in the  13 supply chain -- and I'm not picking on PSI -- are  14 shipping and not reporting suspicious orders, this  15 type of thing could be a foreseeable outcome,  16 correct?  17 MR. RICARD: Objection to form.  18 A. Yes. But these are -- you're talking  19 about 6 million prescriptions.  20 Q. That's a lot.  21 A. That's a lot.  22 Q. I mean, particularly when five years ago  23 it was only 300,000 --  24 A. Correct.</p>

Page 86

1 Q. -- a 2,000 percent increase?

2 A. Mm-hmm.

3 Q. Now, I agree with you there's plenty of

4 blame to go around. Doctors had to write those

5 scripts, right?

6 A. That's right.

7 Q. But we know there's bad doctors out

8 there, too, don't we?

9 A. That's right.

10 Q. Now, we also are not -- as being a

11 member of the supply chain, Prescription Supply,

12 we're not going to condone any manufacturers who

13 may be mismarketing their drugs either?

14 A. No.

15 Q. That's absolutely inappropriate,

16 correct?

17 A. Correct.

18 Q. It's absolutely detrimental to the

19 American public, correct?

20 A. Yes.

21 Q. Without question?

22 A. Without question.

23 Q. We're not going to condone any other

24 wholesale distributors who may be shrugging their

Page 87

1 duties to report and stop suspicious orders

2 either, are we?

3 A. No.

4 Q. I'm not saying you or picking on anybody

5 else here, but if it's happening, Prescription

6 Supply isn't going to stand for it?

7 A. Prescription Supply isn't going to do it

8 for sure.

9 Q. For sure. And doesn't think anybody

10 else should be able to get away with it?

11 A. That's correct.

12 Q. Okay.

13 MR. FULLER: I need 206.

14 BY MR. FULLER:

15 Q. It's another big book, but at least my

16 boxes are going to be a lot lighter going home.

17 A. I'm happy for you and the airlines.

18 Q. And you don't have to take this with

19 you?

20 A. I'm happy for you and the airlines.

21 Q. All right. This is going to be

22 Plaintiff's Exhibit Number 12.

23 ---

24 (PSI-Schoen Exhibit 12 marked.)

Page 88

1 ---

2 Q. Now, Mr. Schoen, this is the National

3 Center On Addiction and Substance Abuse, Cornell

4 University. You know of Cornell University, heard

5 of it at least, correct?

6 A. Yes.

7 Q. A very prestigious entity -- university?

8 A. Yes.

9 Q. And it's funded by -- well, excuse me.

10 It's "Under the Counter: The Diversion and Abuse

11 of Controlled Prescription Drugs in the U.S.," and

12 it's dated -- what date do you see there,

13 Mr. Schoen?

14 A. July '05.

15 Q. So a couple years after those other

16 documents we looked at, right?

17 A. Correct.

18 Q. And it's funded by an unrestricted grant

19 from who?

20 A. From Purdue apparently.

21 Q. Purdue Pharma LP?

22 A. Okay.

23 Q. The maker of OxyContin, right?

24 A. Yes.

Page 89

1 Q. And there's only one area I want to

2 touch on. If you go to page 9, again, Bates

3 number in the upper right-hand corner.

4 A. It happens to agree with the lower page.

5 Okay.

6 Q. Sir?

7 A. It happens to agree with the lower.

8 Q. Oh, it does. You're right. You're

9 right.

10 It says, "The bottom line: Our nation

11 is in the throws of an epidemic of controlled

12 prescription drug abuse and addiction. Today

13 15.1 million people admit abusing prescription

14 drugs, more than the combined number who admit

15 abusing cocaine, hallucinogens, and heroin

16 combined." Oh, and inhalants as well.

17 Do you see that there?

18 A. I see it.

19 Q. And, again, you may not have ever been

20 provided this report or seen this report, but PSI

21 has no reason to disagree with this report that in

22 the early 2000s, we were in the throws of a

23 prescription drug abuse and addiction epidemic,

24 correct?

<p style="text-align: right;">Page 90</p> <p>1 MR. RICARD: Objection to form.  2 Objection to scope.  3 A. I assume that this is accurate then,  4 yes.  5 Q. And then here's what was most shocking  6 to me at least, and you tell me. "Children are  7 especially at risk."  8 Do you see that?  9 A. I see that.  10 Q. "In 2003" -- so about that time frame  11 you were just talking about -- "2.3 million teens  12 between the ages of 12 and 17 admit abusing  13 prescription drugs in the past year. 83 percent  14 of them admitted abusing opioids."  15 Now, understanding that that was going  16 on back 15 years ago, that causes Prescription  17 Supply great concern, doesn't it?  18 A. It does.  19 Q. Because these are our kids, right?  20 A. Right.  21 Q. These are part of the people that we  22 are -- and I say "we." Prescription Supply is  23 trying to keep safe by abiding by the Controlled  24 Substances Act?</p>	<p style="text-align: right;">Page 92</p> <p>1 Q. Prescription Supply also recognizes  2 that -- strike that.  3 So with that information that I showed  4 you provided by the GAO, the Congressional  5 hearings, and now Cornell University, while you  6 may not have known it at the time, Prescription  7 Supply agrees that the evidence indicates that we  8 were in an opioid epidemic even in the early  9 2000s?  10 MR. RICARD: Objection to form.  11 Objection to scope.  12 A. Yes, based on what you've shown me.  13 Q. And assuming that it's true?  14 A. Assuming.  15 Q. Because you haven't done anything to  16 independently verify this stuff?  17 A. I have not.  18 Q. All right. Mr. Schoen, we're going to  19 talk now a little bit about interaction and  20 communication with the DEA. So here's what my  21 hope is -- and counsel probably picked up on this  22 already.  23 We're flowing through a bunch of  24 different topics, subjects, most of which are set</p>
<p style="text-align: right;">Page 91</p> <p>1 A. Yes.  2 Q. We shouldn't have -- would Prescription  3 Supply agree that we shouldn't have 2.3 million  4 teens, kids between the ages of 12 and 17, abusing  5 opioids in this country?  6 A. Yes.  7 Q. And this would be an indication that we  8 are in an epidemic even in the early 2000s,  9 correct?  10 MR. RICARD: Objection to form.  11 A. Yes.  12 Q. Now, Prescription Supply is aware that  13 when you're talking about oxycodone or hydrocodone  14 or any of the other derivatives, you're dealing  15 with opioids, right?  16 A. Yes.  17 Q. Hydrocodone was -- I say recently.  18 What? 2014, I think rescheduled from a III to a  19 II?  20 A. Yes.  21 Q. That's because of the dangerous  22 propensities with that medication as well, right?  23 MR. RICARD: Objection to form.  24 A. Yes.</p>	<p style="text-align: right;">Page 93</p> <p>1 out in the 30(b) notices, the Exhibits 1 and 2  2 that we looked at earlier. Through the  3 progression through these subject areas, we're  4 going to cover -- at least my goal is -- most of  5 the subjects set out in the 30(b).  6 There may be some that we need to go  7 back and -- that I didn't ask about that we'll  8 clean up at the end, just to get the information  9 out, but I'm just trying to do this in sort of  10 organic conversation type instead of running  11 through one after the other, which, trust me,  12 would be even more boring than this already is for  13 you. Okay?  14 A. Yes.  15 Q. All right. Now, my understanding is  16 that -- strike that.  17 PSI has had interaction with the DEA in  18 the past, correct?  19 A. Yes.  20 Q. As of -- shoot. I think I saw a --  21 A. The DEA is a regulatory body --  22 MR. RICARD: There's no question  23 pending.  24 Q. If you want to go ahead and start</p>

<p style="text-align: right;">Page 94</p> <p>1 talking, we all -- I'm kidding. I'm kidding.  2 Listen to the advice of your counsel.  3 Now, as recent as April, I think, of  4 '16, PSI had a meeting and a presentation done by  5 the DEA. Does that sound correct?  6 A. Yes.  7 Q. Okay. But you're correct, the  8 regulatory body, at least at the federal level, is  9 the DEA; is that right?  10 A. Yes.  11 Q. Prescription Supply also recognizes that  12 they have to comply with the board of pharmacies  13 in the respective states that they do business in,  14 particularly the state we're sitting in, the State  15 of Ohio --  16 A. Yes.  17 Q. -- correct?  18 And they may have slightly different  19 rules and regulations, some of which we saw  20 earlier today?  21 A. Yes.  22 Q. But it doesn't change the fact that  23 Prescription Supply is obligated to comply with  24 those regulations?</p>	<p style="text-align: right;">Page 96</p> <p>1 A. Correct.  2 Q. Okay. This particular letter, however,  3 is to Cardinal Health, right?  4 A. Yes.  5 Q. Not Prescription Supply?  6 A. That's correct.  7 Q. Now, I'll tell you -- and it may be  8 because it wasn't saved or it wasn't kept -- I  9 never got in discovery one that was sent to  10 Prescription Supply. I'm not faulting anybody.  11 It's just I didn't get it.  12 Do you know whether Prescription Supply  13 ever got such a letter from the DEA?  14 A. I don't know that we got it. I assume  15 we got it, but I don't know that we have it.  16 Q. So let me ask you a different question.  17 Assuming that the DEA sent one to every  18 registrant in the country in September of 2006,  19 presumptively the same letter would have been sent  20 to Prescription Supply because it was a registrant  21 as well, correct?  22 A. Correct.  23 Q. Okay. But sitting here today, you have  24 no independent recollection of actually getting</p>
<p style="text-align: right;">Page 95</p> <p>1 A. Yes.  2 Q. Okay.  3 MR. FULLER: 301.  4 And, Counsel, this is the Dear Registrant  5 letter from 2006. In the production, I didn't get one  6 that was specifically to Prescription Supply --  7 MR. RICARD: Right.  8 MR. FULLER: -- so I just grabbed  9 Cardinal's, so I'm assuming that he will testify  10 that they got one.  11 MR. RICARD: Yeah. You can ask him.  12 ---  13 (PSI-Schoen Exhibit 13 marked.)  14 ---  15 BY MR. FULLER:  16 Q. So, Mr. Schoen, this letter is what we  17 refer to as a Dear Registrant letter. And if you  18 look at the very beginning, it says, "This letter  19 is being sent to every commercial entity in the  20 United States registered with the DEA to  21 distribute controlled substances."  22 And certainly we've established that  23 Prescription Supply would fall into that category,  24 correct?</p>	<p style="text-align: right;">Page 97</p> <p>1 this letter?  2 A. No, I don't.  3 Q. Okay. And that's fair enough, all  4 right? Like I told you before, if you don't know  5 or you don't remember, just tell me, and I don't  6 have any problem with that, okay?  7 A. Yes.  8 Q. All right. Now, we're going to go  9 through some areas of this letter and just talk  10 about them briefly.  11 So it says -- after that first sentence,  12 it says, "The purpose of this letter is to  13 reiterate the responsibilities of controlled  14 substance distribution in view of the prescription  15 drug abuse problem our nation currently faces."  16 Do you see that?  17 A. I see it.  18 Q. If we roll down to the -- under the  19 Background section --  20 MR. FULLER: Yeah. How did you know I  21 was going there? Is that highlighted on yours?  22 MS. VELDMAN: No. I was just cheating  23 looking --  24 MR. FULLER: She's good.</p>

<p style="text-align: right;">Page 98</p> <p>1 BY MR. FULLER:</p> <p>2 Q. All right. If you go down to the</p> <p>3 paragraph -- well, you have it highlighted, so I</p> <p>4 don't need to specify, but the highlighted section</p> <p>5 there says, "Distributors are, of course, one of</p> <p>6 the key components of the distribution chain. If</p> <p>7 the closed system is to function properly as</p> <p>8 Congress envisioned, distributors must be vigilant</p> <p>9 in deciding whether a proposed customer can be</p> <p>10 trusted to deliver controlled substances only for</p> <p>11 lawful purposes."</p> <p>12 PSI agrees and accepts that</p> <p>13 responsibility as set out by the DEA in this</p> <p>14 letter, correct?</p> <p>15 MR. RICARD: Objection to form.</p> <p>16 A. Yes.</p> <p>17 Q. PSI also agrees that that has been the</p> <p>18 obligation since 1971, right?</p> <p>19 A. Yes.</p> <p>20 Q. That PSI, along with the other</p> <p>21 registered distributors, is a key component in the</p> <p>22 distribution chain and must be, as it says here,</p> <p>23 vigilant in deciding whether to ship controlled</p> <p>24 substances, correct?</p>	<p style="text-align: right;">Page 100</p> <p>1 business, correct?</p> <p>2 A. Correct.</p> <p>3 Q. Okay. If you go to the next page,</p> <p>4 Mr. Schoen.</p> <p>5 A. Yes.</p> <p>6 Q. It says, "The statutory factors DEA must</p> <p>7 consider in deciding whether to revoke a</p> <p>8 distributor's registration are set forth in 21</p> <p>9 U.S.C. 823(e). Listed first among these factors</p> <p>10 is the duty of the distributors to maintain</p> <p>11 effective controls against diversion of controlled</p> <p>12 substances into other than legitimate medical,</p> <p>13 scientific, and industrial channels."</p> <p>14 Prescription Supply agrees and accepts</p> <p>15 that duty and responsibility to maintain effective</p> <p>16 controls against diversion, correct?</p> <p>17 MR. RICARD: Objection to form.</p> <p>18 A. It does.</p> <p>19 Q. Okay. And then it goes down, and it</p> <p>20 says, "The DEA regulations require" -- do you see</p> <p>21 that section?</p> <p>22 A. No.</p> <p>23 Q. Hold on. She'll get there. Yeah,</p> <p>24 that's it.</p>
<p style="text-align: right;">Page 99</p> <p>1 A. Yes.</p> <p>2 Q. And PSI takes extreme caution in</p> <p>3 ensuring that the persons that it is shipping to</p> <p>4 are the type that are not going to divert, as we</p> <p>5 discussed earlier? You even declined to take on</p> <p>6 new customers because of that concern, correct?</p> <p>7 A. Yes.</p> <p>8 Q. It says, "This responsibility is</p> <p>9 critical, as Congress has expressly declared that</p> <p>10 the illegal distribution of controlled substances</p> <p>11 has a substantial and detrimental effect on the</p> <p>12 health and general welfare of the American</p> <p>13 people."</p> <p>14 Again, Prescription Supply accepts and</p> <p>15 agrees with that statement?</p> <p>16 A. Yes.</p> <p>17 Q. We've already seen that written several</p> <p>18 other times in the Congressional history, as well</p> <p>19 as the Controlled Substances Act, correct?</p> <p>20 A. Yes.</p> <p>21 Q. That shouldn't come as a surprise to</p> <p>22 anybody?</p> <p>23 A. No.</p> <p>24 Q. At least nobody in your line of</p>	<p style="text-align: right;">Page 101</p> <p>1 A. All right.</p> <p>2 Q. And this recites 21 C.F.R. 1301.74(b),</p> <p>3 and that's the suspicious order obligation that we</p> <p>4 talked about earlier, right?</p> <p>5 A. Yes.</p> <p>6 Q. And Prescription Supply still accepts</p> <p>7 and recognizes that that has been in place since</p> <p>8 1971, correct?</p> <p>9 MR. RICARD: Objection to form.</p> <p>10 A. Yes.</p> <p>11 Q. Then here's where it gets interesting,</p> <p>12 and here's where I want to make sure that you and</p> <p>13 I, Mr. Schoen, are on the same page.</p> <p>14 It next says, "It bears emphasis that</p> <p>15 the foregoing reporting requirement is in addition</p> <p>16 to, and not in lieu of, the general requirement</p> <p>17 under 21 U.S.C. 823(e) that a distributor maintain</p> <p>18 effective controls against diversion."</p> <p>19 MR. RICARD: Hang on.</p> <p>20 MS. MONAGHAN: Objection to form.</p> <p>21 MR. RICARD: Do you see where --</p> <p>22 THE WITNESS: I see that, yes.</p> <p>23 MR. FULLER: There we go.</p> <p>24 THE WITNESS: Yes.</p>

<p style="text-align: right;">Page 102</p> <p>1 MR. RICARD: Take a look at it.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. And I'll read it again, Mr. Schoen. "It</p> <p>4 bears emphasis that the foregoing reporting</p> <p>5 requirement is in addition to, and not in lieu of,</p> <p>6 the general requirement under 21 U.S.C. 823(e)</p> <p>7 that a distributor maintain effective controls</p> <p>8 against diversion."</p> <p>9 And let's talk about that for one</p> <p>10 second, Mr. Schoen. What the DEA is pointing out</p> <p>11 is the two separate code sections we looked at</p> <p>12 earlier. We know, and Prescription Supply agrees,</p> <p>13 that it has a statutory obligation to maintain</p> <p>14 effective controls against diversion, correct?</p> <p>15 MR. RICARD: Objection to form.</p> <p>16 Q. And that means put systems and practices</p> <p>17 and policies in place to try to prevent diversion.</p> <p>18 Does PSI agree?</p> <p>19 MR. RICARD: Same objection.</p> <p>20 A. Yes.</p> <p>21 Q. And that code section has been in full</p> <p>22 force and effect since 1970 when the Controlled</p> <p>23 Substances Act was passed, correct?</p> <p>24 MR. RICARD: Objection to form.</p>	<p style="text-align: right;">Page 104</p> <p>1 the United States Code that's actually passed by</p> <p>2 the U.S. Congress.</p> <p>3 A. Okay.</p> <p>4 Q. Okay?</p> <p>5 A. Okay.</p> <p>6 Q. So we're dealing with two different</p> <p>7 statutory schemes. And, again -- and I'm doing</p> <p>8 this, Mr. Schoen, so that you and I -- like I</p> <p>9 mentioned earlier, we can make sure we're on the</p> <p>10 same page because I want to make sure you</p> <p>11 understand what you're answering so I know that</p> <p>12 I'm getting -- I'm understanding what you're --</p> <p>13 the answer I'm getting as well.</p> <p>14 Okay. Now, I'm just going to hold it</p> <p>15 up.</p> <p>16 A. Okay.</p> <p>17 Q. So we have -- I hope you don't mind, but</p> <p>18 I like changing colors for emphasis. And you see</p> <p>19 if this makes sense and whether you agree, okay?</p> <p>20 So, number one, we have the U.S. code section --</p> <p>21 or excuse me. And I got that backwards. I can't</p> <p>22 write it right much less explain it right. Jeez.</p> <p>23 So, number one, the first thing we</p> <p>24 looked at this morning was the U.S. code section?</p>
<p style="text-align: right;">Page 103</p> <p>1 A. Yes.</p> <p>2 Q. Separate from that, separate and</p> <p>3 distinct, on this side, we have the suspicious</p> <p>4 order reporting requirement, which is different,</p> <p>5 right?</p> <p>6 A. Yes.</p> <p>7 Q. It is a mechanism in which the wholesale</p> <p>8 distributor, in this case PSI -- I'm sorry.</p> <p>9 A. Go ahead.</p> <p>10 Q. You seemed bothered there for a second.</p> <p>11 A. Well, I'm just trying to make sure that</p> <p>12 I'm not misunderstanding.</p> <p>13 Q. No. And I'm going to try to make it as</p> <p>14 simple as I can because this is how --</p> <p>15 A. That's good because I need it to be</p> <p>16 simple.</p> <p>17 Q. This is how I know how to do it.</p> <p>18 21 C.F.R. -- so when we say "C.F.R.," we're</p> <p>19 referring to the Code of Federal Regulation.</p> <p>20 A. Yes.</p> <p>21 Q. And that's a rule promulgated by the</p> <p>22 DEA.</p> <p>23 A. Okay.</p> <p>24 Q. That's different than U.S.C., which is</p>	<p style="text-align: right;">Page 105</p> <p>1 A. Okay.</p> <p>2 Q. And Prescription Supply recognizes that</p> <p>3 U.S. -- 21, U.S. Code 823(e) requires effective</p> <p>4 controls against diversion, correct?</p> <p>5 MR. RICARD: Objection to form.</p> <p>6 A. Yes.</p> <p>7 Q. And that regulatory -- or excuse me.</p> <p>8 That statutory obligation has been in place in</p> <p>9 full effect since 1970 when the CSA was passed?</p> <p>10 MR. RICARD: Same objection.</p> <p>11 A. Yes.</p> <p>12 Q. In addition to that, what we saw was</p> <p>13 passed in 1971 was the Code of Federal Regulation,</p> <p>14 21 C.F.R. 1301.74(b), which is the suspicious</p> <p>15 order reporting requirement, correct?</p> <p>16 MR. RICARD: Objection to form.</p> <p>17 A. Mm-hmm.</p> <p>18 Q. Is that a yes?</p> <p>19 A. Yes.</p> <p>20 Q. And Prescription Supply agrees that it</p> <p>21 also in addition to effective controls against</p> <p>22 diversion has a suspicious order reporting</p> <p>23 requirement since 1971?</p> <p>24 MR. RICARD: Same objection.</p>

<p style="text-align: right;">Page 106</p> <p>1 Q. Correct?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. And when I say there's two</p> <p>4 distinct -- and when Mr. Rannazzisi is explaining</p> <p>5 in his letter, he's saying there's two distinct</p> <p>6 obligations; one, you have to maintain effective</p> <p>7 control to try to prevent diversion yourself.</p> <p>8 And you agree with that, correct?</p> <p>9 MR. RICARD: Objection to form.</p> <p>10 A. Yes.</p> <p>11 Q. You also have a suspicious order</p> <p>12 reporting requirement in addition to that you have</p> <p>13 to report suspicious orders to the DEA, correct?</p> <p>14 MR. RICARD: Objection to form.</p> <p>15 A. Yes.</p> <p>16 Q. Okay. And if anybody wants to, I'll --</p> <p>17 MS. MONAGHAN: Can we mark that as an</p> <p>18 exhibit?</p> <p>19 MR. FULLER: Yeah. My artwork, that</p> <p>20 will be Plaintiff's 14.</p> <p>21 ---</p> <p>22 (PSI-Schoen Exhibit 14 marked.)</p> <p>23 ---</p> <p>24</p>	<p style="text-align: right;">Page 108</p> <p>1 or not. That's just what it indicates on the</p> <p>2 letter.</p> <p>3 A. Yes.</p> <p>4 Q. Now, in all fairness, you don't have any</p> <p>5 reason to dispute that, do you?</p> <p>6 A. No.</p> <p>7 Q. Okay. Now, going back to page 2 of the</p> <p>8 document. That's what Mr. Rannazzisi is saying</p> <p>9 when he says, "It bears emphasis that the</p> <p>10 foregoing reporting requirement is in addition to,</p> <p>11 and not lieu of, the general requirement under 21</p> <p>12 U.S.C. 823(e) that a distributor maintain</p> <p>13 effective controls against diversion"?</p> <p>14 MR. RICARD: Objection to form.</p> <p>15 Q. And PSI agrees and accepts those</p> <p>16 responsibilities, correct?</p> <p>17 A. We do.</p> <p>18 MR. RICARD: Same objection.</p> <p>19 Q. Okay. Now, he goes on to explain it</p> <p>20 more, and we're going to read through that just</p> <p>21 for the fun of it, I guess.</p> <p>22 He says, "Thus, in addition to reporting</p> <p>23 all suspicious orders, a distributor has a</p> <p>24 statutory responsibility to exercise due diligence</p>
<p style="text-align: right;">Page 107</p> <p>1 BY MR. FULLER:</p> <p>2 Q. And that's where Mr. Rannazzisi who</p> <p>3 was -- I forget what his actual title was. Let's</p> <p>4 see if he puts it on his letter. Joseph</p> <p>5 Rannazzisi who did this letter was the Deputy</p> <p>6 Assistant Administrator, Office of Diversion</p> <p>7 Control, in 1996.</p> <p>8 A. Mm-hmm.</p> <p>9 MR. RICARD: You need to respond yes or</p> <p>10 no.</p> <p>11 A. I'm sorry. I don't know what the -- I</p> <p>12 didn't hear a question there.</p> <p>13 Q. No, there wasn't. I was just stating</p> <p>14 who -- what his title was.</p> <p>15 So let me state it differently. If you</p> <p>16 go to page 4 of the document, this document</p> <p>17 indicates that it was -- it is signed off on by</p> <p>18 Joseph Rannazzisi, correct?</p> <p>19 A. Yes.</p> <p>20 Q. And it indicates that his position is</p> <p>21 Deputy Assistant Administrator of the Office of</p> <p>22 Diversion Control, correct?</p> <p>23 A. Yes.</p> <p>24 Q. Now, you don't know whether that's right</p>	<p style="text-align: right;">Page 109</p> <p>1 to avoid filling suspicious orders that might" --</p> <p>2 might -- "be diverted into other than legitimate</p> <p>3 medical, scientific, and industrial channels.</p> <p>4 Failure to exercise such due diligence could, as</p> <p>5 circumstances warrant, provide a statutory basis</p> <p>6 for revocation or suspension of a distributor's</p> <p>7 registration."</p> <p>8 And PSI recognizes and accepts that</p> <p>9 responsibility and obligation, correct?</p> <p>10 MR. RICARD: Objection to form.</p> <p>11 A. Yes.</p> <p>12 Q. Okay. He goes on to say, "In a similar</p> <p>13 vein, given the requirement under Section</p> <p>14 823(e)" --</p> <p>15 MR. RICARD: Can you wait until it's up?</p> <p>16 MR. FULLER: Yeah. Sorry.</p> <p>17 BY MR. FULLER:</p> <p>18 Q. All right. "In a similar vein, given</p> <p>19 the requirement under Section 823(e) that a</p> <p>20 distributor maintain effective controls against</p> <p>21 diversion, a distributor may not simply rely on</p> <p>22 the fact that the person placing the suspicious</p> <p>23 order is a DEA registrant and turn a blind eye to</p> <p>24 the suspicious circumstances."</p>

<p style="text-align: right;">Page 110</p> <p>1 Prescription Supply agrees that that is  2 the status of the law and has been since 1971,  3 correct?  4 MR. RICARD: Objection to form.  5 A. Yes.  6 Q. That just because the person you're  7 sending to is a registrant doesn't mean that you  8 can turn a blind eye when it's suspicious?  9 MR. RICARD: Same objection.  10 A. That's correct.  11 Q. That's the same thing that you guys did  12 at PSI repeatedly when those registrants wanted to  13 become a new customer and there was something  14 fishy going on, or at least you suspected  15 something, and you turned them down, right?  16 A. Yes. That's -- there was some reason  17 why we turned them down, yes.  18 Q. Sure. And, listen, I went through the  19 applications because they were provided by your  20 counsel, and a lot of the times it's like, "Look,  21 this just doesn't smell right."  22 A. That's right.  23 Q. For whatever reason --  24 A. We didn't take them off.</p>	<p style="text-align: right;">Page 112</p> <p>1 Q. Which was --  2 A. NDWA a long time ago.  3 Q. Right.  4 (Reporter clarification.)  5 A. NDWA, National Drug Wholesalers  6 Association.  7 Q. And HDMA has changed its name to HDA, I  8 think, now?  9 A. Yes.  10 Q. Okay. And not only is Prescription  11 Supply a member, but at different times -- and  12 maybe the entire time -- I'm not sure -- had  13 directors or had a director on the board.  14 A. Recently, as the number of wholesalers  15 has decreased, and it's been decreasing pretty  16 fast.  17 Q. So you made your way up the totem pole?  18 A. Yeah. Now anybody -- any member,  19 wholesaler member, has a board member.  20 Q. Oh, currently?  21 A. Currently. Now, some big wholesalers  22 have more than one board member.  23 Q. Sure, sure.  24 A. But everybody has a board member.</p>
<p style="text-align: right;">Page 111</p> <p>1 Q. And you didn't take them off?  2 A. At least as controlled substance  3 receivers.  4 Q. And fair enough. You would agree to  5 ship other things to them?  6 A. But not controlled substances.  7 Q. But that's not what they wanted,  8 usually?  9 A. Generally, yes.  10 Q. And the reason you were doing that is  11 because you knew of the heightened obligation you  12 had and the potential for abuse and the fact that  13 these drugs are dangerous if not handled  14 correctly?  15 MR. RICARD: Objection to form.  16 A. Yes.  17 Q. And Prescription Supply took that  18 obligation very, very serious?  19 A. Yes.  20 MR. FULLER: So now I'm going -- 601.  21 BY MR. FULLER:  22 Q. So Prescription Supply is also a member  23 of the H -- or what was the HDMA, correct?  24 A. Yes.</p>	<p style="text-align: right;">Page 113</p> <p>1 Q. Oh, really? I didn't realize that.  2 A. Yeah, mm-hmm.  3 Q. Huh. Okay. Well, we're going to look  4 at some of that.  5 - - -  6 (PSI-Schoen Exhibit 15 marked.)  7 - - -  8 Q. Plaintiff's Exhibit 15. So there's a  9 lot of stuff on here that's irrelevant I'm not  10 going to ask you about. We'll wade through it.  11 And I'm going to go to page 12 right off  12 the bat. So page 12 is an e-mail.  13 MR. FULLER: Can you blow that up for  14 me?  15 MS. VELDMAN: Yes.  16 BY MR. FULLER:  17 Q. So if you look on the screen, there is a  18 J -- it's a Harbauer?  19 A. That's Harbauer.  20 Q. Harbauer?  21 A. Mm-hmm.  22 Q. And I'm assuming you know who that it  23 is?  24 A. My sister.</p>

<p style="text-align: right;">Page 114</p> <p>1 Q. Okay. Well, there you go. Let's hope</p> <p>2 you know who she is.</p> <p>3 A. She's 89.</p> <p>4 Q. Bless her heart.</p> <p>5 So this is an e-mail coming from</p> <p>6 Brian -- or no. This is from Robert</p> <p>7 G-i-a-c-a-l-o-n-e.</p> <p>8 Do you know how to pronounce that?</p> <p>9 A. No.</p> <p>10 Q. Okay. Well, we'll go with Robert G.</p> <p>11 And he is forwarding an e-mail -- I say that -- if</p> <p>12 you read down, the subject matter is "Summary of</p> <p>13 September 7th Meeting with DEA and Attachments."</p> <p>14 Do you see that?</p> <p>15 A. All right. Yes.</p> <p>16 Q. We're blowing it up for you.</p> <p>17 A. Mm-hmm.</p> <p>18 Q. And the attachments include a Final</p> <p>19 Summary of DEA Meeting 9-7-07. There's another</p> <p>20 attachment -- there's a total of three</p> <p>21 attachments. At least that's what it says.</p> <p>22 Do you see that there?</p> <p>23 A. Yes. I see it says three attachments,</p> <p>24 yes, I do.</p>	<p style="text-align: right;">Page 116</p> <p>1 I told you there may be some things that don't</p> <p>2 look familiar. And what I want to go to is the</p> <p>3 summary, and that's on page 32 of the document, I</p> <p>4 believe.</p> <p>5 MS. VELDMAN: 31.</p> <p>6 MR. FULLER: One more, page 31. There</p> <p>7 you go. We'll start with the title though, Gina.</p> <p>8 BY MR. FULLER:</p> <p>9 Q. All right. You see page 31 there,</p> <p>10 Mr. Schoen?</p> <p>11 A. I do.</p> <p>12 Q. It says "Summary of the DEA-HDMA Meeting</p> <p>13 on Suspicious Orders. Meeting Date: September 7,</p> <p>14 2007." Right?</p> <p>15 A. Yes.</p> <p>16 Q. And if we go to the key takeaways from</p> <p>17 the meeting, we can see what the highlights sort</p> <p>18 of were. It says, "The DEA's policy was to expect</p> <p>19 more than just reporting 'suspicious orders.' If</p> <p>20 there was a suspicious order, the distributor</p> <p>21 should either stop the delivery or should evaluate</p> <p>22 the customer further before delivering it."</p> <p>23 Does PSI agree that that has been the</p> <p>24 obligation as it understood it since 1971?</p>
<p style="text-align: right;">Page 115</p> <p>1 Q. And then it says, "Attention RAC</p> <p>2 Members."</p> <p>3 Do you know what it means, RAC members?</p> <p>4 A. No.</p> <p>5 Q. Okay. Either do I. It wasn't a trick</p> <p>6 question.</p> <p>7 But then it reads, "HDMA met with the</p> <p>8 DEA officials last Friday to discuss the Agency's</p> <p>9 current policy position on suspicious orders. A</p> <p>10 summary highlighting the key points made during</p> <p>11 the meeting are attached above for your review.</p> <p>12 Three additional attachments containing a DEA</p> <p>13 slide presentation on suspicious orders and the</p> <p>14 DEA's Office of Diversion Control are also</p> <p>15 enclosed. Please contact me if you have any</p> <p>16 questions regarding the attached materials."</p> <p>17 So this e-mail was apparently forwarded</p> <p>18 to your sister back on September 10th of 2007; is</p> <p>19 that correct?</p> <p>20 A. That's what it seems to show, yes.</p> <p>21 Q. Now, have you had an opportunity to see</p> <p>22 this before today?</p> <p>23 A. Not that I recall.</p> <p>24 Q. Okay. That's fair enough. And, again,</p>	<p style="text-align: right;">Page 117</p> <p>1 MR. RICARD: Objection to form.</p> <p>2 A. Yes.</p> <p>3 Q. Without question, correct?</p> <p>4 MS. MONAGHAN: Objection; form.</p> <p>5 A. Yes.</p> <p>6 Q. Okay. This says, "Simply complying with</p> <p>7 the suspicious orders regulatory requirement does</p> <p>8 not mean, in the agency's view, that the</p> <p>9 registrant is maintaining effective programs to</p> <p>10 detect and prevent diversion."</p> <p>11 That's what we talked about, the two</p> <p>12 separate requirements, correct?</p> <p>13 A. Yes.</p> <p>14 Q. And PSI agrees that simply reporting</p> <p>15 suspicious orders and following the regulation</p> <p>16 doesn't mean you're still following and complying</p> <p>17 with the U.S. code, correct?</p> <p>18 MR. RICARD: Objection to form.</p> <p>19 A. Yes.</p> <p>20 Q. Then the next key takeaway is, "DEA</p> <p>21 indicated they did not have the resources to</p> <p>22 inspect every pharmacy; therefore it was important</p> <p>23 for the distributor to know their customers."</p> <p>24 A. Yes.</p>

<p style="text-align: right;">Page 118</p> <p>1 Q. Does PSI agree simply with the notion</p> <p>2 that it's important for the distributor to know</p> <p>3 their customers?</p> <p>4 A. Yes.</p> <p>5 Q. PSI also recognizes that -- strike that.</p> <p>6 MR. FULLER: 204, Gina.</p> <p>7 - - -</p> <p>8 (PSI-Schoen Exhibit 16 marked.)</p> <p>9 - - -</p> <p>10 BY MR. FULLER:</p> <p>11 Q. And we're going to flip-flop back and</p> <p>12 forth between two exhibits for a moment, only</p> <p>13 because I think it's important for complete</p> <p>14 understanding.</p> <p>15 What counsel is going to hand you is a</p> <p>16 memorandum, and it's from the U.S. Inspector</p> <p>17 General, Glenn Fine. And the subject matter is</p> <p>18 "Review of Drug Enforcement Administration's</p> <p>19 Investigations of the Diversion of Controlled</p> <p>20 Pharmaceuticals."</p> <p>21 This was done in 2002, so about five</p> <p>22 years before this meeting that we were just</p> <p>23 looking at, okay?</p> <p>24 A. All right.</p>	<p style="text-align: right;">Page 120</p> <p>1 A. It would be very difficult to do it</p> <p>2 perfectly.</p> <p>3 Q. It's like having police officers out</p> <p>4 there trying to maintain and catch people</p> <p>5 speeding. If you and I are in the State of Ohio</p> <p>6 and we're told there's only ten cops in the entire</p> <p>7 State of Ohio that are going to police speeding,</p> <p>8 we know they're not going to do a very good job,</p> <p>9 right?</p> <p>10 MR. RICARD: Same objection.</p> <p>11 A. They'll only catch a certain number of</p> <p>12 speeders.</p> <p>13 Q. Because they can't.</p> <p>14 A. Correct.</p> <p>15 Q. It's not possible. Well, the point is</p> <p>16 the same thing with the DEA back during this time</p> <p>17 frame. They didn't have enough field diversion</p> <p>18 officers to police every pharmacy. They're even</p> <p>19 admitting that to the HDMA in 2007, right?</p> <p>20 MR. RICARD: Same objection.</p> <p>21 A. Yes.</p> <p>22 Q. That's what they say. They said the DEA</p> <p>23 indicated they did not have the resources to</p> <p>24 inspect every pharmacy; therefore, it was</p>
<p style="text-align: right;">Page 119</p> <p>1 Q. And if you'll turn to page 12. Gina is</p> <p>2 going to blow up the highlighted section for us</p> <p>3 there. And this is talking about -- and so you</p> <p>4 know, Mr. Schoen, in looking at the resources that</p> <p>5 the DEA had and the resources that were being</p> <p>6 allocated for diversion control purposes.</p> <p>7 Now, this document reads that "Diversion</p> <p>8 investigators represent 10 percent, or 523, of the</p> <p>9 DEA's 5,124 authorized investigator positions in</p> <p>10 fiscal year 2001. The authorized diversion</p> <p>11 investigator positions were assigned as follows:</p> <p>12 55 at headquarters, 455 at domestic field offices,</p> <p>13 and the remaining 13 at overseas offices."</p> <p>14 So out in the field around the country</p> <p>15 during this time, we had 455 diversion officers.</p> <p>16 That's to police all the wholesale distributors</p> <p>17 and all the shipments and all the pharmacies</p> <p>18 around this entire country.</p> <p>19 A. Mm-hmm.</p> <p>20 Q. You and I can agree there's no way 455</p> <p>21 guys are going to be able to get that done for the</p> <p>22 entire country, correct?</p> <p>23 MR. RICARD: Objection to form.</p> <p>24 Objection to scope.</p>	<p style="text-align: right;">Page 121</p> <p>1 important for the distributors --</p> <p>2 A. To know their customers.</p> <p>3 Q. Exactly. A statutory obligation that</p> <p>4 they should be doing anyway, right?</p> <p>5 MR. RICARD: Objection to form.</p> <p>6 A. Yes.</p> <p>7 Q. Certainly what PSI has done from the</p> <p>8 very beginning?</p> <p>9 A. We've tried.</p> <p>10 Q. Best you can, correct?</p> <p>11 A. That's correct.</p> <p>12 Q. Not to say people don't make mistakes,</p> <p>13 right?</p> <p>14 A. Hopefully not.</p> <p>15 Q. Fair enough. Let's go to the --</p> <p>16 MR. FULLER: Gina, back to 60- whatever,</p> <p>17 601, page 32 now.</p> <p>18 MS. VELDMAN: Okay.</p> <p>19 THE WITNESS: This one?</p> <p>20 MR. RICARD: This one.</p> <p>21 THE WITNESS: On page 32 now?</p> <p>22 MR. RICARD: You said 32, Mike?</p> <p>23 MR. FULLER: Yes, sir.</p> <p>24</p>

<p style="text-align: right;">Page 122</p> <p>1 BY MR. FULLER:</p> <p>2 Q. Okay. So if you see the section "HDMA</p> <p>3 Questions and Assessment."</p> <p>4 A. Mm-hmm.</p> <p>5 Q. Is that a yes?</p> <p>6 A. Yes.</p> <p>7 Q. And I apologize, but it has to be verbal</p> <p>8 so she can write it down. I'm not trying to pick</p> <p>9 on you, Mr. Schoen. I promise.</p> <p>10 So if you look at the second bullet</p> <p>11 point there, it says, "DEA's expectations are</p> <p>12 clearly heightened. HDMA would like to ask its</p> <p>13 members about the impact of these expectations."</p> <p>14 For example, in an indented bullet point, "Are</p> <p>15 members capable of inspecting their pharmacy</p> <p>16 customers?"</p> <p>17 Do you see that there?</p> <p>18 A. I see it.</p> <p>19 Q. Prescription Supply would agree that all</p> <p>20 distributors should be investigating or inspecting</p> <p>21 their pharmacy customers anyway, right?</p> <p>22 MR. RICARD: Objection to form.</p> <p>23 A. I agree, but --</p> <p>24 Q. Now, you don't know what the others are</p>	<p style="text-align: right;">Page 124</p> <p>1 duty --</p> <p>2 A. Yes.</p> <p>3 Q. -- take on that obligation, with great</p> <p>4 power also comes great responsibility, correct?</p> <p>5 A. Mm-hmm.</p> <p>6 MS. MONAGHAN: Objection; form.</p> <p>7 Q. Is that a yes?</p> <p>8 A. Yes.</p> <p>9 Q. And whether others -- no matter how</p> <p>10 large or small they want to be or choose to be,</p> <p>11 they still need to comply with the law?</p> <p>12 MR. RICARD: Objection to form.</p> <p>13 Q. Right?</p> <p>14 A. Yes.</p> <p>15 Q. And if they don't, whoever they may be,</p> <p>16 they need to be held accountable for not complying</p> <p>17 with the law --</p> <p>18 MR. RICARD: Same objection.</p> <p>19 Q. -- right?</p> <p>20 A. Yes.</p> <p>21 Q. Okay. So I understand your point, and</p> <p>22 you're saying you guys have 150 to 200 people who</p> <p>23 buy controlled substances, so your realm of</p> <p>24 entities you have to investigate is probably</p>
<p style="text-align: right;">Page 123</p> <p>1 doing?</p> <p>2 A. I don't know what the others are doing.</p> <p>3 I know that Prescription Supply is a \$70 million</p> <p>4 house. We're very small. We have probably two or</p> <p>5 three thousand customers of which maybe 150 or so</p> <p>6 are buying controlled substances on a regular</p> <p>7 basis.</p> <p>8 It is easier for us to control our 150</p> <p>9 in some way. And we're not perfect, but it's</p> <p>10 easier for us to control 150 than it is for</p> <p>11 perhaps some of the bigger operations to</p> <p>12 control -- how many, I have no idea.</p> <p>13 Q. Oh, sure. Now, let's talk about that</p> <p>14 just for a second. We're going to push back from</p> <p>15 the document for a minute.</p> <p>16 A. Okay.</p> <p>17 Q. No one forces anybody to get into this</p> <p>18 line of business, do they?</p> <p>19 A. That's correct.</p> <p>20 Q. People choose to get into this line of</p> <p>21 business as an entity in this controlled substance</p> <p>22 supply chain, right?</p> <p>23 A. That's correct.</p> <p>24 Q. And if you're going to take on that</p>	<p style="text-align: right;">Page 125</p> <p>1 smaller than a lot of other people, right?</p> <p>2 A. That's correct.</p> <p>3 Q. And you have how many employees?</p> <p>4 A. Seventy some.</p> <p>5 Q. Others have tens of thousands of</p> <p>6 employees.</p> <p>7 A. That's correct.</p> <p>8 Q. They should be able to train those</p> <p>9 people, just like you train your people, to</p> <p>10 conduct these investigations? You would agree</p> <p>11 with that, correct?</p> <p>12 MR. BUSHUR: Objection; form.</p> <p>13 A. I certainly try.</p> <p>14 Q. Fair enough. Fair enough.</p> <p>15 And my only point is, just because</p> <p>16 others chose to grow larger doesn't exempt them</p> <p>17 from the requirement to know their customer --</p> <p>18 MR. RICARD: Objection to form.</p> <p>19 Q. -- right?</p> <p>20 A. That's correct.</p> <p>21 Q. Okay. Let's go down to the fourth</p> <p>22 bullet point, which I think is a great question.</p> <p>23 It says, "Do we have recommendations for the DEA</p> <p>24 as to how to approach this problem in a way that</p>

<p style="text-align: right;">Page 126</p> <p>1 simplifies things for the wholesale distributor?"</p> <p>2 Do you see that?</p> <p>3 A. I see it.</p> <p>4 Q. And wouldn't it make sense that the</p> <p>5 trade organization and the distributors, that if</p> <p>6 they could come up with a better system, that they</p> <p>7 maybe propose that to the DEA?</p> <p>8 A. Yes, yes.</p> <p>9 Q. I mean, listen, DEA doesn't have -- or</p> <p>10 the Department of Justice doesn't have the lock,</p> <p>11 stock, and barrel on good ideas, right?</p> <p>12 A. Correct.</p> <p>13 Q. I mean, you guys are operating in the</p> <p>14 industry. Maybe there are ideas that can come</p> <p>15 from the industry to help deal with this situation</p> <p>16 of controlled substances?</p> <p>17 A. Yes.</p> <p>18 Q. Do you know if that's ever been done?</p> <p>19 MR. RICARD: Objection to form.</p> <p>20 Objection to scope.</p> <p>21 A. Do I know? I don't know that that's</p> <p>22 been done. I'm sure it has been done, but I don't</p> <p>23 know that it's been done.</p> <p>24 Q. Right. You don't know one way or</p>	<p style="text-align: right;">Page 128</p> <p>1 correct?</p> <p>2 A. Correct.</p> <p>3 Q. Okay. Now, I'm going to go through the</p> <p>4 same sort of qualifiers. This has the same</p> <p>5 introduction that is being sent to every</p> <p>6 registrant, manufacturer, or distributor of</p> <p>7 controlled substances, which during this time</p> <p>8 frame, Prescription Supply, Inc., was one of</p> <p>9 those, right?</p> <p>10 A. That's correct.</p> <p>11 Q. And assuming that Mr. Rannazzisi is</p> <p>12 correct and he sent this letter out to everybody,</p> <p>13 presumptively Prescription Supply would have</p> <p>14 gotten that, correct?</p> <p>15 A. Yes.</p> <p>16 Q. Now, however, sitting here today, I'm</p> <p>17 assuming that you have not seen this letter and</p> <p>18 don't ever recall receiving it?</p> <p>19 A. I don't recall seeing it.</p> <p>20 Q. Fair enough.</p> <p>21 A. We may have received it. I don't --</p> <p>22 Q. Sure. And, listen, that may have been</p> <p>23 issues that you delegated to someone else within</p> <p>24 the business, and that's absolutely fine, okay?</p>
<p style="text-align: right;">Page 127</p> <p>1 another?</p> <p>2 A. I don't from personal knowledge have --</p> <p>3 MR. FULLER: Now, we're going to go 303.</p> <p>4 This will be Plaintiff's Exhibit 17.</p> <p>5 MR. PELINI: 17, Mike?</p> <p>6 MR. FULLER: Yes, sir.</p> <p>7 ---</p> <p>8 (PSI-Schoen Exhibit 17 marked.)</p> <p>9 ---</p> <p>10 Q. Mr. Schoen, I'm going to represent to</p> <p>11 you this is going to look a little familiar</p> <p>12 because it's another letter from the DEA. And if</p> <p>13 you look on the second page, I think the same</p> <p>14 gentleman signed it, Joe Rannazzisi, Deputy</p> <p>15 Assistant Administrator, Office of Diversion</p> <p>16 Control.</p> <p>17 Do you see that?</p> <p>18 A. I see it.</p> <p>19 Q. Seems to be the same guy as last time,</p> <p>20 right?</p> <p>21 A. It appears.</p> <p>22 Q. But this letter is dated December 27th</p> <p>23 of 2007, so about a year and three or four months</p> <p>24 after the first letter in September of 2006,</p>	<p style="text-align: right;">Page 129</p> <p>1 So the letter starts off after that</p> <p>2 introductory sentence that "The purpose of this</p> <p>3 letter is to reiterate the responsibilities of</p> <p>4 controlled substance manufacturers and</p> <p>5 distributors to inform the DEA of suspicious</p> <p>6 orders in accordance with 21 C.F.R. 1301.74(b).</p> <p>7 Do you see that there?</p> <p>8 A. I see it, yes.</p> <p>9 Q. And he, again, is reiterating what he</p> <p>10 talked about, it appears, in the September of '06</p> <p>11 letter, right?</p> <p>12 MR. RICARD: Objection to form.</p> <p>13 A. Mm-hmm.</p> <p>14 Q. We saw that the HDMA met with him in</p> <p>15 April of 2007 and had a summary of those</p> <p>16 conversations related to these same issues,</p> <p>17 correct?</p> <p>18 A. Correct.</p> <p>19 Q. All right. So let's see if they have</p> <p>20 anything new or different to say now. He starts</p> <p>21 off with, "In addition to, and not lieu of" --</p> <p>22 hold on. Give her a second to get that</p> <p>23 highlighted for you.</p> <p>24 "In addition to, and not in lieu of, the</p>

<p style="text-align: right;">Page 130</p> <p>1 general requirement under 21 U.S.C. 823, that  2 manufacturers and distributors maintain effective  3 controls against diversion, DEA regulations  4 require all manufacturers and distributors to  5 report suspicious orders of controlled  6 substances."  7 And I know we've been talking about this  8 ad litem, but you would agree that Prescription  9 Supply recognizes that duty and obligation,  10 correct?  11 MR. RICARD: Objection to form.  12 A. Yes.  13 Q. That Prescription Supply recognizes that  14 that's been the duty and obligation as a  15 registrant since 1971?  16 MR. RICARD: Same objection.  17 A. Yes.  18 Q. Okay. Now, if we go down -- yep.  19 The next paragraph starts off "The  20 regulation also requires that the registrant  21 inform local DEA Division Office of suspicious  22 orders when discovered by the registrant."  23 Does Prescription Supply agree and  24 recognize that it has an obligation to report</p>	<p style="text-align: right;">Page 132</p> <p>1 clear to the industry what they expect from its  2 registrants, correct?  3 MR. RICARD: Objection to form.  4 A. Yes.  5 Q. Prescription Supply agrees that there is  6 no question what the DEA expects in fulfilling the  7 statutory and the regulatory requirement that  8 we've looked at today?  9 A. Yes.  10 MR. RICARD: Same objection.  11 MR. FULLER: It's 11:44. We've been  12 going over an hour. Do you want to stop now for  13 lunch? Do you want to push till noon?  14 Mr. Schoen, what's your druthers?  15 THE WITNESS: You know, I just want to  16 get it over with.  17 MR. FULLER: I've never heard that  18 before.  19 MR. RICARD: If now is a good spot to  20 take a break, then we could do lunch now.  21 MR. FULLER: Yeah. I was going to jump  22 into the policies and procedures next, but that's  23 going to take a bit, so why don't we go ahead  24 and --</p>
<p style="text-align: right;">Page 131</p> <p>1 suspicious orders when they're first discovered?  2 MR. RICARD: Objection to form.  3 A. Yes.  4 Q. And we'll skip down a little bit to  5 "Registrants are." There you go, right there.  6 "Registrants are reminded that their  7 responsibility does not end merely with filing a  8 suspicious order report. Registrants must conduct  9 an independent analysis of suspicious orders prior  10 to completing a sale to determine whether the  11 controlled substances are likely to be diverted  12 from legitimate channels. Reporting an order as  13 suspicious will not absolve the registrant of  14 responsibility if the registrant knew or should  15 have known that the controlled substances were  16 being diverted."  17 Prescription Supply again agrees with  18 that obligation, correct?  19 MR. RICARD: Objection to form.  20 A. Yes.  21 Q. Now, at least by the end of 2007, we've  22 known we've had the Controlled Substances Act and  23 the regulation since 1970 and '71, but at least by  24 the end of 2007, the DEA has made it abundantly</p>	<p style="text-align: right;">Page 133</p> <p>1 MR. RICARD: Sure.  2 THE VIDEOGRAPHER: The time now is  3 11:43. Going off the record.  4 - - -  5 Thereupon, at 11:43 a.m. a lunch  6 recess was taken until 12:49 p.m.  7 - - -  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24</p>

<p style="text-align: right;">Page 134</p> <p>1                   Wednesday Afternoon Session 2                   September 5, 2018 3                   12:59 p.m. 4                   --- 5                   THE VIDEOGRAPHER: The time is now 6                   12:59. Back on the record. 7                   --- 8                   (PSI-Schoen Exhibit 18 marked.) 9                   --- 10                  BY MR. FULLER: 11                  Q. Mr. Schoen, we're going to pass to your 12                  counsel Plaintiff's Exhibit 18. I'm going to have 13                  him take a look at it first and then pass you a 14                  copy. 15                  And so what you'll be looking at, 16                  Mr. Schoen, is this is a document from the HDMA, 17                  Healthcare Distribution Management Association. 18                  We talked a little bit about them earlier, right? 19                  A. Yes. 20                  Q. And PSI is a member of that 21                  organization; is that correct? 22                  A. That's correct. 23                  Q. And if you look at the title of the 24                  document you have in front of you -- it's also on                     the screen. It's "Healthcare Distribution</p>	<p style="text-align: right;">Page 136</p> <p>1                  MR. RICARD: Same objection. 2                  A. Yes. 3                  Q. And you have an understanding, just like 4                  with the HDMA, that in order for the guidelines to 5                  come out, all the members of the HDMA have to 6                  approve it, correct? 7                  A. I suppose, yeah. 8                  Q. Okay. And then -- so in the 9                  introduction -- and I'm going to skip the first 10                  sentence and go to the next sentence that begins 11                  with "Manufacturers." 12                  It says, "Manufacturers, distributors, 13                  pharmacies, and healthcare practitioners share a 14                  mission and responsibility to continuously 15                  monitor, protect, and enhance the safety and 16                  security of this system to combat the increasing 17                  sophisticated criminals who attempt to breach the 18                  security of the legitimate supply chain." 19                  And I'm sure PSI would agree that that 20                  is the goal of the industry. 21                  MR. RICARD: Object to form. 22                  A. Yes. 23                  Q. All right. If you go down to the third 24                  paragraph on the page. It says, "At the center of</p>
<p style="text-align: right;">Page 135</p> <p>1                  Management Association (HDMA) Industry Compliance 2                  Guidelines." What this appears to be -- and 3                  correct me if I am wrong -- is it's guidelines put 4                  out by the HDMA for its industry, which is the 5                  wholesale distribution industry, right? 6                  A. That's correct. 7                  Q. All right. And it says, "Reporting 8                  Suspicious Orders and Preventing Diversion of 9                  Controlled Substances." 10                  Correct? 11                  A. Yes. 12                  Q. And Prescription Supply, Inc., would 13                  agree that part of how we prevent diversion is by 14                  reporting suspicious orders, correct? 15                  A. Yes. 16                  Q. Now, these are, for lack of a better 17                  term -- we looked at the federal regulations and 18                  the federal code. These are the industry's own 19                  safety rules, if you will, that the industry came 20                  up with themselves, correct? 21                  MR. RICARD: Objection to form. 22                  A. Yes. 23                  Q. In regulating how they're going to deal 24                  with controlled substances?</p>	<p style="text-align: right;">Page 137</p> <p>1                  a sophisticated supply chain, distributors are 2                  uniquely situated to perform due diligence in 3                  order to help support the security of the 4                  controlled substances they deliver to their 5                  customers." 6                  Does Prescription Supply, Inc., agree 7                  and accept that responsibility? 8                  MR. RICARD: Object to form. 9                  A. Yes. 10                  Q. And it talks about due diligence. That 11                  would be what we were referring to earlier when we 12                  talked about knowing your customers and 13                  investigating potential suspicious orders and 14                  things of that nature, correct? 15                  A. Yes. 16                  Q. And is that what Prescription Supply 17                  does when it's operating in this realm? 18                  A. Yes. 19                  Q. It says, "Due diligence can provide a 20                  greater level of assurance that those who purchase 21                  controlled substances from distributors intend to 22                  dispense them for legally acceptable purposes." 23                  And, again, that's part of the goal of 24                  having the system in place and doing due</p>

<p style="text-align: right;">Page 138</p> <p>1 diligence, is to ensure that it's only being used</p> <p>2 for legitimate means, correct?</p> <p>3 MR. RICARD: Object to form.</p> <p>4 A. Yes.</p> <p>5 Q. "Such due diligence can reduce the</p> <p>6 possibility that controlled substances within the</p> <p>7 supply chain will reach locations they are not</p> <p>8 intended."</p> <p>9 Does Prescription Supply agree with</p> <p>10 that, that doing the due diligence can help</p> <p>11 prevent diversion?</p> <p>12 A. Yes.</p> <p>13 MR. RICARD: Object to form.</p> <p>14 Q. Does Prescription Supply agree with the</p> <p>15 reverse, that not doing due diligence can</p> <p>16 potentially lead to diversion?</p> <p>17 MR. RICARD: Object to form.</p> <p>18 A. Yeah, I suppose.</p> <p>19 Q. So, for example, with Prescription</p> <p>20 Supply, if you had taken -- or Prescription Supply</p> <p>21 had taken on some of those shady customers that we</p> <p>22 had talked about who --</p> <p>23 A. Customers that we didn't take on, yes.</p> <p>24 Q. You don't want to call them shady. I</p>	<p style="text-align: right;">Page 140</p> <p>1 Do you see that?</p> <p>2 A. Yes.</p> <p>3 Q. And under the introduction, it says,</p> <p>4 "Before opening an account for a new customer, the</p> <p>5 distributor should (i) obtain background</p> <p>6 information on the customer and the customer's</p> <p>7 business; (ii) review that information carefully</p> <p>8 and, where appropriate, verify the information,</p> <p>9 and; (iii) independently investigate the potential</p> <p>10 customer."</p> <p>11 Would you agree that that is the type of</p> <p>12 due diligence that needs to be done before opening</p> <p>13 a new customer account?</p> <p>14 MR. RICARD: Objection to form.</p> <p>15 A. Yes.</p> <p>16 Q. Okay. B on that page deals with</p> <p>17 information gathering. And we're going to skip</p> <p>18 sort of down to the bullet points. Do you see</p> <p>19 "The information gathering step would include"?</p> <p>20 And it provides a whole laundry list there.</p> <p>21 Do you see that?</p> <p>22 A. I see it.</p> <p>23 Q. Including credit application, background</p> <p>24 questionnaires, business background, number of</p>
<p style="text-align: right;">Page 139</p> <p>1 get that. But I've read some of what they've said</p> <p>2 and didn't say, and clearly they were shady. I'll</p> <p>3 rephrase it.</p> <p>4 A. There were reasons why we didn't take</p> <p>5 them on, yes.</p> <p>6 Q. I'll rephrase it. If Prescription</p> <p>7 Supply had taken on those customers they didn't</p> <p>8 deem desirable for whatever reason, maybe</p> <p>9 documented in the file, there's a greater chance</p> <p>10 that diversion would have occurred with those</p> <p>11 entities?</p> <p>12 A. Yes.</p> <p>13 Q. And that's the reason that you declined</p> <p>14 to accept those new customers?</p> <p>15 A. Yes.</p> <p>16 Q. Okay.</p> <p>17 Go to page 4. "Know Your Customer Due</p> <p>18 Diligence."</p> <p>19 And this industry guideline, these safety</p> <p>20 rules that the HDMA put out, addresses each one of these</p> <p>21 issues, or at least some of them, that we've talked</p> <p>22 about, Mr. Schoen, in order. So number I -- or I there</p> <p>23 at the beginning of the page is "Know Your Customer Due</p> <p>24 Diligence."</p>	<p style="text-align: right;">Page 141</p> <p>1 prescriptions filled each day, so forth and so on.</p> <p>2 Are those the type of things that</p> <p>3 Prescription Supply undertakes in reviewing and</p> <p>4 obtaining prior to opening a new customer account?</p> <p>5 A. Yes.</p> <p>6 Q. Is that the type of, to your</p> <p>7 knowledge -- strike that.</p> <p>8 Now, let's go to page 7.</p> <p>9 And, Mr. Schoen, let's talk just a</p> <p>10 second. So we have this due diligence, know your</p> <p>11 customer requirement which we've talked about</p> <p>12 some, and we also have something that's referred</p> <p>13 to as thresholds.</p> <p>14 Have you ever heard of the term</p> <p>15 "threshold" before?</p> <p>16 A. Yes.</p> <p>17 Q. So now we're going to talk a little bit</p> <p>18 about that under this auspice of monitoring for</p> <p>19 suspicious orders, okay? And it says "Identifying</p> <p>20 Product and Customer Characteristics."</p> <p>21 Now, before I read to you what is here</p> <p>22 in the HDMA safety rules, let me ask you, when</p> <p>23 you're looking at thresholds at PSI, do you break</p> <p>24 it down by drug families?</p>

<p style="text-align: right;">Page 142</p> <p>1 A. Yes.</p> <p>2 Q. Okay. So technically --</p> <p>3 A. Can I at least --</p> <p>4 Q. Absolutely.</p> <p>5 A. I think we broke it down by drug</p> <p>6 families from about 2006 on.</p> <p>7 Q. Okay.</p> <p>8 A. Up until then we did each and every item</p> <p>9 separately, okay? So if they were different</p> <p>10 brands or different manufacturers, we would know</p> <p>11 if it was this -- if it was this item,</p> <p>12 40-milligram, whatever size. So we would have the</p> <p>13 total of that. But we didn't put them in drug</p> <p>14 families until, I think, '06.</p> <p>15 Q. Okay. So, for example, if we had --</p> <p>16 prior to '06, if we had OxyContin -- which is a</p> <p>17 name brand, right?</p> <p>18 A. Mm-hmm.</p> <p>19 Q. -- and we had a 40-milligram and an</p> <p>20 80-milligram --</p> <p>21 A. Yes, it would be two different lines.</p> <p>22 Q. Okay. And there would be a separate</p> <p>23 threshold for each?</p> <p>24 A. Yeah -- well, yes, I guess. Yes.</p>	<p style="text-align: right;">Page 144</p> <p>1 Q. Got it. So we'll go from 2006 forward,</p> <p>2 or since then, PSI has been categorizing them by</p> <p>3 drug families?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. And that's what this says, I</p> <p>6 think. "Identify Product and Customer</p> <p>7 Characteristics."</p> <p>8 Now, let me break out the second part.</p> <p>9 Does PSI break out separate thresholds for</p> <p>10 different customer characteristics, say larger</p> <p>11 pharmacies versus smaller pharmacies or a</p> <p>12 hospital-based pharmacy versus a retail chain</p> <p>13 pharmacy or so forth?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. Then these HDMA safety rules</p> <p>16 read, "Separate/classify/group customers into</p> <p>17 appropriate/different classes of trade. For</p> <p>18 example, retail, pharmacies, hospitals, doctors,</p> <p>19 and dentists -- or dentists."</p> <p>20 A. Mm-hmm.</p> <p>21 Q. And that's what PSI did, correct?</p> <p>22 A. Yes.</p> <p>23 Q. "Separate the controlled substances, or</p> <p>24 CS, the distributor sells into groups or families</p>
<p style="text-align: right;">Page 143</p> <p>1 Q. Okay.</p> <p>2 A. There would be a certain -- yeah, yeah.</p> <p>3 Q. To the best of your --</p> <p>4 A. We unfortunately didn't put them</p> <p>5 together at that time.</p> <p>6 Q. Right. You did them separately?</p> <p>7 A. We did them separately, because at that</p> <p>8 time, it was what we could do.</p> <p>9 Q. And you say "what you could do." Is it</p> <p>10 just because of the way the computer software was</p> <p>11 or --</p> <p>12 A. It's because we didn't have -- we</p> <p>13 probably could have put the 80s and 40s together</p> <p>14 or whatever, but there were a lot of things that</p> <p>15 we just didn't realize this was that and something</p> <p>16 else.</p> <p>17 Q. Okay.</p> <p>18 A. When we got into -- we finally were able</p> <p>19 to get a -- from a source, we were able to get how</p> <p>20 we could put together the families. And then as</p> <p>21 soon as we were able to do that, we did put</p> <p>22 together the families, which made more sense. We</p> <p>23 should have done it that way, but we just weren't</p> <p>24 able to before that.</p>	<p style="text-align: right;">Page 145</p> <p>1 of drugs, i.e., all controlled items containing</p> <p>2 codeine. The following information may be useful</p> <p>3 for identifying the families of drugs."</p> <p>4 And then it give us a long laundry list</p> <p>5 of ways of characterizing them.</p> <p>6 If you turn to the next page, here's</p> <p>7 where it talks about the "Develop Thresholds to</p> <p>8 Identify Orders of Interest."</p> <p>9 Do you see that there?</p> <p>10 A. Yes.</p> <p>11 Q. And it gives several that could be</p> <p>12 considered in developing thresholds. It says,</p> <p>13 "Patterns of ordering, such as comparing the</p> <p>14 present order to: Past orders from the same</p> <p>15 consumer."</p> <p>16 Do you see that?</p> <p>17 A. Yes.</p> <p>18 Q. "Orders from extraordinary quantities</p> <p>19 outside of normal purchasing patterns typically</p> <p>20 followed by the customer or the customers within</p> <p>21 the same class of trade and geographical areas,"</p> <p>22 so forth and so on.</p> <p>23 And then it goes on to say that</p> <p>24 "Distributors are also encouraged to consider the</p>

Page 146

1 following when developing thresholds: Quantities  
 2 of product the dispenser initially indicated  
 3 during the 'Know Your Customer Due Diligence'  
 4 phase that is expected to be purchased -- that it  
 5 expected to purchase"?  
 6 A. Mm-hmm.  
 7 Q. "A minimum of six months sales history  
 8 and a maximum of 24 months sales history are  
 9 recommended."  
 10 And when it "sales history," it means  
 11 from the potential customer, correct?  
 12 A. It does.  
 13 Q. And you can ask the pharmacies to  
 14 provide you with their -- I think it's been  
 15 referred to as different things, but their dosage  
 16 history --  
 17 A. That's correct.  
 18 Q. -- or sales history, right?  
 19 A. We can and do.  
 20 Q. And are the pharmacies -- if they want  
 21 your business or they want you to sell to them,  
 22 are they usually willing to provide you with that  
 23 information?  
 24 A. Yes.

Page 147

1 Q. Now, if they don't, would that send up a  
 2 red flag?  
 3 A. Yes.  
 4 Q. And why is that?  
 5 A. Well, I mean, if they don't want to tell  
 6 us what they're going to buy or what their usage  
 7 is, it -- I mean, I probably wouldn't be doing --  
 8 well, I probably -- it certainly would send up a  
 9 red flag.  
 10 Q. Okay. And because it causes you concern  
 11 because that's part of the due diligence you have  
 12 to do --  
 13 A. That's right.  
 14 Q. -- as a distributor to know your  
 15 customer?  
 16 A. That's right.  
 17 Q. And without that, you can't complete  
 18 your tasks, right?  
 19 A. That's true.  
 20 Q. Sort of like failing to report  
 21 suspicious orders doesn't give the DEA the  
 22 information they need to do their job, right?  
 23 A. Right.  
 24 MR. RICARD: Object to form.

Page 148

1 Q. And Prescription Supply agrees with  
 2 these safety guidelines put out by the HDMA --  
 3 A. Yes.  
 4 Q. -- that this is what should be done?  
 5 MR. RICARD: Object to form.  
 6 A. Yes.  
 7 Q. All right. We're going to jump to page  
 8 11. There's a section there on documentation.  
 9 Mr. Schoen, Prescription -- PSI would agree that  
 10 documentation in this area is very important,  
 11 correct?  
 12 MR. RICARD: Object to form.  
 13 A. Yes.  
 14 Q. Because we need to be able to look back  
 15 and see and know what has transpired in the course  
 16 of dealing with customers. We need to  
 17 substantiate the Know Your Customer investigation  
 18 we've done, so forth and so on, correct?  
 19 MR. RICARD: Same objection.  
 20 A. Yes.  
 21 Q. And it says here, "All investigation  
 22 should be fully documented, and all records of the  
 23 investigation should be retained in the  
 24 appropriate location within the firm."

Page 149

1 Within parentheses it says "such as with  
 2 other records relating to the particular  
 3 customer."  
 4 Does Prescription Supply agree with  
 5 that --  
 6 MR. RICARD: Object to form.  
 7 Q. -- safety rule as stated by the HDMA?  
 8 A. Yes. We probably haven't always done it  
 9 properly, but yes.  
 10 Q. But that's the best practice; that's the  
 11 safest practice?  
 12 A. That would be the safest practice.  
 13 Q. "At a minimum, documentation should  
 14 include the name, title, and other relevant  
 15 identification of the representative of the  
 16 customer contacted, dates of contact, and a full  
 17 description of the questions asked and requests  
 18 for information made by the distributor and of  
 19 information provided by the customer."  
 20 The document should -- "the  
 21 documentation should include a clear statement of  
 22 the final conclusion of the investigation,  
 23 including why the order investigated was or was  
 24 not determined to be suspicious."

<p style="text-align: right;">Page 150</p> <p>1 Do you see that there?</p> <p>2 A. Okay. All right.</p> <p>3 Q. And do you agree with that, that that is</p> <p>4 the proper standard to conduct yourself as a</p> <p>5 registrant?</p> <p>6 MR. RICARD: Objection to form.</p> <p>7 A. Yes. But I don't think we've always</p> <p>8 done it. We've always asked the questions, but I</p> <p>9 don't know if we've always appropriately noted</p> <p>10 them.</p> <p>11 Q. Right. And I've looked at the discovery</p> <p>12 that has been provided, and we're going to just</p> <p>13 sort of put out there that 8,000-pound gorilla</p> <p>14 that may be standing over my shoulder.</p> <p>15 Prescription Supply did not report any</p> <p>16 suspicious orders, did they?</p> <p>17 A. That's correct.</p> <p>18 Q. Okay. But -- and let's continue with</p> <p>19 that. You believe that they did do the best job</p> <p>20 they could investigating new clients, new</p> <p>21 customers?</p> <p>22 A. Yes.</p> <p>23 Q. And as I mentioned to you earlier,</p> <p>24 there's documentation throughout the files of the</p>	<p style="text-align: right;">Page 152</p> <p>1 questions. I was not in a position to say there</p> <p>2 was something wrong with this customer. I just</p> <p>3 didn't want to do business with them because I was</p> <p>4 concerned.</p> <p>5 Q. Right. Of potential issues dealing with</p> <p>6 controlled substances?</p> <p>7 A. Potential issues.</p> <p>8 Q. With controlled substances, correct?</p> <p>9 A. Among other things, yeah.</p> <p>10 Q. Sure.</p> <p>11 Now, we're not going to spend the rest</p> <p>12 of the time going over all the -- I don't know how</p> <p>13 many pages are in this document total, 15 -- 14,</p> <p>14 15. But Prescription Supply would agree, would it</p> <p>15 not, with the HDMA safety rules that were</p> <p>16 previously provided to it?</p> <p>17 A. Yes.</p> <p>18 MR. RICARD: Object to form.</p> <p>19 MR. FULLER: So next is going to be 404.</p> <p>20 BY MR. FULLER:</p> <p>21 Q. So next, Mr. Schoen, I think we're going</p> <p>22 to go to something that you probably have seen</p> <p>23 before, some of your policies and procedures that</p> <p>24 you guys had at PSI.</p>
<p style="text-align: right;">Page 151</p> <p>1 discovery of Prescription Supply even declining</p> <p>2 potential customers --</p> <p>3 A. Yes.</p> <p>4 Q. -- because of we'll call them red flags?</p> <p>5 A. Yes. But I don't know if we actually</p> <p>6 put down why we declined them.</p> <p>7 Q. I will --</p> <p>8 A. It became obvious, but ...</p> <p>9 Q. Right. I will represent to you that</p> <p>10 there were issues of concern in some of the</p> <p>11 documents I reviewed.</p> <p>12 A. Yes.</p> <p>13 Q. And it said "Ask Tom."</p> <p>14 A. Mm-hmm.</p> <p>15 Q. And then there would be a handwritten</p> <p>16 note that "Tom says tell them no."</p> <p>17 So I think on some of them, it was</p> <p>18 abundantly clear what the issues were based on the</p> <p>19 investigation.</p> <p>20 A. I hope so, yes. But we didn't -- I</p> <p>21 don't think we put down any specific reason.</p> <p>22 Q. And you recognize that you probably</p> <p>23 should have?</p> <p>24 A. It was abundantly clear that there were</p>	<p style="text-align: right;">Page 153</p> <p>1 ---</p> <p>2 (PSI-Schoen Exhibit 19 marked.)</p> <p>3 ---</p> <p>4 Q. And I'll be honest with you. Some of</p> <p>5 them I completely understood and got it. Some I</p> <p>6 didn't. And there's some issues that I want to</p> <p>7 hit real briefly and go over with you.</p> <p>8 So what has been marked for -- or I</p> <p>9 guess attached as Plaintiff's Exhibit 19, which</p> <p>10 you have there, is a Prescription Supply, Inc.,</p> <p>11 document; is that right?</p> <p>12 A. It is.</p> <p>13 Q. Okay. And I think this is the first one</p> <p>14 where we have a Bates number for this case, which</p> <p>15 is PSI0000648, and is this document named</p> <p>16 "Inventory Controls."</p> <p>17 A. Yes.</p> <p>18 Q. Okay. And this is one of your policies</p> <p>19 and procedures at Prescription Supply; is that</p> <p>20 correct?</p> <p>21 A. It is.</p> <p>22 Q. Okay. Now, it has an effective date of</p> <p>23 what?</p> <p>24 A. 7/30/09 apparently.</p>

<p style="text-align: right;">Page 154</p> <p>1 Q. No. Look right above that.</p> <p>2 A. I'm sorry. I keep reading it back.</p> <p>3 Well, from 12/08 to --</p> <p>4 Q. Look a little bit above that.</p> <p>5 A. Oh, I see. June 2000. Okay.</p> <p>6 Q. I'm telling you, use the screen as kind</p> <p>7 of like your little cheat sheet. That's exactly</p> <p>8 where I'm at.</p> <p>9 So this document at least indicates that</p> <p>10 it was effective as of June of 2000, correct?</p> <p>11 A. Well, it's been revised, yes.</p> <p>12 Q. And it's been revised, and we have the</p> <p>13 revision dates there?</p> <p>14 A. Yes.</p> <p>15 Q. And do you believe those to be accurate?</p> <p>16 A. Yes.</p> <p>17 Q. To the best of your knowledge?</p> <p>18 A. Yes.</p> <p>19 Q. Do you believe this to be an accurate</p> <p>20 copy of a document that's kept in the normal</p> <p>21 course of business for Prescription Supply?</p> <p>22 A. Yes.</p> <p>23 Q. Okay. And I'll tell you, I'm going to</p> <p>24 sort of go through that with each document, and</p>	<p style="text-align: right;">Page 156</p> <p>1 same last name as your sister, I'm assuming she is</p> <p>2 related.</p> <p>3 A. Her daughter, yes.</p> <p>4 Q. Okay.</p> <p>5 A. She's my niece.</p> <p>6 Q. Got it. Got it.</p> <p>7 A. There's a lot of family in the business.</p> <p>8 Q. I saw the org chart. I agree with you.</p> <p>9 A. Yes, and a lot that you don't even</p> <p>10 recognize.</p> <p>11 Q. Probably so. Probably so. It's truly a</p> <p>12 family business. No, I get that.</p> <p>13 A. Yes.</p> <p>14 Q. Is Candy still employed with the</p> <p>15 company?</p> <p>16 A. She is.</p> <p>17 Q. Okay. Great. And she would probably be</p> <p>18 the best one to check with; is that right?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. Now, this says -- this policy</p> <p>21 is -- it says, "Prescription Supply, Inc., will</p> <p>22 monitor inventory for: Critical [sic] accounts,</p> <p>23 suspicious purchases and losses, theft, or</p> <p>24 otherwise missing products. "</p>
<p style="text-align: right;">Page 155</p> <p>1 it's just a predicate that I have to lay for legal</p> <p>2 purposes, okay?</p> <p>3 A. Okay.</p> <p>4 Q. So don't get frustrated with me because</p> <p>5 it's the same question every time, all right?</p> <p>6 A. All right.</p> <p>7 Q. And I inquired of counsel of this. And</p> <p>8 there's some of these where I have a couple</p> <p>9 different versions, maybe an older version and</p> <p>10 then the newer version.</p> <p>11 A. Perhaps.</p> <p>12 Q. Do you know if Prescription Supply has</p> <p>13 maintained copies from the original of June of</p> <p>14 2000?</p> <p>15 A. I don't know.</p> <p>16 Q. Who would be the best person at</p> <p>17 Prescription Supply to ask? Any idea?</p> <p>18 A. Well, yeah. I mean the --</p> <p>19 Q. And what I'm looking for, is there</p> <p>20 someone that would just deal with this</p> <p>21 administrative stuff that maybe --</p> <p>22 A. Candy would have -- Candy Harbauer would</p> <p>23 have probably been doing most of this.</p> <p>24 Q. And Candy Harbauer, because she has the</p>	<p style="text-align: right;">Page 157</p> <p>1 And if you go down --</p> <p>2 MR. RICARD: It says "cyclical,"</p> <p>3 Counsel.</p> <p>4 MR. FULLER: I'm sorry. Cyclical. What</p> <p>5 did I say?</p> <p>6 MR. RICARD: "Critical."</p> <p>7 MR. FULLER: Oh. I apologize.</p> <p>8 BY MR. FULLER:</p> <p>9 Q. If you go down the page -- there you go.</p> <p>10 Under Responsibilities, it says, "Customer service</p> <p>11 representatives and/or warehouse manager shall</p> <p>12 forward all suspicious prescription product orders</p> <p>13 to the director of purchasing prior to</p> <p>14 fulfillment. Suspicious orders can be identified</p> <p>15 as, but not limited to, those orders of unusual</p> <p>16 size, orders deviating substantially from a normal</p> <p>17 pattern, and orders of unusual frequency.</p> <p>18 Suspicious orders may or may not be criminally</p> <p>19 suspected."</p> <p>20 Did I read that right?</p> <p>21 A. You did.</p> <p>22 Q. All right. So the way the process -- my</p> <p>23 understanding of the process is the customer</p> <p>24 service representative or warehouse manager would</p>

<p style="text-align: right;">Page 158</p> <p>1 pick up on a suspicious order and bring it to the 2 director of purchasing prior to shipping, correct? 3 A. Actually, the computer stops any order 4 that would have been out of -- would be of 5 interest, okay? 6 Q. Okay. And when you say any order that 7 would be out of interest, do you know how the 8 computer determines what would be of interest or 9 suspicious? 10 A. All of the -- it takes into 11 consideration everything that we've talked about 12 here. The -- if it's over the threshold, if 13 it's -- remember that Prescription Supply in 2000 14 or -- we had a lot of accounts that were -- that 15 we were the primary of, okay? In 2018, we have 16 relatively few accounts that we are a primary 17 supplier for -- 18 Q. Right. 19 A. -- okay? Things have evolved in that 20 way. 21 In 2000, we were in a position -- we had 22 actually an advantage over the big three or other 23 wholesalers, in that you could fax us a C-II blank. We 24 could fill it from the fax -- because we used our own</p>	<p style="text-align: right;">Page 160</p> <p>1 Q. Because you could turn them around more 2 quickly? 3 A. Because we could turn them around right 4 away. 5 What was my -- go back and give the 6 question again so I -- 7 Q. Well, we were starting to talk about how 8 the computer stops it. 9 A. Oh, okay. All right. As time went on, 10 we developed a suspicious order monitoring system, 11 okay? Actually, probably by around -- dates are a 12 bit of a problem. But, anyway, somewhere around 13 2- -- well, in '96, we had some kind of an order. 14 We have different systems that we use to 15 check sales by customer and send off orders to -- 16 or actually reports to the DEA on excessive 17 purchases or -- not excessive but out-of-line 18 purchases. 19 We continued doing that right up until 20 2013 when they asked us to stop, okay? Now, we 21 had other suspicious order systems over -- 22 evolving through that time period, but we did 23 actually report an awful lot of stuff. The 24 problem is that they didn't have the ability to</p>
<p style="text-align: right;">Page 159</p> <p>1 delivery people -- so they were our employees -- we 2 could deliver that item the same day, have that delivery 3 person, that employee, check and pick up the actual 4 physical narcotic blank, check it to make sure the 5 number was the same, and that the -- no other items had 6 been added to or subtracted on it, which was relatively 7 easy to do -- 8 Q. Sure. 9 A. -- okay? And bring it back to us, and 10 we would file that in our system, okay? And we'd 11 process it. But we had already processed the 12 drugs out to the pharmacy. 13 Q. Based on the facts? 14 A. Based on the facts, yes. 15 Q. Got it. 16 A. All right. Because we could do that and 17 because there wasn't an electronic order 18 processing system at that time, which there is 19 now, we did an inordinate amount of C-II business, 20 okay? 21 I'm not saying we did anything wrong. 22 We didn't, okay? But we got a far greater 23 percentage of C-II orders than our size would have 24 indicated, okay, because of our advantage.</p>	<p style="text-align: right;">Page 161</p> <p>1 look into all these. It was too much paperwork, 2 too much stuff, okay? 3 So we stopped sending those orders, 4 okay, those -- what we considered a suspicious 5 order -- or maybe not a suspicious order. An 6 out-of-line order, okay? 7 Q. Order of interest? 8 A. Order of interest, okay? 9 Q. Okay. 10 A. Now, the computer does stop an order 11 before it's -- before it can be shipped, okay? 12 Q. Yes, sir. 13 A. Then we do -- we look at that order and 14 make the decision, and take whatever due diligence 15 is necessary, make calls to the customer, and 16 decide if we should ship it or not. And that's 17 the way we operate. 18 Q. So -- and let me back up. 19 You mentioned at one time you were 20 sending stuff to the DEA. 21 A. Yes. 22 Q. Okay. Now, you've always been reporting 23 ARCOS data to the DEA? 24 A. Oh, of course.</p>

<p style="text-align: right;">Page 162</p> <p>1 Q. And that hasn't stopped?</p> <p>2 A. No.</p> <p>3 Q. Always been there?</p> <p>4 A. Yes.</p> <p>5 Q. Still going on today?</p> <p>6 A. Of course, yes.</p> <p>7 Q. Okay. So we're not referring to ARCOS</p> <p>8 data?</p> <p>9 A. No, no.</p> <p>10 Q. Now, you mentioned excessive order</p> <p>11 reports?</p> <p>12 A. Yes.</p> <p>13 Q. That may be at one time what was being</p> <p>14 sent to the DEA, correct?</p> <p>15 A. You could say that, yes. Yes.</p> <p>16 Q. Okay. Now, excessive order reports are</p> <p>17 different than suspicious order reports?</p> <p>18 A. That's correct.</p> <p>19 Q. Okay. Do you -- during this time prior</p> <p>20 to '13, do you recollect ever reporting suspicious</p> <p>21 orders?</p> <p>22 A. No, we never reported suspicious orders.</p> <p>23 Q. Okay. And you mentioned --</p> <p>24 A. Nor have we ever shipped a suspicious</p>	<p style="text-align: right;">Page 164</p> <p>1 Q. Did PSI ever report any suspicious order</p> <p>2 to the Board of Pharmacy as required by the code?</p> <p>3 MR. RICARD: Object to form.</p> <p>4 A. No. But we were -- actually, we only</p> <p>5 saw the State -- we saw them in '95, and we saw</p> <p>6 them in '18. I believe it was '18.</p> <p>7 Q. I think it may have been '17.</p> <p>8 A. It could have been '17.</p> <p>9 Q. Yeah.</p> <p>10 A. In '17. Those are the only two times we</p> <p>11 saw the State Board. I talked to State Board</p> <p>12 people, but they never came into Prescription</p> <p>13 Supply, okay? When they did come into</p> <p>14 Prescription Supply, they asked -- they did their</p> <p>15 investigation. They did ask about a number of</p> <p>16 stores.</p> <p>17 Q. Four of them, actually, right?</p> <p>18 A. Four actually, yes. And why and how, we</p> <p>19 checked in and what we did in those stores, okay?</p> <p>20 And we gave them I believe in three of four</p> <p>21 appropriate documentation. I believe the fourth</p> <p>22 store -- in my own memory, the fourth store, they</p> <p>23 wanted to know why we stopped shipping to them,</p> <p>24 and it's because they stopped buying from us.</p>
<p style="text-align: right;">Page 163</p> <p>1 order.</p> <p>2 Q. Okay. Now, let's break that down before</p> <p>3 we move on.</p> <p>4 A. Okay.</p> <p>5 Q. The suspicious order requirement under</p> <p>6 the C.F.R., the Code of Federal Regulation, does</p> <p>7 not require you to have shipped it before you</p> <p>8 reported it, right?</p> <p>9 MR. RICARD: Object to form.</p> <p>10 A. In fact, I believe you're not supposed</p> <p>11 to ship it.</p> <p>12 Q. Right. So while you mentioned you</p> <p>13 didn't ship any suspicious orders, that doesn't</p> <p>14 relieve PSI of its obligation to still report</p> <p>15 them?</p> <p>16 MR. RICARD: Object to form.</p> <p>17 Q. You would agree with that, correct?</p> <p>18 A. Yes.</p> <p>19 Q. Okay. Now, let's take that -- let's go</p> <p>20 another way. We also looked at the Ohio</p> <p>21 Administrative Code, and that also requires</p> <p>22 certain types of orders to be reported; is that</p> <p>23 right?</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 165</p> <p>1 Q. That was the one that was sold to CVS?</p> <p>2 A. That's right.</p> <p>3 Q. Yeah, I remember that.</p> <p>4 A. Yes.</p> <p>5 Q. Now, so you said PSI has had two</p> <p>6 encounters with the Board of Pharmacy, that one</p> <p>7 that we were just talking about in '17.</p> <p>8 A. Yeah, way back in '95 when we opened --</p> <p>9 that's when we built -- that's when we moved into</p> <p>10 our new facility.</p> <p>11 Q. The building you're currently in?</p> <p>12 A. That's right.</p> <p>13 Q. Got it. Got it.</p> <p>14 Now, was that just when -- your</p> <p>15 interaction with the Board of Pharmacy back in</p> <p>16 '95, was that just the inspections and whatnot on</p> <p>17 your building?</p> <p>18 A. It was.</p> <p>19 Q. Okay. Did the DEA come out and inspect</p> <p>20 the building, too?</p> <p>21 A. Of course.</p> <p>22 Q. Now, Prescription Supply currently has,</p> <p>23 like you mentioned, a computer system in place --</p> <p>24 A. Correct.</p>

Page 166

1 Q. -- that prevents suspicious orders or  
2 orders of interest, whatever you want to call  
3 them, from being shipped. It stops them from  
4 before they get --

5 A. It stops them before they're shipped,  
6 yes.

7 Q. That some sort of red flag brings --

8 A. That's right.

9 Q. -- it to someone's attention?

10 A. Yes.

11 MR. RICARD: Wait until he's finished  
12 with the question. You're doing fine.

13 BY MR. FULLER:

14 Q. Does -- strike that.

15 When did that computer system first come  
16 into place, best you can recollect?

17 MR. RICARD: Don't guess.

18 A. Don't guess. I honestly can't tell you  
19 that, when they became --

20 Q. Are we talking in the last two or  
21 three -- let me ask you this --

22 A. No.

23 Q. Was it --

24 A. Before then.

Page 167

1 Q. Okay. Let me ask you specifically. Was  
2 it before or after the Board of Pharmacy came to  
3 you?

4 A. Oh, long before.

5 Q. Long before?

6 A. Yeah. I just don't know if it was  
7 before 2006 or -- it was at least operational in  
8 2006.

9 Q. Okay. So that kind of time frame we're  
10 talking about?

11 A. Yes.

12 Q. Maybe even further back?

13 A. Yes, but I can't tell you for sure when.

14 Q. Fair enough. Fair enough.

15 So if we continue down on the page,  
16 starting on the bottom of the page and rolling on  
17 to the next. Okay. It says, "The IT manager  
18 shall be responsible for suspicious order  
19 monitoring reports and sharing concerns with the  
20 DR/DR supervisor. He/she is responsible for  
21 sending all reports to the DEA and governing state  
22 agencies and maintaining records for at least six  
23 years or as required by law."

24 Do you see that?

Page 168

1 A. I see that.

2 Q. And who was the IT or is the IT manager?

3 A. Kirk Harbauer.

4 (Reporter clarification.)

5 A. Kirk, like in Captain Kirk.

6 Q. Harbauer. Is that your nephew?

7 A. My nephew.

8 Q. Okay. And how long has he been the IT  
9 manager? For quite sometime?

10 A. Quite sometime.

11 Q. Okay. So I'm assuming because he's IT,  
12 he's working with computer systems and that's --  
13 the flags would come to him; is that correct, or  
14 do you know?

15 A. No. The flags would come to the -- into  
16 the filling area --

17 Q. Okay.

18 A. -- okay? Those decisions would be made  
19 in the -- where the process -- I'm trying -- yes,  
20 the computer person, you know, makes sure that the  
21 system is functioning, okay?

22 Q. Okay.

23 A. But ...

24 Q. So Kirk would be responsible for the

Page 169

1 suspicious order monitoring reports and sharing  
2 those concerns with the DR or DR supervisor. And  
3 I'm not sure what a DR is.

4 A. To be honest with you, I'm not sure what  
5 a DR is. We got into having DRs and DR  
6 supervisors because we had to pass certain  
7 requirements by the national board of state --  
8 national board of state boards, okay?

9 Q. Okay.

10 A. Okay? And they came in and required us  
11 to type up thousands of pages of -- which is why  
12 you have all these pages, okay?

13 Q. Fair enough.

14 A. Unfortunately, we probably wouldn't have  
15 had them without that.

16 Q. Now, can you tell me what a DR or DR  
17 supervisor does? Probably not a good question,  
18 huh?

19 A. That's not a good question.

20 Obviously a DR supervisor supervises the  
21 DR. I believe -- I'm not even sure who the -- if  
22 I'm the DR or the DR supervisor by definition,  
23 okay?

24 Q. Does DR stand for something other than

<p style="text-align: right;">Page 170</p> <p>1 doctor?</p> <p>2 A. Yeah. It stands for something other</p> <p>3 than doctor, yes.</p> <p>4 Q. You're not sure what?</p> <p>5 A. I'm not sure what.</p> <p>6 Q. Fair enough.</p> <p>7 But, still, and according to this, the</p> <p>8 IT manager is responsible for sending all reports</p> <p>9 to the DEA and the state agencies, right?</p> <p>10 A. Right.</p> <p>11 Q. But that never got done?</p> <p>12 A. Because it never got that far, because</p> <p>13 when we had an order of interest, we would do due</p> <p>14 diligence on that order. We didn't discover</p> <p>15 anything that was criminally reportable.</p> <p>16 Q. Well -- so it's PSI's position that they</p> <p>17 never -- well, strike that. Let me ask it</p> <p>18 differently.</p> <p>19 So were there ever orders that got cut?</p> <p>20 A. Yeah.</p> <p>21 Q. Well, would -- and you cut them because</p> <p>22 they were --</p> <p>23 A. Because they were -- they beat the</p> <p>24 threshold.</p>	<p style="text-align: right;">Page 172</p> <p>1 determined how at Prescription Supply, Inc.?</p> <p>2 A. There's a lot of things that go into</p> <p>3 thresholds, okay?</p> <p>4 Q. Okay. Now, and I'll tell you before we</p> <p>5 get started, I didn't see a policy and procedure</p> <p>6 related to setting thresholds. I saw where the</p> <p>7 Board of Pharmacy asked, I think, in this area in</p> <p>8 follow-up to the investigation from last year --</p> <p>9 A. Right.</p> <p>10 Q. -- "Explain to us how you set</p> <p>11 thresholds." And I didn't see a reply from PSI</p> <p>12 going back. So can you explain to the jury how</p> <p>13 PSI sets thresholds?</p> <p>14 A. There are a lot of things that go into</p> <p>15 setting thresholds. Number one would be the</p> <p>16 number of prescriptions the pharmacy fills per</p> <p>17 day, for example, or per month or whatever. So if</p> <p>18 he's a much bigger pharmacy, he could probably</p> <p>19 have a larger threshold. Number two --</p> <p>20 Q. Sure.</p> <p>21 A. -- he gives us an estimate of what his</p> <p>22 use is, okay? We look at the number of</p> <p>23 prescriptions he fills, okay, relative to the</p> <p>24 usage of controlled substances that he's getting,</p>
<p style="text-align: right;">Page 171</p> <p>1 Q. Okay.</p> <p>2 A. All right. If a pharmacy were to beat</p> <p>3 the threshold and it was October the 27th, we</p> <p>4 don't backorder those orders, but we cut them.</p> <p>5 And if he wanted it after the 1st or 2nd, again,</p> <p>6 he could probably get it, but then he'd be working</p> <p>7 on his next threshold, okay?</p> <p>8 Q. Right. So the thresholds reset?</p> <p>9 A. That's right, which is perfectly legal</p> <p>10 and perfectly reasonable. In other words, he may</p> <p>11 place an order on the 27th and we can't fill all</p> <p>12 of it or part of it or any of it. I don't know.</p> <p>13 It depends on what it is.</p> <p>14 Q. Well, it depends on what the</p> <p>15 threshold --</p> <p>16 A. On the other hand, it isn't unreasonable</p> <p>17 to think that he wanted this product because he</p> <p>18 uses it in his normal operation. He just happened</p> <p>19 to place it a day or two early. In other words,</p> <p>20 he's not buying too much, at least by our</p> <p>21 definition, by what we're able to tell, by our due</p> <p>22 diligence.</p> <p>23 Q. Well, and let's talk about that. So he</p> <p>24 exceeds a threshold. And thresholds are set and</p>	<p style="text-align: right;">Page 173</p> <p>1 and that has an effect on what threshold we may</p> <p>2 initially set, okay?</p> <p>3 Number three, things can happen. He</p> <p>4 can -- maybe he picks up a hospice, okay, and he's</p> <p>5 supplying a hospice. Well, if he's supplying a</p> <p>6 hospice, he's going to use more controls than he</p> <p>7 would if he didn't supply that hospice, okay?</p> <p>8 For example, maybe it's no more -- maybe</p> <p>9 it's no more -- not anything bigger than, gee,</p> <p>10 he's going on vacation for three weeks, he doesn't</p> <p>11 want his replacement pharmacist to be filling</p> <p>12 C-II -- be buying C-IIs. He buys them now so that</p> <p>13 they have the C-IIs in hand to process the orders</p> <p>14 that they expect to have.</p> <p>15 There's all kinds of reasons why you</p> <p>16 look at -- and that's why you do your due</p> <p>17 diligence, and that's why you have to know your</p> <p>18 customer. And, like I said, we have a relatively</p> <p>19 limited number of customers, and we look at those</p> <p>20 customers very closely. And we don't take on</p> <p>21 everybody.</p> <p>22 And money, frankly, is not -- is not a</p> <p>23 big thing. You know, I was probably doing</p> <p>24 30 percent of my sales -- 10 or 15 years ago were</p>

<p style="text-align: right;">Page 174</p> <p>1 controlled substances. Right now it's 12 and a  2 half, and it's going to go down next year, okay?  3 It's been going down steadily. Probably only half  4 of those are what we're talking about here, okay?  5 Q. Right.  6 A. It was way up there because we had an  7 advantage in shipping at that time. We don't have  8 that advantage anymore. And actually  9 prescriptions have gone down for controlled  10 substances, okay? Doctors are writing fewer or  11 smaller, which I'm actually glad to hear. And,  12 therefore, the sales are going down naturally. Do  13 I need to --  14 MR. RICARD: Wait for another question.  15 Q. No. And you're doing fine. You're more  16 than welcome to explain your answers.  17 So now we know thresholds are based on  18 the number of scripts, generally speaking, the  19 estimates provided by the potential new customer.  20 We talked earlier about getting their usage data.  21 A. Yes. I mean, we look at other things  22 obviously. We look at the -- we check out the  23 doctors and the -- as to where their primary  24 prescriptions are being -- are coming from,</p>	<p style="text-align: right;">Page 176</p> <p>1 PSI is a secondary supplier. When we were a  2 primary supplier, it was easier for us to apply  3 the multipliers that are, you know, involved in  4 that.  5 Q. Right.  6 A. Now we could get an order from someone  7 who is -- who places it maybe once or twice a  8 year, okay? And obviously that order just because  9 it's placed once or twice a year is out of the  10 ordinary and is a red flag, but it doesn't mean  11 there's anything wrong with that order. It's just  12 that that's how often the guy buys that from us.  13 Q. Right. And when you're dealing as a  14 secondary provider --  15 A. Yes.  16 Q. -- that creates a heightened obligation  17 to be careful --  18 A. Which is why --  19 MR. RICARD: Objection to form.  20 Q. Go ahead.  21 A. Which is why we do due diligence and why  22 we know our customers and why we don't have as  23 many customers as maybe somebody else will. Maybe  24 I don't have as many customers because they don't</p>
<p style="text-align: right;">Page 175</p> <p>1 particularly controls, okay?  2 Q. Right.  3 A. And does this doctor have any -- is  4 there a reason that he would write more controls  5 than somebody else, okay?  6 Q. Right.  7 A. Maybe if he's a dental surgeon, okay, he  8 might -- and he's pulling wisdom teeth all day, he  9 may write more prescriptions for pain than  10 somebody else.  11 Q. Than a regular dentist?  12 A. Than a regular dentist does.  13 Q. Sure, sure. Now --  14 A. Just for example.  15 Q. Yes, sir. Yes, sir.  16 And correct me if I am wrong, but the  17 goal in setting these thresholds is to create an  18 upper limit for our customers?  19 A. Mm-hmm.  20 Q. Is that a yes?  21 A. That's a yes.  22 Q. Okay. And does PSI use any type of  23 multiplier to a threshold number?  24 A. We have. But as I pointed out to you,</p>	<p style="text-align: right;">Page 177</p> <p>1 want to buy from me, okay? But --  2 Q. It could be that, too.  3 A. But there are customers that we don't  4 want to sell to, okay?  5 Q. As well?  6 A. As well.  7 Q. Now -- and understand what I'm trying to  8 do. I'm trying to determine what else, if  9 anything, PSI considers when it's setting  10 thresholds.  11 A. Yes.  12 Q. And we went through some of them, and  13 you gave us some great examples, absolutely. And  14 correct me if I am wrong, but the goal is to set  15 thresholds that are reasonable for that particular  16 client?  17 A. That's correct.  18 Q. You may have things that change the  19 circumstances --  20 A. Correct. That would perhaps change the  21 threshold.  22 Q. And, therefore, we would see the due  23 diligence in the documentation supporting that  24 change, or at least we should?</p>

<p style="text-align: right;">Page 178</p> <p>1 A. We should.</p> <p>2 Q. Can we agree on that?</p> <p>3 A. Yes.</p> <p>4 Q. Okay. And when you're looking at</p> <p>5 changes in thresholds, you wouldn't be looking at</p> <p>6 changes in thresholds for some reason that doesn't</p> <p>7 necessarily affect supply or demand. You want to</p> <p>8 look for legitimate reasons for changes in</p> <p>9 thresholds.</p> <p>10 MR. RICARD: Object to form.</p> <p>11 Q. Take, for example, a new pharmacy -- a</p> <p>12 pharmacy down the road closed.</p> <p>13 A. That's a reason.</p> <p>14 Q. That may be a reason?</p> <p>15 A. Um-hmm.</p> <p>16 Q. You may need to look to see and see who</p> <p>17 that pharmacy was providing for in servicing and</p> <p>18 we still need to do our other due diligence and</p> <p>19 verification, correct?</p> <p>20 A. Correct.</p> <p>21 Q. You know, maybe increasing thresholds by</p> <p>22 20, 30 percent because it's St. Patrick's Day may</p> <p>23 not be such a legitimate reason?</p> <p>24 A. That's correct.</p>	<p style="text-align: right;">Page 180</p> <p>1 coordination with the IT manufacturer. He/she</p> <p>2 shall report any unaccounted losses or problems to</p> <p>3 the DR/DR supervisor and, when delegated, to</p> <p>4 appropriate authority (Northwood Police or DEA).</p> <p>5 Controlled substances handler shall also document</p> <p>6 all transactions and communications, holding</p> <p>7 copies of paperwork as required by law for at</p> <p>8 least six years."</p> <p>9 So I was comparing this with the -- your</p> <p>10 org chart, organizational chart, that has all the</p> <p>11 people listed. I didn't see a controlled</p> <p>12 substance handler anywhere. Who is the controlled</p> <p>13 substance handler?</p> <p>14 A. Well, it's -- I've never heard of the</p> <p>15 controlled substance handler either. We're going</p> <p>16 to say that we have a controlled substance</p> <p>17 manager, okay?</p> <p>18 Q. Okay.</p> <p>19 A. We have two people in my cage that, you</p> <p>20 know, do that. They actually look at these orders</p> <p>21 and they make those decisions.</p> <p>22 Q. Now -- and let me ask. And this is not</p> <p>23 meant to be derogatory or negative in any way, so</p> <p>24 don't take it as such. These policies and</p>
<p style="text-align: right;">Page 179</p> <p>1 MS. MONAGHAN: Objection to form.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. I knew they would object.</p> <p>4 So there are legitimate reasons and</p> <p>5 illegitimate reasons that people try to seek</p> <p>6 increases in thresholds, right?</p> <p>7 A. Yes.</p> <p>8 Q. Now, the obligation on the distributor,</p> <p>9 the registrant, is to sort out the legitimate from</p> <p>10 the illegitimate requests doing the due diligence</p> <p>11 that we talked about; is that fair?</p> <p>12 A. That's right.</p> <p>13 Q. Okay. And that's what the regulations</p> <p>14 and code require, correct?</p> <p>15 MR. RICARD: Objection to form.</p> <p>16 A. That's correct.</p> <p>17 Q. Okay. Going to page 2 of that policy</p> <p>18 and procedure.</p> <p>19 MR. FULLER: The first paragraph on that</p> <p>20 page, Gina.</p> <p>21 BY MR. FULLER:</p> <p>22 Q. There it reads, "The controlled</p> <p>23 substance handler shall be responsible for</p> <p>24 monitoring all controlled purchases in</p>	<p style="text-align: right;">Page 181</p> <p>1 procedures as we --</p> <p>2 A. You know, the --</p> <p>3 MR. RICARD: Wait for a question.</p> <p>4 THE WITNESS: Okay.</p> <p>5 Q. And you may be going where I'm going.</p> <p>6 A. No. You go ahead.</p> <p>7 Q. I understand there's requirements that</p> <p>8 you have to have them. It sounds like</p> <p>9 Prescription Supply is such an operation that,</p> <p>10 "Hey, we don't always look at these. We know how</p> <p>11 we do things. We try to do things the right way,</p> <p>12 and" -- go ahead.</p> <p>13 A. The procedures should match the -- the</p> <p>14 policies should match the procedures, okay?</p> <p>15 Q. Yes, sir.</p> <p>16 A. And that is our intention. On the other</p> <p>17 hand, if you throw DR and DR manager in there and</p> <p>18 maybe a name that -- controlled substance handler,</p> <p>19 those are things that are thrown in because the</p> <p>20 person that put them in was far more aware of what</p> <p>21 requirements were for something else, okay,</p> <p>22 than -- so the names may not be accurate, okay?</p> <p>23 Q. Yes, sir.</p> <p>24 A. But the policies should be accurate.</p>

Page 182

1 Yes. I mean, if we have a shortage -- or let's  
2 say we have -- let's say we have a shipment and  
3 we --

4 MR. RICARD: I think you answered the  
5 question.

6 THE WITNESS: Okay.

7 BY MR. FULLER:

8 Q. So we talked about this policy a bit.  
9 And it talks about reporting suspicious orders.

10 A. Yes.

11 Q. And we know Prescription Supply has  
12 never reported a suspicious order. And is it  
13 Prescription Supply's position that's because they  
14 never got a suspicious order?

15 A. We certainly never shipped a suspicious  
16 order.

17 Q. Well -- and I understand that. You've  
18 made that abundantly clear. But my question is a  
19 little different. Is that because Prescription  
20 Supply has never received --

21 A. It depends on how you define a --

22 Q. Suspicious order?

23 A. -- suspicious order. If you define it  
24 the way it is in the code, we've received them,

Page 183

1 okay?

2 Q. Yes, sir.

3 A. If you define them the way the HDMA --  
4 where they say "orders of interest," okay, and you  
5 call those orders of interest and not suspicious  
6 orders, then yes, we've never reported a  
7 suspicious order because we've never gotten one,  
8 okay?

9 Q. That's just because we renamed them,  
10 right?

11 A. That's because we renamed them. But I'm  
12 telling you that, you know, the -- they want to  
13 know when we find something that is truly  
14 suspicious. If we find that Joe Smith Pharmacy  
15 placed an order on the 27th that would put them  
16 over the threshold by a few hundred tablets, the  
17 DEA doesn't want to know that. They don't need to  
18 know it because it's not -- they're not going to  
19 use that.

20 Q. And I get what you're saying. Now,  
21 let's back up and digest what you've just given  
22 us.

23 PSI agrees that if we're looking at the  
24 regs and the statute and the code, that there have

Page 184

1 been suspicious orders which they failed to report  
2 in the past, correct?

3 A. Yes.

4 Q. Okay. If we look at HDMA guidelines  
5 now -- let's transfer. They talk about, you're  
6 right, orders of interest, right?

7 A. Mm-hmm.

8 Q. Is that a yes?

9 A. Yes.

10 Q. Orders of interest are nowhere mentioned  
11 in our regulatory requirements, are they?

12 A. That's correct.

13 Q. Basically what HDMA has done is tried to  
14 reclassify or rename suspicious orders as orders  
15 of interest?

16 MR. RICARD: Object to form.

17 A. Correct.

18 Q. Okay. But just because --

19 A. They did it. Okay. Go ahead.

20 Q. Right. If we call a duck a dog, it  
21 doesn't change the fact that it's still a duck,  
22 right?

23 MR. RICARD: Object to form.

24 A. Correct.

Page 185

1 Q. Okay. Let's go back to thresholds for a  
2 moment.

3 A. Okay.

4 Q. Now, we've talked a little bit about how  
5 thresholds are set initially. And I've seen some  
6 forms, particularly with that Board of Pharmacy  
7 investigation, related to threshold changes or  
8 change requests.

9 Is it assuming a -- strike that.

10 When we know our customer, we should be  
11 able to set a threshold and have that threshold  
12 maintained, correct?

13 A. Yes.

14 Q. Now, there may be things in the real  
15 world and in changes in the business that cause us  
16 to have to adjust that threshold, correct?

17 A. Correct.

18 Q. But that should be the exception instead  
19 of the rule, meaning that we should be able to set  
20 a threshold that maintains over a period of time?

21 A. Mm-hmm.

22 Q. We shouldn't see two, three, five, six,  
23 seven threshold changes within one month?

24 MR. RICARD: Object to form.

Page 186

1 A. For one pharmacy?  
 2 Q. For one pharmacy. Correct?  
 3 A. I would think not.  
 4 Q. Because then either -- something is  
 5 wrong. Either we didn't set our threshold right  
 6 at the very beginning, or maybe there's a red flag  
 7 or something going on, correct?  
 8 MR. RICARD: Object to form.  
 9 A. Mm-hmm.  
 10 Q. Do you agree?  
 11 A. Yes.  
 12 Q. Okay. And --  
 13 A. Although I have to -- if we had two or  
 14 the three changes, there probably were reasons for  
 15 those changes. I don't know that there were three  
 16 versions.  
 17 Q. Yes, sir. And if there is and there is  
 18 legitimate reason, then we should see that  
 19 documented, correct?  
 20 A. Correct.  
 21 Q. And just for the record -- I know you're  
 22 chuckling, not because you're not taking it  
 23 seriously --  
 24 A. Not because -- no, because --

Page 187

1 Q. -- but because the reality is maybe  
 2 sometimes it doesn't get documented?  
 3 A. I'm afraid that's true.  
 4 Q. It doesn't change the fact that it  
 5 should?  
 6 A. No.  
 7 Q. Because it makes it much more --  
 8 A. On the other hand, it doesn't make it  
 9 criminal or illegal either.  
 10 Q. Well, listen, when the IRS comes and  
 11 tells me I didn't document money I made, that does  
 12 make it criminal.  
 13 A. You know, Prescription Supply had the  
 14 pleasure of entertaining the IRS for a six-month  
 15 audit in-house.  
 16 Q. Oh, God bless you.  
 17 A. Yes. They left after three months, and  
 18 they gave us a letter of no change.  
 19 Q. Well, congratulations.  
 20 A. The only reason they left was because  
 21 other people were more interesting than we were.  
 22 We just weren't very interesting.  
 23 Q. Well, there you go. That's a good thing  
 24 when it comes to the IRS.

Page 188

1 A. It is.  
 2 Q. All right. We've been going --  
 3 A. And the same thing applies --  
 4 MR. RICARD: There's --  
 5 THE WITNESS: Okay.  
 6 MR. RICARD: -- no question --  
 7 MR. FULLER: We've been going another  
 8 hour. Let's take a break.  
 9 MR. RICARD: Sure.  
 10 THE VIDEOGRAPHER: The time is now 2:02.  
 11 We're going off the record.  
 12 (Recess taken.)  
 13 THE VIDEOGRAPHER: The time is now 2:19.  
 14 Back on the record.  
 15 BY MR. FULLER:  
 16 Q. We were talking about thresholds,  
 17 Mr. Schoen. Tell me -- you mentioned that back  
 18 when you did have a bunch of primaries, that you  
 19 guys used a multiplier. Do you know what the  
 20 multiplier was that you used?  
 21 A. No.  
 22 Q. Okay.  
 23 A. I can't say that we don't still use a  
 24 multiplier.

Page 189

1 MR. RICARD: Wait for a question, Tom.  
 2 THE WITNESS: Okay.  
 3 BY MR. FULLER:  
 4 Q. Well, I think you were trying to  
 5 clarify, because I think you said earlier that you  
 6 didn't use a multiplier anymore, but you think you  
 7 might?  
 8 A. I don't know.  
 9 Q. Okay. Who would know that?  
 10 A. The IT people.  
 11 Q. Kirk?  
 12 A. Kirk.  
 13 MR. FULLER: So we're going to mark for  
 14 identification purposes Exhibits 21 and 22 [sic].  
 15 Gina, it's 407 and 408.  
 16 MS. VELDMAN: What was the number?  
 17 MR. FULLER: 407 and 408.  
 18 And for the record, it's PSI0000280 and  
 19 PSI0000274.  
 20 MS. VELDMAN: Are you going to do one at  
 21 a time?  
 22 MR. FULLER: Oh, no. We're going to do  
 23 three at a time. Are you kidding me? We're  
 24 getting done. No. I'm kidding.

<p style="text-align: right;">Page 190</p> <p>1               ---</p> <p>2       (PSI-Schoen Exhibits 20 and 21 marked.)</p> <p>3               ---</p> <p>4 BY MR. FULLER:</p> <p>5       Q. So we have two more exhibits there in</p> <p>6 front of you, Mr. Schoen.</p> <p>7           I'm going to deal with Bates Number 2 --</p> <p>8 or 280 first, the one that has at the top "Maximum</p> <p>9 Monthly Quantity Prescription Supply."</p> <p>10       A. Mm-hmm.</p> <p>11       Q. And I'll tell you, I've read through it.</p> <p>12 I don't really understand what this is or what it</p> <p>13 does. Do you?</p> <p>14       A. I honestly haven't read through it</p> <p>15 recently, so I don't -- I don't know that I do or</p> <p>16 don't.</p> <p>17       Q. Now, there's references to maximum</p> <p>18 units, medication families, and it looks like</p> <p>19 somewhat of a bunch of computer stuff talking</p> <p>20 about order processing system modifications. And</p> <p>21 the other document, which is 274, seems to, at</p> <p>22 least from my simple perspective, be written in</p> <p>23 more of an understandable English.</p> <p>24           Do you have that one in front of you?</p>	<p style="text-align: right;">Page 192</p> <p>1 monitoring system has evolved over time.</p> <p>2       Q. Yes, sir.</p> <p>3       A. This was surely part of it and is part</p> <p>4 of what's being used, but is it everything? Other</p> <p>5 changes have been made, yes.</p> <p>6       Q. Sure. Now, I guess my question is, we</p> <p>7 talked earlier about that software that prevents</p> <p>8 orders above thresholds from going out now --</p> <p>9       A. Mm-hmm.</p> <p>10       Q. -- or being shipped. Is OLS the group</p> <p>11 that wrote that software?</p> <p>12       A. Some of it.</p> <p>13       Q. Okay. And maybe some of it isn't?</p> <p>14       A. Some of it we wrote ourselves.</p> <p>15       Q. Okay.</p> <p>16       A. Some of it -- we gain software from</p> <p>17 numerous entities, okay? Online Solutions is on</p> <p>18 the West Coast. We have an East Coast provider of</p> <p>19 software also for Online Solutions. This is --</p> <p>20 the West Coast is really Online Solutions. The</p> <p>21 East Coast are people that have developed software</p> <p>22 for Online Solutions. So we're getting it from --</p> <p>23       Q. Multiple sources?</p> <p>24       A. Multiple sources.</p>
<p style="text-align: right;">Page 191</p> <p>1       A. This one?</p> <p>2       Q. Yes, sir.</p> <p>3       A. Yeah.</p> <p>4       Q. It says, "Prescription Supply Maximum</p> <p>5 Monthly Units of OLS" --</p> <p>6       A. Oh, okay.</p> <p>7       Q. -- which my understanding is --</p> <p>8       A. They're a software company.</p> <p>9       Q. -- Online Solutions. Okay. That's your</p> <p>10 software company?</p> <p>11       A. Online Solutions. Yes.</p> <p>12       Q. So explain to me what OLS is.</p> <p>13       A. Online Solutions.</p> <p>14       Q. Yeah, but it's a software company that</p> <p>15 does what?</p> <p>16       A. That's the name. They wrote our</p> <p>17 software, our entire package.</p> <p>18       Q. Okay.</p> <p>19       A. They still are writing some.</p> <p>20       Q. And is this the software that manages</p> <p>21 and sets the -- or stops the orders that come in</p> <p>22 that may be above threshold and things of that</p> <p>23 nature?</p> <p>24       A. It is. As I said, suspicious order</p>	<p style="text-align: right;">Page 193</p> <p>1       Q. Got it. Got it.</p> <p>2           So when this refers to maximum monthly</p> <p>3 units, we're talking about a threshold type of</p> <p>4 situation, is that correct, or do you know?</p> <p>5       A. Well, it is talking about a</p> <p>6 threshold-type situation, yes.</p> <p>7       Q. Okay.</p> <p>8       A. Yes.</p> <p>9           MR. FULLER: Next is 503.</p> <p>10 BY MR. FULLER:</p> <p>11       Q. Mr. Schoen, we're going to look next at</p> <p>12 the -- yeah, this is going to be Plaintiff's</p> <p>13 Exhibit Number 22.</p> <p>14           ---</p> <p>15           (PSI-Schoen Exhibit 22 marked.)</p> <p>16           ---</p> <p>17 BY MR. FULLER:</p> <p>18       Q. And have you seen --</p> <p>19           MR. RICARD: Can I just state for the</p> <p>20 record that although not marked as confidential,</p> <p>21 it was our intention to mark these as confidential</p> <p>22 documents not to be distributed outside the scope</p> <p>23 of this deposition.</p> <p>24           MR. FULLER: And we won't let the</p>

<p style="text-align: right;">Page 194</p> <p>1 witness keep them. I'm kidding.  2 BY MR. FULLER:  3 Q. All right. Have you seen this document  4 before?  5 A. Well, yes.  6 Q. Okay. And this is where the Ohio State  7 Board of Pharmacy came in and initially did a  8 visit to Prescription Supply, Inc., in May of  9 2017, this document being your response thereof,  10 and ultimately what the Board of Pharmacy said is,  11 "Why is it that Prescription Supply has not  12 reported suspicious orders in 2014, 2015, 2016,  13 and 2017?"  14 Right?  15 MR. RICARD: Objection to form.  16 A. Apparently, mm-hmm.  17 Q. And Prescription Supply responded much  18 like you said and said, "Because we don't get  19 suspicious orders."  20 MR. RICARD: Objection to form.  21 Q. Right?  22 A. That's the response.  23 Q. And then BOP comes back and says, "But,  24 hey, what about these four pharmacies and what was</p>	<p style="text-align: right;">Page 196</p> <p>1 Woodville.  2 A. Correct.  3 Q. Now, we talked a little bit earlier,  4 Gibsonburg Pharmacy in Woodville is the one that  5 eventually got sold to CVS; is that correct?  6 A. Correct.  7 Q. Okay. And the Board of Pharmacy had  8 questions about the other three?  9 A. Yes.  10 Q. And, particularly, the other three,  11 they're talking about spikes, and spikes that  12 occurred anywhere from April of '14 through  13 January of '15, at least according to this  14 document; is that fair?  15 A. Yes.  16 Q. Okay. And if you turn to page 60.  17 A. 60?  18 Q. Yes, sir. Oh, no, it's not 60. Try 59.  19 I'm sorry.  20 Do you recognize this form? Have you  21 ever seen this type of form before, Mr. Schoen?  22 A. Yes.  23 Q. This is a form that's called -- or at  24 the top, it says "Prescription Supply, Inc., 2233</p>
<p style="text-align: right;">Page 195</p> <p>1 going on with them?"  2 Right?  3 MR. RICARD: Objection to form.  4 A. That's correct.  5 Q. Then you guys provided, as you mentioned  6 earlier, various responses; is that right?  7 A. Mm-hmm, yes.  8 Q. And the four entities -- if you go to  9 page -- I think it's page 5. Yep. That provides  10 you a listing of the four pharmacies they asked  11 about; is that correct?  12 A. Correct.  13 Q. A Kahler Pharmacy. Am I pronouncing  14 that right?  15 A. Yes.  16 Q. A Shaffer Pharmacy. Both in Toledo. A  17 Medicine Shoppe, which is in --  18 A. Bellevue.  19 Q. Bellevue. Which that's part of a chain,  20 is it not, or a bunch of franchises?  21 A. Franchises, I believe.  22 Q. Okay.  23 A. I believe franchises.  24 Q. And then Gibsonburg Pharmacy in</p>	<p style="text-align: right;">Page 197</p> <p>1 Tracy Road, Northwood, Ohio 43619. And that's  2 the name and location of your business; is that  3 correct?  4 A. That's correct.  5 Q. And it says, "Increased purchase request  6 for controlled substances."  7 Is this what you guys used to increase  8 basically thresholds for controlled substances?  9 A. Among other things, yes.  10 Q. Okay. And it says, "We understand the  11 changes in usage occur. To facilitate increased  12 purchasing, please have the Owner, Business  13 Officer, or Authorized Signatory complete and  14 return this form."  15 And so this is a form that would be  16 provided to your customers to fill out and provide  17 back to PSI to indicate that they were seeking  18 some sort of increase related to controlled  19 substances?  20 A. Correct.  21 Q. And the form asks for a variety of  22 differing types of information. And this  23 particular one is filled out by the Medicine  24 Shoppe that was part of that Ohio Board of</p>

<p style="text-align: right;">Page 198</p> <p>1 Pharmacy investigation; is that right?</p> <p>2 A. That's correct.</p> <p>3 Q. Okay. Now, if you go on down the form,</p> <p>4 we have questions 1 through 6 -- well, actually, 1</p> <p>5 through 7. But it doesn't look like Medicine</p> <p>6 Shoppe filled out anything other than number 6.</p> <p>7 A. That's correct.</p> <p>8 Q. Now, what did they say in number 6?</p> <p>9 A. That Cardinal was unable to supply.</p> <p>10 Q. So this would have been a facility in</p> <p>11 which you were a secondary source for, correct?</p> <p>12 A. Correct.</p> <p>13 Q. Presumptively then Cardinal would have</p> <p>14 been the primary; and for some reason, they</p> <p>15 couldn't provide them with the Oxy 30s?</p> <p>16 MR. BUSHUR: Objection; form.</p> <p>17 A. Correct.</p> <p>18 Q. At least that's what's indicated on this</p> <p>19 document?</p> <p>20 A. That's what's indicated, yeah.</p> <p>21 Q. Okay. Now, I'm assuming, sitting here</p> <p>22 today, you have no idea whether that's true or</p> <p>23 not?</p> <p>24 A. Well, yes, I don't know that it's true.</p>	<p style="text-align: right;">Page 200</p> <p>1 looked, we would see a threshold event for this</p> <p>2 particular increased purchase request, or at least</p> <p>3 we should, correct?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. Now, if we go to page 61, we'll</p> <p>6 have another one of these forms; is that right?</p> <p>7 A. Yes.</p> <p>8 Q. Okay. And this is for Shaffer Pharmacy,</p> <p>9 correct?</p> <p>10 A. Yes.</p> <p>11 Q. That was another one of those that was</p> <p>12 looked into by the Board of Pharmacy for the State</p> <p>13 of Ohio, correct?</p> <p>14 A. Correct.</p> <p>15 Q. And here we have -- there's a stamp</p> <p>16 which provides most of that information on those</p> <p>17 first few lines. And then we have answers to</p> <p>18 numbers 1 through 7.</p> <p>19 Do you see that there?</p> <p>20 A. I see it.</p> <p>21 Q. And question 1 asks "Has the pharmacy</p> <p>22 prescription count increased?"</p> <p>23 And the answer is?</p> <p>24 A. Yes.</p>
<p style="text-align: right;">Page 199</p> <p>1 Q. Now, let's talk about how the system</p> <p>2 worked. So if they were a secondary customer for</p> <p>3 PSI and they would have placed an order, assuming</p> <p>4 that order would have been within their threshold,</p> <p>5 it would get filled in the normal course, right?</p> <p>6 Is that a yes?</p> <p>7 A. That's correct.</p> <p>8 Q. Okay. What may happen, though, is</p> <p>9 because they're a secondary customer, they may</p> <p>10 have a very low threshold?</p> <p>11 A. That's correct.</p> <p>12 Q. So that an order will set off that</p> <p>13 system, which you described to us earlier,</p> <p>14 triggering this type of documentation, the</p> <p>15 necessity for this type of documentation to ship</p> <p>16 an order beyond that set threshold?</p> <p>17 A. Correct.</p> <p>18 Q. Okay. So -- and I'll represent to you</p> <p>19 that we do have provided through your counsel a</p> <p>20 list of threshold events for all your businesses</p> <p>21 or all your transactions going back, I think,</p> <p>22 until 2008.</p> <p>23 MR. RICARD: Correct.</p> <p>24 Q. So being that this is in 2015, if we</p>	<p style="text-align: right;">Page 201</p> <p>1 Q. Okay. Which in your line of business,</p> <p>2 explain to us what that means. It means they're</p> <p>3 getting more prescriptions, right?</p> <p>4 A. That's what it means.</p> <p>5 Q. Okay. "2. Did the pharmacy change its</p> <p>6 business activity?"</p> <p>7 And the answer is?</p> <p>8 A. No.</p> <p>9 Q. "3. Has there been an increase in</p> <p>10 prescribers?"</p> <p>11 And the answer is?</p> <p>12 A. Yes.</p> <p>13 Q. 4, "Is the pharmacy serving additional</p> <p>14 long-term care, or LTC, hospice, pain management,</p> <p>15 Urgent Care?"</p> <p>16 And the answer is?</p> <p>17 A. No.</p> <p>18 Q. "Name/Drug Family" is what?</p> <p>19 A. Oxycodone.</p> <p>20 Q. And then it says, "If new pain</p> <p>21 management clinic/physicians/hospice/urgent care,</p> <p>22 long-term care, please list each prescriber name</p> <p>23 with their DEA number."</p> <p>24 And it indicates whom?</p>

<p style="text-align: right;">Page 202</p> <p>1 A. Two doctors, I'm guessing. They have 2 DEA numbers. 3 Q. Correct. Now, number 6 asks for the 4 reason for the request. Read the reason for the 5 request to us. 6 A. "Supplier mentioned an industry short 7 supply." New MDs named [sic] in building -- new 8 doctors in the building. 9 Q. And I think it says "New MDs moved in 10 the building." 11 A. Okay. 12 Q. Right? 13 A. Yes. 14 Q. And, now, it's signed by a Tom Tadsen? 15 A. Tadsen. 16 Q. But it's not dated, is it? 17 A. No. 18 Q. Now, it should be, correct? 19 A. Yes. 20 Q. Now, as we stated earlier, we should be 21 able to look and see a threshold increase that hit 22 during this time frame, correct? 23 A. Yes. 24 Q. Otherwise, if there was no threshold</p>	<p style="text-align: right;">Page 204</p> <p>1 A. No. 2 Q. But it should, right? 3 A. Yes. 4 Q. And then the reason. Can you read the 5 reason for us? 6 A. "We have seen an increase in 7 prescriptions over the past six months on the 8 average of about 110 new prescriptions monthly." 9 Q. Now, if you and I are doing the due 10 diligence on this and looking to determine whether 11 we're going to increase this, that doesn't really 12 give us enough information, does it? 13 MR. RICARD: Object to form. 14 A. It says -- well, what other information 15 would you want to see? 16 Q. Well, let's talk about that. So it says 17 the number of people coming with prescriptions is 18 increasing, right? 19 A. Mm-hmm. 20 Q. Well, we don't know if those people are 21 driving up from Florida. We don't know if they're 22 driving from West Virginia or Kentucky or anywhere 23 else. If we're going to see a potential spike 24 that may be from diversion, we're going to see</p>
<p style="text-align: right;">Page 203</p> <p>1 event, there would be no purpose or reason that we 2 would have this form, at least the way our system 3 works, correct? 4 A. Right. 5 Q. Okay. So now let's go to two more pages 6 back, 63, and I think we'll see the form for the 7 third pharmacy. Now, Tabb Enterprises, I'm 8 assuming, is a -- it indicates there is a d/b/a 9 for that Kahler -- I know I pronounced that right 10 last time. Is it Kahler or Kahler? 11 A. Kahler. 12 Q. Kahler, Kahler Pharmacy. And that's in 13 Toledo, right? 14 A. Correct. 15 Q. And there it asks the same questions. 16 Has the prescription count increased? They say 17 yes. 18 Did the pharmacy change business 19 activity? No. 20 Has there been an increase in 21 prescribers? No. 22 Is it servicing an LTC, pain management, 23 or urgent care? No. 24 Name and drug family? Does it give one?</p>	<p style="text-align: right;">Page 205</p> <p>1 more prescriptions, aren't we? 2 MR. RICARD: Objection to form. 3 A. Yes. 4 Q. So the information that we have doesn't 5 provide us anything to tell us whether it's 6 potential diversion or otherwise? 7 MR. RICARD: Objection to form. 8 Q. Correct? 9 A. Yes, but we -- well, we feel we know 10 Kahler. 11 Q. And I understand that, and that may be 12 true. But, again, we're wanting to look at the 13 documentation we have to make sure we can 14 substantiate what we're doing, and that's the way 15 it's supposed to be done, right? 16 A. Yes. 17 Q. Okay. All right. So -- 18 MR. FULLER: Gina, can you pull up the 19 macro spreadsheet. 20 And, AJ, I need just -- oh, actually, hold on. 21 I think I -- I think we have it in the -- bring me up 22 904. 23 MS. VELDMAN: Are you talking to me? 24 MR. FULLER: Yes, ma'am.</p>

<p style="text-align: right;">Page 206</p> <p>1 MS. VELDMAN: What did you say, 94?</p> <p>2 MR. FULLER: 904. And for the record, I</p> <p>3 don't know that I'm going to use it right now, but</p> <p>4 I'm going to be using a macro spreadsheet in a</p> <p>5 bit, and I'll attach the thumb drive as Exhibit</p> <p>6 23.</p> <p>7 And, Counsel, here's a copy of that for y'all.</p> <p>8 - - -</p> <p>9 (PSI-Schoen Exhibit 23 marked.)</p> <p>10 - - -</p> <p>11 BY MR. FULLER:</p> <p>12 Q. All right. So let me tell you what I've</p> <p>13 been provided and what I've done, is, Mr. Schoen,</p> <p>14 I've been provided, as I mentioned to you earlier,</p> <p>15 the transactional data, as well as all the</p> <p>16 threshold events that your company received from</p> <p>17 2008 to present, okay?</p> <p>18 And what I've done and went through is</p> <p>19 sort of separate them out, because they were all</p> <p>20 in chronological order. And as you know from</p> <p>21 running the business, that's a whole bunch of</p> <p>22 lines with a whole bunch of different pharmacies</p> <p>23 with a whole bunch of different drugs.</p> <p>24 So what I've separated out is anything</p>	<p style="text-align: right;">Page 208</p> <p>1 MR. FULLER: There you go. Great.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. All right. So we see in March,</p> <p>4 March 5th, you see there we have an order that the</p> <p>5 total units sold of oxycodone is 6,100, and our</p> <p>6 max threshold is 7,000, correct?</p> <p>7 A. Correct.</p> <p>8 Q. And when we have one of these flags,</p> <p>9 that's because the next order was going to send</p> <p>10 them over the limit; is that right?</p> <p>11 A. Apparently, yes.</p> <p>12 Q. Okay. And that's on the 5th. Then on</p> <p>13 the 7th, we've now sold to Kahler 11,800, and</p> <p>14 apparently back on the 5th, we increased their</p> <p>15 threshold from 7- to 12,000.</p> <p>16 Do you see that?</p> <p>17 MR. RICARD: Objection to form.</p> <p>18 A. Yes. I suppose -- it's the family.</p> <p>19 Okay.</p> <p>20 Q. It's the family. So it means --</p> <p>21 A. It's a different product, but yeah.</p> <p>22 Q. Correct. Well, it's a different dosage;</p> <p>23 is that right?</p> <p>24 A. That's correct.</p>
<p style="text-align: right;">Page 207</p> <p>1 but for oxies and hydros, two drug families which</p> <p>2 we talked about earlier that you guys do</p> <p>3 thresholds within since 2006, correct?</p> <p>4 A. Correct.</p> <p>5 Q. Okay. So as you can see from on the</p> <p>6 screen, this is Kahler Pharmacy, right?</p> <p>7 A. Kahler, but yes.</p> <p>8 Q. Kahler. I'm sorry. I keep messing that</p> <p>9 up now.</p> <p>10 And it starts -- the first threshold</p> <p>11 event we have is in March of 2012.</p> <p>12 Do you see that there?</p> <p>13 A. I do.</p> <p>14 Q. Okay. Now, if we could slide it over to</p> <p>15 the right, we'll see as we go across, at the end</p> <p>16 of the columns, we have column S, which is the</p> <p>17 total number of units ordered -- or units sold</p> <p>18 that month, and then T is the maximum units which</p> <p>19 indicates the threshold; is that right?</p> <p>20 A. Yes.</p> <p>21 MR. FULLER: And, Gina, can you get the</p> <p>22 date on there as well? Slide it over just a</p> <p>23 little bit. Can you shrink some of those down?</p> <p>24 MS. VELDMAN: Yeah.</p>	<p style="text-align: right;">Page 209</p> <p>1 Q. Okay. But still it's, I think,</p> <p>2 oxycodone. So then on the 12th, we have another</p> <p>3 event there where now Kahler has ordered -- and,</p> <p>4 again, our initial threshold at the beginning of</p> <p>5 the month was 7,000. Now they've ordered 15,300,</p> <p>6 and we've apparently increased their threshold to</p> <p>7 18,000.</p> <p>8 MR. RICARD: Object to form.</p> <p>9 Q. Do you see that there, Mr. Schoen?</p> <p>10 A. I see it.</p> <p>11 Q. Then on the 19th, another five days</p> <p>12 later, of March of 2012, we've now sold them</p> <p>13 20,500 and have previously increased their</p> <p>14 threshold to 22,000.</p> <p>15 Then on the 19th again, same day, we've</p> <p>16 sold them 24,500 and increased their threshold to</p> <p>17 25,000. On the 21st of March, we've now sold them</p> <p>18 25,500 and increased their threshold to 26,000.</p> <p>19 The 26th of March, we've now sold them 28,400</p> <p>20 oxycodone pills of varying strength, right?</p> <p>21 A. Correct.</p> <p>22 Q. And we've now raised their threshold to</p> <p>23 29,000 pills. But wait. We're not done.</p> <p>24 MR. RICARD: Object to form.</p>

Page 210

1 Q. On the 30th, we've now sold them 33,000  
2 pills, and we've increased their threshold to  
3 33,000 pills. That is seven threshold increases  
4 increasing the threshold over 400 percent within  
5 25 days.

6 MR. RICARD: Objection to form.

7 Q. Now, I can tell already that this  
8 concerns you, doesn't it?

9 A. It does.

10 Q. You did not know that things like this  
11 may have been going on in your company?

12 MR. RICARD: Objection to form.

13 A. I don't know -- I mean, what do I say?  
14 No. I mean no, huh-uh.

15 Q. Now, let's drop down. Because we  
16 separate into two drug families oxycodone --

17 A. And hydrocodone.

18 Q. -- and hydrocodone. In August of the  
19 same year, on the 7th of August, we have a  
20 hydrocodone threshold event, correct?

21 A. Mm-hmm.

22 Q. And they ordered 5,500, and already on  
23 the 7th.

24 Now, you would agree with me that these

Page 212

1 You would agree with that?

2 MR. RICARD: Objection to form.

3 A. It certainly draws my interest, yes.

4 Q. And who knows, you may go back to the  
5 office either later today or tomorrow and ask for  
6 someone to look into this and see if there is an  
7 explanation. And certainly if there is  
8 documentation that sets out, I would absolutely  
9 ask you to provide it to your counsel so he can  
10 forward it to us, because, again, we're not here  
11 to make accusations or anything that is  
12 inaccurate. We want to have all the information,  
13 as I'm sure you do, correct?

14 A. Correct.

15 Q. Okay. So this doesn't have to do  
16 necessarily with a time frame when Kahler was --  
17 and the Board of Pharmacy was looking in, but  
18 this, too, is a concerning issue; you would agree  
19 with that?

20 MR. RICARD: Objection to form.

21 A. It's certainly of interest, yes.

22 MR. FULLER: Okay. Now, let's go to --  
23 we're going to need to go to the macro.

24 And, AJ, help her get to where the -- all the

Page 211

1 threshold events -- the threshold should be set  
2 and shouldn't necessarily be hit so early in a  
3 month? It's not something you would expect to  
4 see, generally speaking?

5 A. Generally.

6 MR. RICARD: Objection to form.

7 Q. So the threshold, while they're at 5,500  
8 pills, is at 6,000. On the 17th, ten days later,  
9 they're up to 12,000 pills, and the threshold is  
10 at 12,000.

11 On the 23rd, another week later, they're  
12 at the 12,100 pills, and we've increased our  
13 threshold to 14,000 pills. On the 29th, the last  
14 transaction of the month, they're at 15,100, and  
15 we've increased their threshold to 16,000 pills.  
16 We have more than doubled it within this month  
17 of -- well, within this 21 days basically.

18 Does that cause you concern?

19 MR. RICARD: Objection to form.

20 A. I would want to look into it.

21 Q. And we would want to see the  
22 documentation as to the reasons, because just  
23 looking at what's happening with the threshold and  
24 the number of pills going out, it's concerning.

Page 213

1 threshold events, and then bring it up for Shaffer  
2 Pharmacy, please, unless I have it.

3 Actually, 905 I think does it. Sorry. I  
4 should have known that.

5 BY MR. FULLER:

6 Q. Okay. So this is Shaffer's Pharmacy in  
7 Toledo. You're familiar that that's a client of  
8 yours, right?

9 A. Yes.

10 Q. Okay. These are the threshold events,  
11 and I believe these are all the threshold events I  
12 have for Shaffer's, which is less -- looks less  
13 than Kahler, doesn't it?

14 A. Yes.

15 Q. Now, Shaffer's Pharmacy and the issue  
16 with the Board of Pharmacy was in April of 2014.  
17 If you get the date on that. There you go. And  
18 it dealt with oxycodone.

19 So do you see a threshold event in April  
20 of 2014 --

21 MR. FULLER: I need the date on there.  
22 Right there. You're good.

23 BY MR. FULLER:

24 Q. In April of 2014 for Shaffer's Pharmacy?

Page 214

1 A. No.  
 2 Q. We see March of '13, and then the next  
 3 one chronologically we see is September of '14,  
 4 correct?  
 5 A. Right.  
 6 Q. Okay. So that begs the question,  
 7 doesn't it, how do we get an increased purchase  
 8 request if there was no event that would trigger  
 9 an increased purchase request?  
 10 MR. RICARD: Objection to form.  
 11 A. This is dated -- that's different. I'd  
 12 have to --  
 13 Q. Because the increased purchase request  
 14 form that we had that we looked in our Board of  
 15 Pharmacy investigation packet --  
 16 A. Um-hmm.  
 17 Q. Do you have that back in front of you?  
 18 A. I do now.  
 19 Q. It's not dated, is it?  
 20 A. No.  
 21 Q. Now -- and I'm not suggesting that you  
 22 did this, Mr. Schoen. I'm asking PSI, because  
 23 you're sitting here as Prescription Supply, Inc.,  
 24 do we know whether someone went to Shaffer

Page 216

1 Q. You don't know whether it happened or  
 2 no?  
 3 A. I -- yeah.  
 4 Q. Now, we know there's no triggering  
 5 event, and we know the increased request form is  
 6 not dated, which it's supposed to be dated,  
 7 correct?  
 8 A. Mm-hmm.  
 9 Q. Is that a yes?  
 10 A. Yes, that's correct.  
 11 Q. And, again, I encourage you when you go  
 12 back, if you want to look into it, and if there's  
 13 anything that you can provide to counsel, I'm sure  
 14 they will forward it to me, and maybe we can get  
 15 to the bottom of this.  
 16 A. I would have to go back and look at the  
 17 whole thing.  
 18 Q. Well, and understand, you don't need to  
 19 write anything down. I know you were reaching for  
 20 your pen, but counsel is going to have all this  
 21 information. And if he needs anything from me, I  
 22 can point him to where it was or what we were  
 23 looking at, and he can get with you, okay?  
 24 A. Mm-hmm. Um --

Page 215

1 Pharmacy once the Board of Pharmacy came to do  
 2 their investigation and said, "Hey, we need an  
 3 increased purchase request from you for April of  
 4 2014," when the Board of Pharmacy is looking at  
 5 this spike."  
 6 MR. RICARD: Objection to form.  
 7 A. I have no idea.  
 8 Q. Because there's no triggering event --  
 9 A. I see that, yes.  
 10 Q. -- to set off this documentation. And  
 11 here's my concern. I'm going to be very --  
 12 A. It's not dated either though.  
 13 Q. Right. And that was my concern, is that  
 14 someone -- and, again, I have no idea who. But it  
 15 appears someone could have went to Shaffer's  
 16 Pharmacy and asked them to do an increased  
 17 purchase request in 2017 once this investigation  
 18 got on its way?  
 19 MR. RICARD: Objection to form. Calls  
 20 for speculation.  
 21 Q. Which you would agree would be very  
 22 disconcerting, wouldn't it?  
 23 A. It would be disconcerting, but I  
 24 don't --

Page 217

1 MR. RICARD: There's no question  
 2 pending.  
 3 MR. FULLER: Go to 506, Gina.  
 4 BY MR. FULLER:  
 5 Q. Now, let me ask you -- and, again, we'll  
 6 get to the bottom of it, and we'll figure it out  
 7 one way or another. If somebody was doing  
 8 documents in 2017 to support shipments in 2014,  
 9 you would agree with me that would be completely  
 10 inappropriate?  
 11 MR. RICARD: Objection to form.  
 12 A. Yes.  
 13 Q. It would potentially be illegal as well?  
 14 A. Yes.  
 15 MR. RICARD: Objection.  
 16 Q. And you would --  
 17 A. Okay.  
 18 Q. You wouldn't stand for that in your  
 19 company, would you, if you knew it was going on?  
 20 A. No.  
 21 Q. Okay. And I know you want to explain,  
 22 but I would just suggest listen to your advice of  
 23 counsel and just answer the questions being asked.  
 24 MR. FULLER: All right. 506. And if

<p style="text-align: right;">Page 218</p> <p>1 you can blow up this area here (indicating). This  2 is going to be Plaintiff's Exhibit Number 24.  3 - - -  4 (PSI-Schoen Exhibit 24 marked.)  5 - - -  6 BY MR. FULLER:  7 Q. Now, Mr. Schoen, I think this was  8 actually an e-mail that was actually sent to you.  9 A. Mm-hmm.  10 Q. Is that a yes?  11 A. Yes.  12 MR. RICARD: You need to respond out  13 loud.  14 Q. Take a minute. We're going to look at  15 just the second -- I want to say paragraph, but I  16 don't even know that it's a paragraph. This is  17 from the Board of Pharmacy, is that right, for the  18 State of Ohio, relating to the investigation that  19 they were already conducting that they started in  20 2017; is that correct?  21 A. Yes.  22 Q. And it's to  23 schoen@prescriptionsupply.com. You and your  24 sister, it appears, right?</p>	<p style="text-align: right;">Page 220</p> <p>1 And it gives you the Medicine Shoppe and  2 Shaffer, correct?  3 A. Yes.  4 Q. Okay. Do you know if you guys -- and I  5 say "you guys." Do you know if Prescription  6 Supply has responded to the Board of Pharmacy  7 pursuant to this request as of yet?  8 A. Yes.  9 Q. And in that response --  10 A. No. I can say that the agent was in the  11 building. We may have responded there, and he may  12 have accepted that response. I don't know.  13 Q. Okay.  14 A. I do remember talking to him there, and  15 that may have been -- if we don't have a written  16 one, I can't tell.  17 Q. Okay. Well, and I just wanted to check  18 if you knew of a written one, because this is as  19 far as I have in that process. So what I'll do is  20 after the deposition, I'll follow up with your  21 counsel on anything else, okay?  22 A. Yes.  23 Q. Now, you believe that investigation to  24 be over; is that correct?</p>
<p style="text-align: right;">Page 219</p> <p>1 A. Yes -- well, actually -- the J?  2 Q. Yeah.  3 A. The J is to James.  4 Q. Who's jaharbauer?  5 A. Where is JA?  6 Q. If you look on the screen.  7 A. Oh, okay. Oh, Jacqueline Harbauer.  8 Q. Or did they get --  9 A. It could be -- I mean, it's possible it  10 went to James Harbauer. Although, that's -- I  11 don't believe that's his --  12 Q. E-mail address?  13 A. -- e-mail address.  14 Q. And they may have gotten it wrong. They  15 may have gotten it wrong. But it does appear to  16 have your e-mail address on it?  17 A. It does.  18 Q. Okay. And they say there in the second  19 paragraph, "In order for the Board of Pharmacy to  20 finalize this case, please describe how  21 Prescription Supply determines who to sell to, how  22 the monthly thresholds are set and what is done if  23 a monthly threshold is above what was determined.  24 Please use the following pharmacies as examples."</p>	<p style="text-align: right;">Page 221</p> <p>1 A. That's correct.  2 Q. Okay.  3 A. I was told it was over.  4 Q. By whom?  5 A. By the State.  6 Q. Okay.  7 MR. FULLER: All right. Gina, if you  8 would bring up 905A for me.  9 Here, let me do a couple housekeeping things  10 real quick here. So I'm going to do 25. Plaintiff's  11 Exhibit 25 is going to be that spreadsheet that I showed  12 him.  13 MR. RICARD: You already saw that one.  14 MR. FULLER: Yeah. It's just too hard  15 to see on the printout. Although, we'll have a  16 printout for the record. Here's a copy of 905A.  17 - - -  18 (PSI-Schoen Exhibits 25 through 27 marked.)  19 - - -  20 BY MR. FULLER:  21 Q. So what we have up in front of us is  22 905A, which is now Exhibit 26. And what I've done  23 here, Mr. Schoen, is taken just oxycodone sales  24 for a period of time. You see that period of time</p>

<p style="text-align: right;">Page 222</p> <p>1 being January of '08 through April of '09,  2 correct?  3 Is that a yes?  4 A. Yes.  5 Q. Okay. And sort of plotted it in a bar  6 graph. I'm better with graphs than I am just  7 looking at a bunch of numbers. And you can see  8 that they sort of go along at a consistent clip a  9 little above and below 15,000 pills per month of  10 the oxycodone family, right?  11 A. Correct.  12 Q. Until about October of '08, and then  13 they drop off, but here's what my question is and  14 caused me a concern, is that in March of '09, they  15 spike to 30,000 pills.  16 Do you see that?  17 A. I see it.  18 Q. Which you would agree with me, or PSI  19 would agree, is a significant increase over the  20 normal --  21 A. Yes.  22 Q. -- past pattern?  23 MR. RICARD: Objection to form.  24 Q. Correct?</p>	<p style="text-align: right;">Page 224</p> <p>1 works, we would have seen a threshold event?  2 MR. RICARD: Objection to form.  3 A. There could be a reason for this, but  4 I'm looking and thinking there is one, but I don't  5 know.  6 Q. Right. And, again, like with the other  7 things that we've talked about, you can go back  8 and look at the business and see if there is some  9 sort of explanation, and please feel free to  10 provide it to your counsel, and he'll get with me  11 on it, okay?  12 A. I can see a possibility for this one,  13 but ...  14 Q. But we can agree that based on this  15 purchase history, this would qualify -- this  16 30,000 spike would qualify as a suspicious order,  17 correct?  18 MR. RICARD: Objection to form.  19 A. Maybe.  20 Q. And it should at least be halted --  21 A. Yeah, there should have been something  22 done.  23 Q. It should be halted until it can be  24 investigated, and it should potentially be</p>
<p style="text-align: right;">Page 223</p> <p>1 A. Yes.  2 Q. We would expect to see a threshold event  3 from this type of increase, correct?  4 A. Yes.  5 Q. And we looked earlier --  6 MR. FULLER: And if we can bring back up  7 905, which is Exhibit 25.  8 BY MR. FULLER:  9 Q. We see no threshold events in March of  10 '09, do we?  11 A. No. I don't --  12 Q. We don't see our first threshold --  13 MR. RICARD: It's up on the screen.  14 THE WITNESS: Yes, I see that. Oh, I  15 see it, yes.  16 BY MR. FULLER:  17 Q. We don't see our first threshold event  18 until January of 2011, actually, which would mean  19 that our threshold for some reason must have been  20 set above 30,000 pills per month --  21 MR. RICARD: Objection; form.  22 Q. -- for Shaffer Pharmacy, correct?  23 A. Yes.  24 Q. Otherwise, based on the way the system</p>	<p style="text-align: right;">Page 225</p> <p>1 reported as well --  2 MR. RICARD: Objection to form.  3 Q. -- correct?  4 A. I can see a possible answer to this one,  5 so I don't --  6 Q. Okay. Let's go --  7 A. It may not be accurate.  8 Q. Let's go on --  9 A. Pure guess in this case.  10 Q. Right. Sitting here today, you have no  11 explanation -- any explanation would be a guess,  12 correct?  13 A. At this point.  14 Q. Okay. But just based on the numbers  15 that we're seeing, we can both agree that it  16 was --  17 A. Certainly --  18 Q. Go ahead.  19 A. Yes. Yes.  20 Q. That it should have been flagged, it  21 should have been investigated, and potentially  22 reported as a suspicious order, correct?  23 MR. RICARD: Objection to form. Asked  24 and answered.</p>

<p style="text-align: right;">Page 226</p> <p>1 You can answer again.</p> <p>2 A. I'm sure it was investigated, and I -- I</p> <p>3 don't know.</p> <p>4 Q. You don't know. So just listen to my</p> <p>5 question. Let me read it back. "That this order</p> <p>6 should have been flagged, and it should have been</p> <p>7 investigated, and potentially reported as a</p> <p>8 suspicious order, correct?"</p> <p>9 MR. RICARD: Objection to form. Asked</p> <p>10 and answered.</p> <p>11 Q. You can answer.</p> <p>12 A. I did answer it as best I can. I'm sure</p> <p>13 it was investigated.</p> <p>14 Q. Well, that wasn't --</p> <p>15 A. The question. I understand.</p> <p>16 Q. Yeah. My question is, seeing this --</p> <p>17 and I understand --</p> <p>18 A. All right. The answer to that --</p> <p>19 MR. RICARD: Hang on. Let him ask his</p> <p>20 question.</p> <p>21 Q. And your answer is that you're sure it</p> <p>22 was investigated is a guess at this point,</p> <p>23 correct?</p> <p>24 MR. RICARD: Objection.</p>	<p style="text-align: right;">Page 228</p> <p>1 Pharmacy, and it runs the gamut of January of '13</p> <p>2 through November of '14.</p> <p>3 Do you see that there, Mr. Schoen?</p> <p>4 A. I see it.</p> <p>5 Q. Okay. And these are the sales totals</p> <p>6 for oxycodone on a monthly basis, okay?</p> <p>7 A. Yeah.</p> <p>8 Q. And now again we see a pattern where --</p> <p>9 and I ran the numbers, and you can take my word</p> <p>10 for it, or you can double check me.</p> <p>11 So from January of '13 to November of</p> <p>12 '14, we have the sales data. We have the spike up</p> <p>13 to over 16,000 pills. Now, if you look from</p> <p>14 January of '13 to December of '13, so the whole</p> <p>15 year of 2013, there's an average of 4,467 pills</p> <p>16 per month?</p> <p>17 MR. RICARD: Objection to form.</p> <p>18 Q. 4,400, okay?</p> <p>19 A. All right.</p> <p>20 Q. If you take even further, January</p> <p>21 through March, we have an average of 5,126 pills</p> <p>22 per month --</p> <p>23 MR. RICARD: Objection to form.</p> <p>24 Q. -- okay?</p>
<p style="text-align: right;">Page 227</p> <p>1 Q. You don't know, sitting here today,</p> <p>2 whether it was investigated or not?</p> <p>3 A. I don't know.</p> <p>4 Q. It may be an educated guess based on the</p> <p>5 systems you had in place, but it's still a guess?</p> <p>6 A. It is.</p> <p>7 Q. And remember we talked at the very</p> <p>8 beginning, I don't want you guessing here today.</p> <p>9 A. All right.</p> <p>10 Q. Okay? I only want to know what you know</p> <p>11 or don't know. And I'm phrasing my questions very</p> <p>12 specific to allow you to be able to provide an</p> <p>13 answer.</p> <p>14 A. Okay.</p> <p>15 Q. So, again, my question is that this</p> <p>16 order -- this spike of 30,000, it should have been</p> <p>17 flagged, it should have been halted, it should be</p> <p>18 investigated and potentially reported as a</p> <p>19 suspicious order?</p> <p>20 A. Yes.</p> <p>21 Q. Okay. Now, let's go to 905B, which is</p> <p>22 27, Plaintiff's Exhibit 27. This, again, is</p> <p>23 another diagram again because I deal better with</p> <p>24 diagrams. And, again, it's for Shaffer's</p>	<p style="text-align: right;">Page 229</p> <p>1 A. Okay.</p> <p>2 Q. Understanding those averages, then we</p> <p>3 see a spike to over 14- and over 16,000, we would</p> <p>4 expect to see some sort of threshold event; would</p> <p>5 we not?</p> <p>6 MR. RICARD: Objection to form.</p> <p>7 A. Yes.</p> <p>8 Q. And based on the information that was</p> <p>9 provided, we don't see any threshold events for</p> <p>10 oxy until -- well, we don't see any threshold</p> <p>11 events in 2013 or 2014 for oxycodone, do we?</p> <p>12 MR. RICARD: Objection to form.</p> <p>13 A. I don't know. You know, from looking at</p> <p>14 this, I don't know.</p> <p>15 Q. Well, if you look at --</p> <p>16 A. Okay. All right. Here we go.</p> <p>17 Q. Yes, sir.</p> <p>18 So in 2013, we have a March event for</p> <p>19 hydrocodone which is different, correct?</p> <p>20 A. Yes.</p> <p>21 Q. And then in '14, we have a couple of</p> <p>22 events for -- what is that? Tramadone [sic]?</p> <p>23 MS. VELDMAN: Tramadol.</p> <p>24 Q. Tramadol?</p>

<p style="text-align: right;">Page 230</p> <p>1 A. Mm-hmm.</p> <p>2 Q. And then caris something. Carisoprodol,</p> <p>3 which none of those are the oxy family, correct?</p> <p>4 A. Correct.</p> <p>5 Q. So, again, we see no oxy threshold</p> <p>6 events when we have an increase of over four times</p> <p>7 the average pills going out in one month to</p> <p>8 Shaffer Pharmacy?</p> <p>9 MR. RICARD: Objection to form.</p> <p>10 Q. Does that cause you concern?</p> <p>11 A. I know we know Dave Shaffer, okay? We</p> <p>12 know Shaffer Pharmacy. I have to -- there has to</p> <p>13 be a reason, okay? And what it is, I don't know.</p> <p>14 Q. Right. No, no. I understand that.</p> <p>15 And, therefore, you agree that this does cause you</p> <p>16 concern, seeing what we're seeing today, correct?</p> <p>17 MR. RICARD: Objection to form.</p> <p>18 Mischaracterizes his answer.</p> <p>19 A. Yes.</p> <p>20 Q. Okay. Now, again, like I did earlier, I</p> <p>21 invite you, when you get back to the shop, to do</p> <p>22 some due diligence, do some checking and see if</p> <p>23 there's an explanation. If there's documentation,</p> <p>24 I would love to see it. I'll be honest. Again,</p>	<p style="text-align: right;">Page 232</p> <p>1 Q. And you knew that they lost their</p> <p>2 license, and you guys continued to ship for about</p> <p>3 a month after that. And then two months later,</p> <p>4 the DEA actually had you ship to them in part of a</p> <p>5 sting they were doing, correct?</p> <p>6 A. Mm-hmm.</p> <p>7 MR. RICARD: Objection to form.</p> <p>8 Q. Is that a yes?</p> <p>9 A. That's a yes.</p> <p>10 Q. And then you had certain ventures with</p> <p>11 an Ohliger.</p> <p>12 A. Ohliger.</p> <p>13 Q. Ohliger --</p> <p>14 A. Yes.</p> <p>15 Q. -- Pharmacy?</p> <p>16 A. Yes.</p> <p>17 Q. Brings up some probably pleasant and not</p> <p>18 so pleasant memories, huh?</p> <p>19 MR. RICARD: Objection to form.</p> <p>20 A. He went out of business.</p> <p>21 Q. He did.</p> <p>22 A. He owed us a lot of money.</p> <p>23 Q. He did. And you guys actually had a</p> <p>24 loan with him, correct?</p>
<p style="text-align: right;">Page 231</p> <p>1 we're not here to accuse people of doing things or</p> <p>2 not doing things that should have or shouldn't</p> <p>3 have been done unless we have all the facts. And</p> <p>4 that's what we're trying to get to, is get to all</p> <p>5 the facts, and that's fair, isn't it?</p> <p>6 A. It is. As I said, I know Dave Shaffer.</p> <p>7 I just, you know ... I probably would have felt</p> <p>8 comfortable with him, but ...</p> <p>9 Q. Sir?</p> <p>10 A. I know Dave Shaffer, so I would have</p> <p>11 felt comfortable. There must be a reason.</p> <p>12 Q. But we still have to do our due</p> <p>13 diligence --</p> <p>14 A. Yes.</p> <p>15 Q. -- even though -- absolutely.</p> <p>16 Now, I'm going to test your memory a</p> <p>17 little bit.</p> <p>18 You've had, at least from my review, two</p> <p>19 instances in which you were delivering to entities</p> <p>20 that had lost their license as pharmacies or</p> <p>21 pharmacists, one in Texas in which you actually</p> <p>22 assisted the DEA with, Niko Rx.</p> <p>23 Does that ring a bell?</p> <p>24 A. Could be, yes.</p>	<p style="text-align: right;">Page 233</p> <p>1 A. That's correct.</p> <p>2 Q. He actually -- well, here, we'll look at</p> <p>3 it.</p> <p>4 You had shipped to him after he lost his</p> <p>5 pharmacy license as well, correct?</p> <p>6 A. Not that I know of, no. I never knew</p> <p>7 that we shipped to Ohliger after he lost his</p> <p>8 pharmacy license. Do we have something?</p> <p>9 Q. Did you know old man Ohliger?</p> <p>10 A. Pardon?</p> <p>11 Q. Did you know Mr. Ohliger?</p> <p>12 A. I knew Mr. Ohliger.</p> <p>13 MR. PELINI: Mike, I'm real sensitive</p> <p>14 about the use of the term "old man."</p> <p>15 MR. FULLER: Hey, hey, hey. This isn't</p> <p>16 a litigation to be in if you don't get your</p> <p>17 feelings hurt down there. Toughen up --</p> <p>18 MR. PELINI: All right. I'm sorry.</p> <p>19 MR. FULLER: -- Mr. OSU.</p> <p>20 MR. PELINI: Now we have a problem.</p> <p>21 MR. FULLER: All right. So this is</p> <p>22 going to be Plaintiff's Exhibit 28.</p> <p>23 And that's where I'm going, Gina.</p> <p>24 - - -</p>

<p style="text-align: right;">Page 234</p> <p>1 (PSI-Schoen Deposition Exhibit 28 marked.)</p> <p>2 ---</p> <p>3 BY MR. FULLER:</p> <p>4 Q. So Plaintiff's Exhibit 28 is a document</p> <p>5 from the State of Ohio Board of Pharmacy.</p> <p>6 Do you see that?</p> <p>7 A. I see it.</p> <p>8 Q. And it's the Summary Suspension/Notice</p> <p>9 of Opportunity for Hearing, correct?</p> <p>10 A. Yes.</p> <p>11 Q. And it says, "You are hereby" -- and</p> <p>12 it's to Thomas Ohliger, right?</p> <p>13 A. Yes.</p> <p>14 Q. Okay. Dated October 6 of 2015.</p> <p>15 "You are hereby notified, in accordance</p> <p>16 with Section 119.07 of the Revised Code, the Ohio</p> <p>17 State Board Pharmacy Board hereby summarily</p> <p>18 suspends Thomas Ohliger's Ohio license as a</p> <p>19 pharmacist, under the authority of Section</p> <p>20 3719.121(B) 4729.16 of the Revised Code.</p> <p>21 Do you have any idea what Mr. Ohliger</p> <p>22 did?</p> <p>23 A. No.</p> <p>24 Q. Okay. Well, let's look. So if you go</p>	<p style="text-align: right;">Page 236</p> <p>1 roll onto the next page, Gina. Do C, D, and E.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. "c. During the investigation [sic], you</p> <p>4 struck an Agent of the Board about the body with</p> <p>5 your hand."</p> <p>6 A. Now it starts coming back, yeah.</p> <p>7 Q. Now you're recalling this, huh?</p> <p>8 A. Now I'm recalling it.</p> <p>9 Q. "While a supervisor of the Board spoke</p> <p>10 with police officers dispatched to the pharmacy,</p> <p>11 you took the Board-issued property, a laptop,</p> <p>12 without consent. The supervisor was able to</p> <p>13 complete the inspection once the property was</p> <p>14 returned."</p> <p>15 And "On October 5, 2015, you appeared</p> <p>16 before the Cuyahoga County Court of Common Pleas</p> <p>17 on case number" -- and it gives the case number --</p> <p>18 "where you were indicted on seven counts of</p> <p>19 illegal processing of drug documents and eight</p> <p>20 counts of trafficking. During the hearing, you</p> <p>21 were referred to the court psychiatric clinic to</p> <p>22 determine your competency to stand trial."</p> <p>23 Does that refresh your memory at all --</p> <p>24 A. It does, yes.</p>
<p style="text-align: right;">Page 235</p> <p>1 to the allegations section a little further down</p> <p>2 on the page.</p> <p>3 MR. FULLER: Blow up A, B, and C, too,</p> <p>4 please.</p> <p>5 BY MR. FULLER:</p> <p>6 Q. It says, "You, Thomas Ohliger, are</p> <p>7 engaged in conduct that provides clear and</p> <p>8 convincing evidence that continuation of your</p> <p>9 professional practice presents a danger of</p> <p>10 immediate serious harm to others set forth in</p> <p>11 Section 3719.121(B) of the ORC, to wit: A. On</p> <p>12 September 29th, 2015, you called the Board and</p> <p>13 stated that you had been robbed of your keys to</p> <p>14 your pharmacy, Ohliger Drug of Fairview Park, a</p> <p>15 retail pharmacy licensed by the Board under</p> <p>16 license number" -- it gives the number.</p> <p>17 "On September 29th -- same day -- an</p> <p>18 Agent and Regional Supervisor of the Board</p> <p>19 responded to the pharmacy to investigate the</p> <p>20 current state of security at the pharmacy and the</p> <p>21 security of the dangerous drugs contained within</p> <p>22 the pharmacy.</p> <p>23 "c" --</p> <p>24 MR. FULLER: You're going to need to</p>	<p style="text-align: right;">Page 237</p> <p>1 Q. -- of Mr. Ohliger?</p> <p>2 A. So we sold to him --</p> <p>3 MR. RICARD: Wait until another</p> <p>4 question.</p> <p>5 Q. I believe the records would indicate</p> <p>6 that you sold to him throughout the month of</p> <p>7 October of 2015.</p> <p>8 Now, due diligence would require that we</p> <p>9 stay informed of things like this with our</p> <p>10 customers, correct?</p> <p>11 MR. RICARD: Objection to form.</p> <p>12 A. Yes.</p> <p>13 Q. And while I have not checked, I would</p> <p>14 undoubtedly place a bet that if we looked at the</p> <p>15 papers in Cleveland, we would see newspaper</p> <p>16 clippings about Mr. Ohliger; wouldn't you think?</p> <p>17 MR. RICARD: Objection to form. Calls</p> <p>18 for speculation.</p> <p>19 A. But I don't see the newspapers in</p> <p>20 Cleveland.</p> <p>21 Q. Well, I understand that. I understand</p> <p>22 that. But these are the type of things --</p> <p>23 A. I'm sure -- I'm sure there were, yes.</p> <p>24 Q. But these are the type of things that we</p>

Page 238

1 would certainly try to stay informed of, correct?  
2 A. Yes.  
3 Q. I mean, I was pretty amused when I was  
4 reading it, I have to say. You're slapping the  
5 investigative agent with your hand and then steal  
6 the laptop.  
7 MR. FULLER: I'll strike the commentary  
8 myself.  
9 We've been going for a while. Why don't we  
10 take another break.  
11 MR. RICARD: Sure.  
12 A. Oh, okay. We closed that store for the  
13 State of Ohio, okay?  
14 Q. Because of a suspension?  
15 A. Because of a suspension. We took  
16 control of the drugs, yes, okay, at the request of  
17 the State.  
18 MR. FULLER: Fair enough. We'll take a  
19 quick break.  
20 THE VIDEOGRAPHER: The time is now 3:25.  
21 Going off the record.  
22 (Recess taken.)  
23 THE VIDEOGRAPHER: Okay. The time is  
24 now 3:39. Back on the record.

Page 239

1 BY MR. FULLER:  
2 Q. Mr. Schoen, I was looking at the sales  
3 data provided by counsel. And as I think you  
4 mentioned earlier, there's a significant dropoff  
5 of control IIs at some point for Prescription  
6 Supply, Inc., correct?  
7 A. Correct.  
8 Q. And the information I was looking at  
9 appeared to indicate that it happened at the end  
10 of '09, beginning of 2010, when Discount Drug Mart  
11 left Prescription Supply for its control IIs and  
12 went to Cardinal; is that right?  
13 MR. RICARD: Object to form.  
14 A. Yes.  
15 Q. Okay. Do you know why Prescription --  
16 or excuse me -- Discount Drug Mart left  
17 Prescription Supply for its control IIs and went  
18 to Cardinal?  
19 A. They had the cosi -- or the suspicious  
20 order monitoring system up -- not suspicious  
21 order. The electronic. The electronic C-II  
22 system went up. They no longer -- we no longer  
23 had an advantage. That's why they left us.  
24 Q. Was there also a price differential or a

Page 240

1 better --  
2 A. Well, I think they were probably --  
3 yeah, I would imagine Cardinal might have been  
4 cheaper. I don't know.  
5 Q. Okay. You're not sure either way on  
6 that?  
7 A. I'm not sure what their pricing was.  
8 Q. Now, even with the electronic monitoring  
9 system, even though you could still do it by  
10 fax --  
11 A. Yes. We could do it electronically,  
12 too, but ...  
13 Q. Did that make them any faster than you?  
14 A. It meant that they would deliver it with  
15 every -- the next day.  
16 Q. And would it --  
17 A. Just as we would have delivered the same  
18 day. That differential wasn't significant.  
19 Q. Okay.  
20 A. Okay?  
21 Q. At least that's your understanding of  
22 why Discount Drug Mart went to Cardinal?  
23 A. I'm very sure that that is why.  
24 Q. And how do you know? Did they tell you

Page 241

1 that or ...  
2 A. I honestly can't say that they told us  
3 that.  
4 Q. Okay. That's just your understanding or  
5 based on the business environment?  
6 A. Right. Yes.  
7 Q. Okay. Fair enough.  
8 But you did not have any conversation  
9 with Discount Drug Mart or Cardinal about that?  
10 A. Certainly not with Cardinal.  
11 Q. All right. I'm going to run us through  
12 two more documents real quick, and then we'll turn  
13 it over to your counsel in case he has any  
14 questions, okay?  
15 A. Mm-hmm.  
16 - - -  
17 (PSI-Schoen Deposition Exhibit 29 marked.)  
18 - - -  
19 Q. This is going to be Plaintiff's Exhibit  
20 Number 29.  
21 So I don't know if you know, Mr. Schoen,  
22 but there is a thing called the Wayback Machine.  
23 Have you ever heard of the Wayback  
24 Machine?

<p style="text-align: right;">Page 242</p> <p>1 A. No.</p> <p>2 Q. You can go way, way back.</p> <p>3 A. Way, way back.</p> <p>4 Q. At least on the Internet, and you can</p> <p>5 pull up older websites. What I've done is I've</p> <p>6 pulled up the HDMA website for this -- you know</p> <p>7 what? I think I gave you my copy, guys.</p> <p>8 A. Do you want it back?</p> <p>9 Q. Yeah.</p> <p>10 MR. RICARD: The one with the circles on</p> <p>11 it?</p> <p>12 MR. FULLER: It doesn't matter. The</p> <p>13 other one just doesn't have circles. It will help</p> <p>14 you get to it faster.</p> <p>15 BY MR. FULLER:</p> <p>16 Q. So the Wayback Machine tells me that</p> <p>17 from '04 to 2014, if you look at the second page,</p> <p>18 Christopher Schoen --</p> <p>19 A. Has been on the board.</p> <p>20 Q. Is one of the board members, Vice</p> <p>21 President - Sales, Prescription Supply, Inc.</p> <p>22 And what relation is Christopher to you?</p> <p>23 A. Son.</p> <p>24 Q. Okay. Does he still work at the</p>	<p style="text-align: right;">Page 244</p> <p>1 Cardinal versus the Department of Justice matter.</p> <p>2 MR. FULLER: It is 108. Oh, excuse me.</p> <p>3 107.</p> <p>4 BY MR. FULLER:</p> <p>5 Q. This is part of the pleadings from that</p> <p>6 matter. And in the legal world, there is issues</p> <p>7 of significant importance being considered by a</p> <p>8 court. Different organizations can ask to file</p> <p>9 what's called and amicus curiae brief --</p> <p>10 A. Okay.</p> <p>11 Q. -- meaning of public interest. And the</p> <p>12 HDMA, your trade organization, did that on behalf</p> <p>13 of Cardinal and related to its action involving</p> <p>14 the DOJ.</p> <p>15 A. Okay.</p> <p>16 Q. I'll tell you they also did the same</p> <p>17 related to that Masters Pharmaceuticals case that</p> <p>18 we looked at at the beginning this morning. I</p> <p>19 didn't show you that document, but they did.</p> <p>20 A. Okay.</p> <p>21 Q. It's a service they provide, or</p> <p>22 something that they do related to some legal</p> <p>23 matters. This is that document, and there's a few</p> <p>24 sections that I want to show you. I think I know</p>
<p style="text-align: right;">Page 243</p> <p>1 business?</p> <p>2 A. Yes.</p> <p>3 Q. Is he still in sales?</p> <p>4 A. Yes.</p> <p>5 Q. Is he still a board member of the HDMA?</p> <p>6 A. Yes, mm-hmm.</p> <p>7 Q. Fair enough.</p> <p>8 A. You understand that we have -- all</p> <p>9 right.</p> <p>10 Q. You see, what makes him really nervous</p> <p>11 is he's not exactly sure what you're fixing to</p> <p>12 say. That makes all of us nervous when our</p> <p>13 clients are going to say something we're not sure</p> <p>14 what they're going to say.</p> <p>15 - - -</p> <p>16 (PSI-Schoen Deposition Exhibit 30 marked.)</p> <p>17 - - -</p> <p>18 Q. All right. Plaintiff's Exhibit 30. So</p> <p>19 you understand what this is -- because I told you</p> <p>20 there wouldn't be any more legal documents, but</p> <p>21 then I took that back, and I said there may be</p> <p>22 one. This is my one, okay?</p> <p>23 A. Yes.</p> <p>24 Q. So what this is, is it relates to the</p>	<p style="text-align: right;">Page 245</p> <p>1 what your answer is going to be, but I want to</p> <p>2 take care of it for the record, okay?</p> <p>3 MR. RICARD: Mike, before you get</p> <p>4 started, can I just note an objection to the</p> <p>5 extent you're going to seek a legal conclusion?</p> <p>6 MR. FULLER: Sure. Objection noted for</p> <p>7 the record.</p> <p>8 BY MR. FULLER:</p> <p>9 Q. And the first part I want to ask you</p> <p>10 about is on the bottom of page 1 onto page 2.</p> <p>11 Actually, just the bottom of page 1.</p> <p>12 MR. FULLER: Just give me the bottom of</p> <p>13 page 1, Gina.</p> <p>14 BY MR. FULLER:</p> <p>15 Q. And there it says -- and it's in front</p> <p>16 of you on the electronic screen, Mr. Schoen.</p> <p>17 It says, "HDMA's members" -- which</p> <p>18 Prescription Supply is one of, correct?</p> <p>19 A. Correct.</p> <p>20 Q. -- "have not only statutory and</p> <p>21 regulatory responsibilities to detect and prevent</p> <p>22 diversion of controlled prescription drugs, but</p> <p>23 undertake such efforts as responsible members of</p> <p>24 society."</p>

<p style="text-align: right;">Page 246</p> <p>1 Does Prescription Supply agree with that</p> <p>2 statement?</p> <p>3 MR. RICARD: Objection to form.</p> <p>4 A. Yes.</p> <p>5 Q. "The public health dangers associated</p> <p>6 with the diversion and abuse of controlled</p> <p>7 prescription drugs have been well-recognized over</p> <p>8 the years by Congress, DEA, HDMA, and its members,</p> <p>9 and public health authorities."</p> <p>10 PSI also agrees and accepts that</p> <p>11 statement, correct?</p> <p>12 MR. RICARD: Objection to form.</p> <p>13 A. Yes.</p> <p>14 Q. PSI also agrees that it has not only a</p> <p>15 regulatory and statutory duty as mentioned there,</p> <p>16 but also a duty as a good public actor to protect</p> <p>17 the public from these dangerous controlled</p> <p>18 substances, correct?</p> <p>19 MR. RICARD: Same objection.</p> <p>20 A. Yes.</p> <p>21 Q. Basically a common law duty, if you</p> <p>22 will, correct?</p> <p>23 MR. RICARD: Same objection.</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 248</p> <p>1 THE VIDEOGRAPHER: The time is now 3:49.</p> <p>2 Going off the record.</p> <p>3 (Recess taken.)</p> <p>4 THE VIDEOGRAPHER: Okay. The time is</p> <p>5 now 3:58. Back on the record.</p> <p>6 MR. RICARD: I do not have any questions</p> <p>7 for Mr. Schoen. We would just request that the</p> <p>8 transcript be marked as highly confidential</p> <p>9 pursuant to the protective order that governs this</p> <p>10 case.</p> <p>11 MR. FULLER: Why are you all looking at</p> <p>12 me? I'm already finished.</p> <p>13 Does any other defense counsel have any</p> <p>14 questions?</p> <p>15 MR. PELINI: It's out of respect we're</p> <p>16 looking at you.</p> <p>17 THE VIDEOGRAPHER: The time is now 3:58.</p> <p>18 This concludes the deposition. Going off the</p> <p>19 record.</p> <p>20 (Signature not waived.)</p> <p>21 - - -</p> <p>22 Thereupon, at 3:58 p.m., on Wednesday,</p> <p>23 September 5, 2018, the deposition was concluded.</p> <p>24 - - -</p>
<p style="text-align: right;">Page 247</p> <p>1 Q. Okay. Page 7. Here the HDMA says, "The</p> <p>2 societal costs of prescription drugs are" -- it's</p> <p>3 in front of you on the electric screen, too,</p> <p>4 Mr. Schoen.</p> <p>5 A. Okay.</p> <p>6 Q. So the HDMA says the societal costs of</p> <p>7 prescription drugs are what?</p> <p>8 A. Huge.</p> <p>9 Q. Huge. "The development and</p> <p>10 implementation of practices and procedures to</p> <p>11 detect and prevent diversion are burdens that HDMA</p> <p>12 members willingly bear."</p> <p>13 You agree with that, correct?</p> <p>14 MR. RICARD: Objection to form.</p> <p>15 A. Yes.</p> <p>16 Q. And if members of the HDMA do not</p> <p>17 develop and implement practices and procedures to</p> <p>18 detect and prevent diversion, they should be held</p> <p>19 responsible for their fair share of these huge</p> <p>20 societal costs, correct?</p> <p>21 MR. RICARD: Objection to form.</p> <p>22 A. Yes.</p> <p>23 MR. FULLER: I don't have anything</p> <p>24 further.</p>	<p style="text-align: right;">Page 249</p> <p>1 CERTIFICATE</p> <p>2 STATE OF OHIO : SS: 3 COUNTY OF _____:</p> <p>4</p> <p>5 I, THOMAS G. SCHOEN, do hereby certify that I</p> <p>6 have read the foregoing transcript of my</p> <p>7 cross-examination given on September 5, 2018; that</p> <p>8 together with the correction page attached hereto noting</p> <p>9 changes in form or substance, if any, it is true and</p> <p>10 correct.</p> <p>11 _____ THOMAS G. SCHOEN</p> <p>12</p> <p>13 I do hereby certify that the foregoing</p> <p>14 transcript of the cross-examination of THOMAS G. SCHOEN</p> <p>15 was submitted to the witness for reading and signing;</p> <p>16 that after he had stated to the undersigned Notary</p> <p>17 Public that he had read and examined his</p> <p>18 cross-examination, he signed the same in my presence on</p> <p>19 the _____ day of _____, 2018.</p> <p>20</p> <p>21 _____ NOTARY PUBLIC - STATE OF OHIO</p> <p>22</p> <p>23 My Commission Expires:</p> <p>24 _____, _____.</p>

Page 250

1 CERTIFICATE  
2 STATE OF OHIO :  
3 SS:  
4 COUNTY OF FRANKLIN :  
5 I, Carol A. Kirk, a Registered Merit Reporter  
6 and Notary Public in and for the State of Ohio, duly  
7 commissioned and qualified, do hereby certify that the  
8 within-named THOMAS G. SCHOEN was by me first duly sworn  
9 to testify to the truth, the whole truth, and nothing  
10 but the truth in the cause aforesaid; that the  
11 deposition then given by him was by me reduced to  
12 stenotype in the presence of said witness; that the  
13 foregoing is a true and correct transcript of the  
14 deposition so given by him; that the deposition was  
15 taken at the time and place in the caption specified and  
16 was completed without adjournment; and that I am in no  
17 way related to or employed by any attorney or party  
18 hereto or financially interested in the action; and I am  
19 not, nor is the court reporting firm with which I am  
20 affiliated, under a contract as defined in Civil Rule  
21 28(D).  
22 IN WITNESS WHEREOF, I have hereunto set my  
23 hand and affixed my seal of office at Columbus, Ohio on  
24 this 10th day of September 2018.  
  
\_\_\_\_\_  
CAROL A. KIRK, RMR  
NOTARY PUBLIC - STATE OF OHIO  
My Commission Expires: April 9, 2022.  
- - -

Page 251

1 DEPOSITION ERRATA SHEET  
2 I, THOMAS G. SCHOEN, have read the transcript  
3 of my deposition taken on the 5th day of September 2018,  
4 or the same has been read to me. I request that the  
5 following changes be entered upon the record for the  
6 reasons so indicated. I have signed the signature page  
7 and authorize you to attach the same to the original  
8 transcript.  
9 Page Line Correction or Change and Reason Therefor:  
10 \_\_\_\_\_  
11 \_\_\_\_\_  
12 \_\_\_\_\_  
13 \_\_\_\_\_  
14 \_\_\_\_\_  
15 \_\_\_\_\_  
16 \_\_\_\_\_  
17 \_\_\_\_\_  
18 \_\_\_\_\_  
19 \_\_\_\_\_  
20 \_\_\_\_\_  
21 \_\_\_\_\_  
22 \_\_\_\_\_  
23 \_\_\_\_\_  
24 Date \_\_\_\_\_ Signature \_\_\_\_\_